SK15132000A3 - Substituted indolinones having an inhibiting effect on kinases and cycline/cdk complexes - Google Patents

Substituted indolinones having an inhibiting effect on kinases and cycline/cdk complexes Download PDF

Info

Publication number
SK15132000A3
SK15132000A3 SK1513-2000A SK15132000A SK15132000A3 SK 15132000 A3 SK15132000 A3 SK 15132000A3 SK 15132000 A SK15132000 A SK 15132000A SK 15132000 A3 SK15132000 A3 SK 15132000A3
Authority
SK
Slovakia
Prior art keywords
alkyl
phenyl
group
substituted
amino
Prior art date
Application number
SK1513-2000A
Other languages
Slovak (sk)
Other versions
SK283824B6 (en
Inventor
Armin Heckel
Rainer Walter
Wolfgang Grell
Meel Jacobus C. A. Van
Norbert Redemann
Original Assignee
Boehringer Ingelheim Pharma Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma Kg filed Critical Boehringer Ingelheim Pharma Kg
Publication of SK15132000A3 publication Critical patent/SK15132000A3/en
Publication of SK283824B6 publication Critical patent/SK283824B6/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32Oxygen atoms
    • C07D209/34Oxygen atoms in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

The invention relates to substituted indolinones of general formula (I), wherein R1 to R5 and X have the meanings given in claim 1, to their isomers and to their salts, especially their physiologically compatible salts. The inventive compounds have valuable pharmacological properties, especially an inhibitory effect on various kinases and cycline/CDK complexes, and on the proliferation of various tumour cells. The invention also relates to medicaments containing these compounds, to their use and to methods for producing them.

Description

Substituované indolinóny, spôsob ich prípravy, farmaceutický prostriedok s ich obsahom a ich použitieSubstituted indolinones, processes for their preparation, pharmaceutical compositions containing them and their use

Oblasť technikyTechnical field

Vynález sa týka nových substituovaných indolinónov všeobecného vzorca I, ktoré majú inhibičný účinok na kinázy a komplexy cyklín/CDK.The present invention relates to novel substituted indolinones of the formula I which have an inhibitory effect on kinases and cyclin / CDK complexes.

Podstata vynálezuSUMMARY OF THE INVENTION

Podstatou vynálezu sú substituované indolinóny všeobecného vzorca IThe present invention provides substituted indolinones of formula I

R3 R 3

ich izoméry a soli, najmä ich fýziologicky prijateľné soli, ktoré majú cenné vlastnosti.their isomers and salts, in particular their physiologically acceptable salts, which have valuable properties.

Uvedené zlúčeniny všeobecného vzorca I, v ktorom R1 je atóm vodíka alebo zvyšok prekurzora, majú cenné farmakologické vlastnosti, osobitne inhibičný účinok na rôzne kinázy, predovšetkým na komplexy CDK (CDK1, CDK2, CDK3, CDK4,The compounds of formula I, wherein R 1 is a hydrogen atom or a prodrug group have valuable pharmacological properties, particularly an inhibiting effect on various kinases, especially on complexes of CDKs (CDK1, CDK2, CDK3, CDK4,

CDK6, CDK7, CDK8 a CDK9) so špecifickými cyklínmi (A, B1, B2, C, D1, D2, D3, E, F, G1, G2, H, I a K) a na vírusový cyklín (pozri L. Mengtao v J. Virology 71 (3), 1984-1991 (1997)), a ostatné zlúčeniny uvedeného všeobecného vzorca I, v ktorom R1 nie je atóm vodíka ani zvyšok prekurzora, sú cennými medziproduktmi na prípravu uvedených zlúčenín.CDK6, CDK7, CDK8 and CDK9) with specific cyclins (A, B1, B2, C, D1, D2, D3, E, F, G1, G2, H, I and K) and viral cyclin (see L. Mengtao in J. Virology 71 (3), 1984-1991 (1997)), and other compounds of formula I wherein R 1 is not a hydrogen atom or a precursor residue are valuable intermediates for the preparation of said compounds.

Vynález sa týka uvedených zlúčeniny všeobecného vzorca I, pričom zlúčeniny, v ktorých R1 je atóm vodíka alebo zvyšok prekurzora, majú cennéThe present invention relates to those compounds of formula I, wherein compounds wherein R 1 is a hydrogen atom or a prodrug group have valuable

-2farm ako log ické vlastnosti, farmaceutických prostriedkov obsahujúcich farmakologicky účinné zlúčeniny, ich použitia a spôsobov ich prípravy.As pharmaceuticals, pharmaceutical compositions containing pharmacologically active compounds, their use and methods for their preparation.

V uvedenom všeobecnom vzorci I X je atóm kyslíka alebo síry,In formula I, X is an oxygen or sulfur atom,

R1 je atóm vodíka, C^-alkoxy-karbonylová alebo C^-alkanoylová skupina,R 1 is hydrogen, C 1-4 -alkoxy-carbonyl or C 1-4 -alkanoyl,

R2 je karboxy-, C^-alkoxy-karbonylová alebo aminokarbonylová skupina, v ktorej aminoskupina môže byť substituovaná jednou alebo dvoma C1.3-alkylovými skupinami a substituenty môžu byť rovnaké alebo rôzne,R 2 is a carboxy-, C 1-4 -alkoxy-carbonyl or aminocarbonyl group in which the amino group may be substituted by one or two C 1 . The 3- alkyl groups and substituents may be the same or different,

R3 je fenylová alebo naftylová skupina, ktorá môže byť substituovaná atómami fluóru, chlóru alebo brómu, C^-alkylovou, C^-alkoxy-, kyano-, trifluórmetylovou, nitro-, amino-, C^-alkylamino-, di-íC^-alkylJ-amino-, C^-alkanoyl-amino-, alkyO-C^alkanoylamino-, /V-CC^-alkyO-C^-alkanoylamino-, C1.3-alkylsulfonylamino-, amino-C^-alkylovou, C^-alkylamino-C^-alkylovou, di-ÍC^-alkylj-amino-C^alkylovou, /\/-(C-2^-alkanoyl)-amino-C1.3-alkylovou alebo /V-í^-alkanoylJ-Cualkylamino-C^-alkylovou skupinou a substituenty môžu byť rovnaké alebo rôzne,R 3 is a phenyl or naphthyl group which may be substituted by fluorine, chlorine or bromine atoms, C 1-6 -alkyl, C 1-6 -alkoxy-, cyano-, trifluoromethyl, nitro-, amino-, C 1-6 -alkylamino-, di- ^ -alkylJ-amino, C ^ alkanoyl-amino, alkylamino C ^ alkanoylamino, / V-CC ^ -alkyl-C ^ -alkanoylamino-, C first 3- alkylsulfonylamino-, amino-C 1-4 -alkyl, C 1-4 -alkylamino-C 1-4 -alkyl, di-C 1-4 -alkyl-amino-C 1-4 -alkyl, N - (C 1-2 -alkanoyl) -amino- C 1 . The 3- alkyl or N-N-alkanoyl-C 1-6 alkylamino-C 1 -alkyl group and the substituents may be the same or different,

R4 je atóm vodíka alebo C^-alkylová skupina aR 4 is a hydrogen atom or a C 1-6 -alkyl group;

R5 je atóm vodíka,R 5 is a hydrogen atom,

C^-alkylová skupina voliteľne substituovaná fenylovou, karboxy- alebo C13-alkoxykarbonylovou skupinou,C 1-6 -alkyl optionally substituted by phenyl, carboxy- or C 13 -alkoxycarbonyl,

C3.7-cykloalkylová skupina voliteľne substituovaná C.,.3-alkylovou skupinou, indanylová skupina voliteľne substituovaná C^-alkylovou skupinou,C 3 . A 7- cycloalkyl group optionally substituted with a C 1-6 alkyl group; 3- alkyl, indanyl optionally substituted with C 1-4 -alkyl,

5-členná heteroarylové skupina, ktorá obsahuje iminoskupinu voliteľne substituovanú C^-alkylovou skupinou, atóm kyslíka alebo síry, alebo iminoskupinu voliteľne substituovanú C1.3-alkylovou skupinou a atóm kyslíka, síry alebo dusíka alebo dva atómy dusíka, alebo 6-členná heteroarylové skupina, ktorá obsahuje 1 až 3 atómy dusíka, pričom cez dva susedné atómy uhlíka alebo cez atóm dusíka a susednú iminoskupinu uvedenej 5- a 6-člennej heteroarylovej skupiny možno pripojiť 1,3-butadienylénový mostík a uhlíkové jadro uvedených mono- a bicyklických kruhov môže byť mono- alebo disubstituované atómami chlóru, brómu alebo jódu, C^-alkylovou alebo kyanoskupinou a substituenty môžu byť rovnaké alebo rôzne,5-membered heteroaryl group contains an imino group optionally substituted by C ^ -alkyl, O, S, NH, or an optionally substituted C first A 3- alkyl group and an oxygen, sulfur or nitrogen atom or two nitrogen atoms, or a 6-membered heteroaryl group containing 1 to 3 nitrogen atoms, through two adjacent carbon or nitrogen atoms and the adjacent imino group of said 5- and 6- a 1,3-butadienylene bridge may be attached to the membered heteroaryl group and the carbon core of said mono- and bicyclic rings may be mono- or disubstituted by chlorine, bromine or iodine atoms, the C 1-4 -alkyl or cyano group and the substituents may be the same or different,

-3pyrolidinylová alebo piperidinylová skupina pripojená cez atóm uhlíka, ktorá na atóme dusíka môže byť substituovaná C^-alkylovou skupinou, fenylová skupina voliteľne disubstituovaná atómami fluóru, chlóru, brómu alebo jódu, C^-alkylovou, C^-alkoxy-, karboxy-, C^-alkoxykarbonylovou-, aminosulfonylovou-, nitro- alebo kyanoskupinou, pričom substituenty môžu byť rovnaké alebo rôzne, fenylová, pyridylová, pyrimidylová alebo tienylová skupina, ktorá je substituovaná trifluórmetoxyskupinou, atómom fluóru, chlóru, brómu alebo jódu, C1.3-alkoxyskupinou, ktorá v polohe 2 alebo 3 môže byť substituovaná amino-, C^alkylamino, di-(C.,.3-alkyl)-amino-, fenylovou, C^-alkylamino-, /V-ÍC^-alkylJ-fenylC^-alkylamino-, pyrolidínovou alebo piperidínovou skupinou, fenyl-C1.3-alkylamino-C1.3-alkylamino-C1.3-alkylovou skupinou, ktorá vo fenylovom jadre môže byť mono- alebo disubstituovaná trifluórmetylovou skupinou, atómami fluóru, chlóru, brómu alebo jódu, C^-alkylovými alebo C1.3-alkoxyskupinami, pričom substituenty môžu byť rovnaké alebo rôzne, a na dusíkovom atóme amínu dodatočne C^-alkylovou skupinou, v ktorej atómy vodíka môžu byť od polohy 2 nahradené celkom alebo čiastočne atómami fluóru,A 3-pyrrolidinyl or piperidinyl group attached via a carbon atom, which on the nitrogen atom may be substituted by a C 1-6 alkyl group, a phenyl group optionally disubstituted by fluorine, chlorine, bromine or iodine atoms, C 1-6 alkyl, C 1-6 alkoxy, carboxy-, C 1-4 -alkoxycarbonyl-, aminosulfonyl-, nitro- or cyano, wherein the substituents may be the same or different, phenyl, pyridyl, pyrimidyl or thienyl which is substituted by trifluoromethoxy, fluorine, chlorine, bromine or iodine, C 1 . 3 -alkoxy, which in the 2 or 3 may be substituted with amino, C ^ alkylamino, di- (C.,. 3-alkyl) amino, phenyl, C ^ -alkylamino, / V-IC -alkylJ -phenyl-C 1-4 -alkylamino-, pyrrolidine or piperidine, phenyl-C 1 . 3 -alkylamino-C first 3 -alkylamino-C first 3 -alkyl, in which the phenyl ring may be mono- or di-substituted by trifluoromethyl, fluorine, chlorine, bromine, iodine, C-alkyl or C first 3- alkoxy, wherein the substituents may be the same or different, and additionally on the nitrogen atom of the amine, a C 1-6 -alkyl group in which the hydrogen atoms from the 2-position can be replaced in whole or in part by fluorine atoms,

C^-alkylovou, fenylovou, imidazolylovou, C3.7-cykloalkylovou, C^-alkoxy-C^alkoxy-, fenyl-C1.3-alkoxy-, karboxy-C ^-alkylovou, C^-alkoxykarbonyl-C^alkylovou, karboxy-, C^-alkoxykarbonylovou, aminokarbonylovou, C1_3-alkylaminokarbonylovou, di-ÍC^-alkylJ-aminokarbonylovou, fenyl-C^-alkylaminokarbonylovou, /V-íC^-alkylj-fenyl-C^-alkylaminokarbonylovou, piperazínkarbonylovou, N-(Cr3alkyl)-piperazínkarbonylovou, nitro-, amino-, C^-alkylamino-, di-íC^-alkylJ-amino-, pyrolidínovou, piperidínovou, morfolínovou, C2^-alkanoylamino-, A/-(C1.3-alkyl)-C2-4alkanoylamino-, benzoylamino- alebo A/-(C1.3-alkyl)-benzoylaminoskupinou, /V-íC^-alkyO-C^-alkanoylaminoskupinou, ktorá je v alkylovej časti substituovaná dodatočne karboxy- alebo C^g-alkoxykarbonylovou skupinou,C 1-6 -alkyl, phenyl, imidazolyl, C 3 . 7- cycloalkyl, C 1-4 -alkoxy-C 1-4 alkoxy-, phenyl-C 1 . 3 -alkoxy, carboxy-C ^ -alkyl, C ^ -alkoxycarbonyl-C ^ alkyl, carboxy, C ^ alkoxycarbonyl, aminocarbonyl, C 1 _ 3 -alkylaminokarbonylovou, di-IC -alkylJ-aminocarbonyl, phenyl-C -alkylaminokarbonylovou ^, / V-IC -alkylj-phenyl-C ^ -alkylaminokarbonylovou, piperazinecarbonyl, N (C r 3 alkyl) -piperazínkarbonylovou, nitro, amino, C ^ -alkylamino, di-IC -alkylJ- amino, pyrrolidino, piperidino, morpholino, C ^ 2 -alkanoylamino-, A / - (C first 3 alkyl) C 2-4 alkanoylamino, benzoylamino or A / - (C first 3 alkyl) - benzoylamino, N-C 1-6 -alkyl-C 1-6 -alkanoylamino, which in the alkyl moiety is additionally substituted by carboxy- or C 1-6 -alkoxycarbonyl,

C^-alkylaminokarbonylovou alebo di-(C1.3-alkyl)-aminokarbonylovou skupinou, v ktorých je alkylová časť dodatočne substituovaná di-CC^-alkylj-aminoskupinou, aleboC ^ -alkylaminokarbonylovou or di- (C first 3 alkyl) -aminokarbonylovou group wherein the alkyl moiety is additionally substituted by di-CC ^ -alkylj-amino group, or

-4/V-fC^-alkylJ-C^-alkylsulfonylamino- alebo /V-fC^-alkylj-fenylsulfonylaminoskupinou, v ktorých alkylová časť môže byť dodatočne substituovaná kyano-, karboxy-, C13-alkoxykarbonylovou, C^-alkylamino-, di-íC^-alkylj-amino-, aminokarbonylovou, C^-alkylaminokarbonylovou, di-(C.,.3-alkyl)-aminokarbonylovou, piperidínkarbonylovou alebo 2-[di-(C1.3-alkylamino)]etylaminokarbonylovou skupinou, fenylová alebo tienylová skupina, ktorá je substituovaná C^-alkylovou skupinou, v ktorej alkylová časť je substituovaná hydroxy-, C^-alkoxy-, karboxy-, C^-alkoxykarbonylovou, amino-, C^-alkylamino-, di-ÍC^-alkylj-amino- I ^2-4 -alkanoylamino-, W-(CM-alkyl)-C2^ -alkanoylamino-, pyrolid í novou, dehydropyrolidínovou, piperidínovou, dehydropiperidínovou, 3-hydroxypiperidínovou, 4-hydroxypiperidínovou, hexametylénimino-, morfolínovou, tiomorfolínovou, piperazínovou, 4-(C1.3-alkyl)piperazínovou, 4-fenyl-piperazínovou, 4-(C2_4-alkanoyl)-piperazinovou, 4-benzoylpiperazínovou alebo imidazolylovou skupinou, pričom uvedené nasýtené cykloalkyléniminokruhy, C^-alkylamino- alebo di-fC^alkyl)-aminoskupiny môžu byť dodatočne substituované jednou alebo dvoma C^alkylovými skupinami, C3.7-cykloalkylovou, hydroxy-, C^-alkoxy-, karboxy-, C^alkoxykarbonylovou, aminokarbonylovou, C^-alkylaminokarbonylovou alebo di(C^-alkylj-aminokarbonylovou skupinou, fenyl-C^-alkylovou alebo fenylovou skupinou, ktorá vo fenylovom jadre môže byť dodatočne mono- alebo disubstituovaná atómami fluóru, chlóru, brómu alebo jódu, C^-alkylovými alebo kyanoskupinami, pričom substituenty môžu byť rovnaké alebo rôzne, alebo metylénová skupina susediaca s atómom dusíka v uvedených cykloalkyléniminokruhoch môže byť nahradená karbonylovou alebo sulfonylovou skupinou, a uvedené monosubstituované fenylové skupiny môžu byť dodatočne substituované atómom fluóru, chlóru alebo brómu, metylovou, amino-, C13alkylamino- alebo di-fC^-alkylj-aminoskupinou, alebo na jednom z uvedených nesubstituovaných cykloalkyléniminokruhoch môže byť cez dva susedné atómy uhlíka nakondenzované fenylové jadro voliteľne substituované jednou alebo dvoma C^-alkoxyskupinami.-4- N-C 1-6 -alkyl-C 1-6 -alkylsulfonylamino- or N-C 1-6 -alkyl-phenylsulfonylamino in which the alkyl moiety may be additionally substituted by cyano-, carboxy-, C 13 -alkoxycarbonyl, C 1-6 -alkylamino- , di-IC -alkylj-amino, aminocarbonyl, C ^ -alkylaminokarbonylovou, di (C.,. 3 alkyl) -aminokarbonylovou, piperidinocarbonyl or 2- [di- (C1. 3 -alkylamino)] ethylaminocarbonyl , a phenyl or thienyl group which is substituted by a C 1-6 alkyl group in which the alkyl moiety is substituted by hydroxy-, C 1-6 alkoxy-, carboxy-, C 1-6 alkoxycarbonyl, amino-, C 1-6 alkylamino-, di- -alkylj-amino ^ I ^ 2-4 -alkanoylamino-, N- (C M alkyl) 2, -C ^ -alkanoylamino-, the new pyrrolidine, dehydropyrolidínovou, piperidine, dehydropiperidínovou, 3-hydroxypiperidine, 4-hydroxypiperidine, hexamethyleneimino -, morpholino, thiomorpholino, piperazino, 4- (C first 3 alkyl) piperazine, 4-phenyl-piperazine, 4- (C 2 _ 4 alkanoyl) -piperazine, 4-benz oylpiperazínovou or imidazolyl group wherein said saturated cykloalkyléniminokruhy, C ^ -alkylamino or di-fC ^ alkyl) amino can additionally be substituted by one or two C ^ alkyl groups, C 3. 7- cycloalkyl, hydroxy-, C 1-4 -alkoxy-, carboxy-, C 1-4 -alkoxycarbonyl, aminocarbonyl, C 1-4 -alkylaminocarbonyl or di (C 1-4 -alkyl) aminocarbonyl, phenyl-C 1-4 -alkyl or phenyl, which in the phenyl the nucleus may additionally be mono- or disubstituted with fluorine, chlorine, bromine or iodine atoms, C 1-4 -alkyl or cyano groups, the substituents being the same or different, or the methylene adjacent to the nitrogen in said cycloalkyleneimino rings may be replaced by a carbonyl or sulfonyl group, and said monosubstituted phenyl groups may be additionally substituted by a fluorine, chlorine or bromine atom, methyl, amino, C 13 alkylamino- or di-C 1-6 -alkyl-amino, or may be fused via two adjacent carbon atoms on one of said unsubstituted cycloalkyleneimino rings a phenyl core optionally substituted with one or two C 1-4 -alkoxy groups.

Karboxyskupiny uvedené pri definícii spomenutých zvyškov môžu byť okrem toho nahradené skupinou, ktorú možno in vivo prekonvertovať na karboxyskupinu, aIn addition, the carboxy groups mentioned in the definition of said residues may be replaced by a group which can be converted in vivo to a carboxy group, and

-5amino- a iminoskupiny uvedené pri definícii spomenutých zvyškov môžu byť okrem toho substituované zvyškom, ktorý je in vivo odštiepiteľný.In addition, the amino and imino groups mentioned in the definition of said residues may be substituted by a residue which is cleavable in vivo.

Okrem toho, nasýtené alkylové a alkoxyčasti uvedené pri definícii, ktoré obsahujú viac ako dva atómy uhlíka, zahŕňajú aj ich rozvetvené izoméry, ako je napríklad izopropylová, ŕerc-butylová, izobutylová skupina, atď.In addition, the saturated alkyl and alkoxy moieties mentioned in the definition that contain more than two carbon atoms also include their branched isomers such as isopropyl, tert-butyl, isobutyl, and the like.

Výhodné zlúčeniny všeobecného vzorca I sú tie, v ktorých X je atóm kyslíka alebo síry,Preferred compounds of formula I are those in which X is an oxygen or sulfur atom,

R1 je atóm vodíka, C^-alkoxy-karbonylová alebo C^-alkanoylová skupina,R 1 is hydrogen, C 1-4 -alkoxy-carbonyl or C 1-4 -alkanoyl,

R2 je karboxy-, C^-alkoxy-karbonylová alebo aminokarbonylová skupina, v ktorej aminoskupina môže byť substituovaná jednou alebo dvoma C^-alkylovými skupinami a substituenty môžu byť rovnaké alebo rôzne,R 2 is a carboxy-, C 1-4 -alkoxy-carbonyl or aminocarbonyl group in which the amino group may be substituted by one or two C 1-6 -alkyl groups and the substituents may be the same or different,

R3 je fenylová alebo naftylová skupina, ktorá môže byť substituovaná atómami fluóru, chlóru alebo brómu, C^-alkylovou, C13-alkoxy-, kyano-, trifluórmetylovou, nitro-, amino-, C^-alkylamino-, di-íCva-alkylj-amino-, C2.4-alkanoyl-amino-, N-(C^.3alkyl)-C2_4-alkanoylamino-, /V-ÍC^a-alkylJ-C^-alkanoylamino-, C^alkylsulfonylamino-, amino-C^-alkylovou, C^-alkylamino-C^-alkylovou, diýC^-alkylj-amino-C.,^alkylovou, A/-(C-2^-alkanoyl)-amino-C1.3-alkylovou alebo A/ýC^-alkanoylj-Cvgalkylamino-C^g-alkylovou skupinou a substituenty môžu byť rovnaké alebo rôzne,R 3 is a phenyl or naphthyl group which may be substituted by fluorine, chlorine or bromine atoms, C 1-6 -alkyl, C 13 -alkoxy-, cyano-, trifluoromethyl, nitro-, amino-, C 1-6 -alkylamino-, di- -alkylj-amino, C 2nd 4-alkanoyl-amino, N- (C ^. 3 alkyl) 2-C-_4 alkanoylamino, / V-IC-alkyl is a C ^ -alkanoylamino-, C ^ alkylsulfonylamino, amino-C ^ -alkyl , C ^ alkylamino-C ^ -alkyl, diýC ^ -alkylj-amino-C., ^ alkyl, A / - (2 C ^ alkanoyl) amino-C1. The 3- alkyl or the N 6 -alkanoyl-6-alkylamino-C 6-6 -alkyl group and the substituents may be the same or different,

R4 je atóm vodíka alebo C^-alkylová skupina aR 4 is a hydrogen atom or a C 1-6 -alkyl group;

R5 je atóm vodíka,R 5 is a hydrogen atom,

C^g-alkylová skupina voliteľne substituovaná fenylovou, karboxy- alebo C^-alkoxykarbonylovou skupinou,C 1-6 -alkyl optionally substituted by phenyl, carboxy- or C 1-6 -alkoxycarbonyl,

C3.7-cykloalkylová skupina voliteľne substituovaná C^-alkylovou skupinou, indanylová skupina voliteľne substituovaná Cv3-alkylovou skupinou,C 3 . 7 -cycloalkyl optionally substituted with C ^ -alkyl, indanyl optionally substituted with C v3 -alkyl,

5-členná heteroarylová skupina, ktorá obsahuje iminoskupinu voliteľne substituovanú C^-alkylovou skupinou, atóm kyslíka alebo síry, alebo iminoskupinu voliteľne substituovanú C^-alkylovou skupinou a atóm kyslíka, síry alebo dusíka alebo dva atómy dusíka, alebo 6-členná heteroarylová skupina, ktorá obsahuje 1 až 3 atómy dusíka, pričom cez dva susedné atómy uhlíka alebo cez atóm dusíka a susednú iminoskupinu uvedenej 5- a 6-člennej heteroarylovej skupiny možnoA 5-membered heteroaryl group which contains an amino group optionally substituted with a C 1-6 alkyl group, an oxygen or sulfur atom, or an imino group optionally substituted with a C 1-6 alkyl group and an oxygen, sulfur or nitrogen atom or two nitrogen atoms, or a 6-membered heteroaryl group which contains 1 to 3 nitrogen atoms, wherein via two adjacent carbon atoms or via a nitrogen atom and the adjacent imino group of said 5- and 6-membered heteroaryl group,

-6pripojiť 1,3-butadienylénový mostík a uhlíkové jadro uvedených mono- a bicyklických kruhov môže byť mono- alebo disubstituované atómami chlóru, brómu alebo jódu, C^-alkylovou alebo kyanoskupinou a substituenty môžu byť rovnaké alebo rôzne, pyrolidinylová alebo piperidinylová skupina pripojená cez atóm uhlíka, ktorá na atóme dusíka môže byť substituovaná C^-alkylovou skupinou, fenylová skupina voliteľne disubstituovaná atómami fluóru, chlóru, brómu alebo jódu, C,_5-alkylovou, C,.3-alkoxy-, karboxy-, C,.3-alkoxykarbonylovou, aminosulfonylovou, nitro- alebo kyanoskupinou, pričom substituenty môžu byť rovnaké alebo rôzne, fenylová, pyridylová, pyrimidylová alebo tienylová skupina, ktorá je substituovaná C3.7-cykloalkylovou, C,_3-alkoxy-, fenyl-C13-alkoxy-, karboxy-C13-alkylovou, C,.3alkoxy-karbonyl-C,.3-alkylovou, karboxy-, C^-alkoxykarbonylovou, aminokarbonylovou, C^alkylaminokarbonylovou, di-(C,.3-alkyl)-aminokarbonylovou, nitro-, amino-, C,_3-alkylamino-, di-ÍCva-alkylJ-amino-, C^-alkanoyl-amino-, A/-(C,.3-alkyl)-C2j}alkanoylamino- alebo W-íC^-alkyO-C^-alkanoylaminoskupinou, C,.3-alkylaminokarbonylovou skupinou, v ktorej je alkylová časť dodatočne substituovaná di-(C,.3alkyl)-aminoskupinou, alebo A/-(C1.3-alkyl)-C1.3-alkylsulfonylaminoskupinou, v ktorej alkylová časť môže byť dodatočne substituovaná kyano-, karboxy-, C,.3alkoxykarbonylovou, C,_3-alkylamino- di-(C,_3-alkyl)-aminoskupinou, fenylová alebo tienylová skupina substituovaná C,.3-alkylovou skupinou, v ktorej alkylová časť je substituovaná hydroxy-, C,.3-alkoxy-, karboxy-, C13-alkoxykarbonylovou, amino-, C^-alkylamino-, di-íC^g-alkylJ-amino- > θ2-4 -alkanoylamino-, /V-íCva-alkyO-Cjui-alkanoylamino-, pyrolidí novou, piperidínovou, hexametylénimino, morfolínovou, piperazí novou, 4-(C,.3-alkyl)-piperazínovou, 4-(CM-alkanoyl)piperazínovou, 4-benzoyl-piperazínovou alebo imidazolyiovou skupinou, pričom uvedené cykloalkyléniminokruhy, C,_5-alkylamino- alebo di-(C15-alkyl)- aminoskupiny môžu byť dodatočne substituované C,.5-alkylovou, C3.7-cykloalkylovou, hydroxy-, C,.3-alkoxy-, karboxy-, C,.3-a lkoxy karbony lovou, aminokarbonylovou, C,.3alkylaminokarbonylovou alebo di-C,_3-alkyl)-aminokarbonylovou skupinou, fenyl-C,.3alkylovou alebo fenylovou skupinou, ktorá vo fenylovom jadre môže byť voliteľne-6-attach 1,3-butadienylene bridge and the carbon core of said mono- and bicyclic rings may be mono- or disubstituted with chlorine, bromine or iodine atoms, C 1-4 -alkyl or cyano and the substituents may be the same or different, pyrrolidinyl or piperidinyl attached via a carbon atom which may be substituted on the nitrogen atom by a C 1-6 -alkyl group, a phenyl group optionally disubstituted by fluorine, chlorine, bromine or iodine atoms, a C 1-5 -alkyl, C 1-6 -alkyl group; 3- alkoxy-, carboxy-, C 1-6 -alkyloxy-; 3- alkoxycarbonyl, aminosulfonyl, nitro or cyano, wherein the substituents may be the same or different, a phenyl, pyridyl, pyrimidyl or thienyl group which is substituted by C 3 . 7- cycloalkyl, C 1-3 -alkoxy-, phenyl-C 13 -alkoxy-, carboxy-C 13 -alkyl, C 1-6 -alkyloxy- 3 alkoxycarbonyl-C 1. 3- alkyl, carboxy-, C 1-4 -alkoxycarbonyl, aminocarbonyl, C 1-4 alkylaminocarbonyl, di- (C 1-3 -alkyl) aminocarbonyl, nitro-, amino-, C 1-3 -alkylamino-, di-C 1-4 -alkyl; amino-, C 1-6 -alkanoyl-amino-, N - (C 1-3 -alkyl) -C 21} alkanoylamino- or N 1 -C 1 -alkyl-C 1-6 -alkanoylamino, C 1-6 -alkanoylamino; 3 -alkylaminokarbonylovou group in which the alkyl is additionally substituted by di (C ,. 3 alkyl) amino, and A / - (C first 3 alkyl) -C first A 3- alkylsulfonylamino group in which the alkyl moiety may be additionally substituted with cyano, carboxy-, C1-6alkynyl, C1-6alkynyl, C1-6alkynyl, C1-6alkynyl, C1-6alkynyl or C1-6alkylamino; 3 alkoxycarbonyl, C, _ 3 alkylamino- di (C, _ 3 alkyl) amino, phenyl or thienyl substituted with C ,. A 3- alkyl group in which the alkyl moiety is substituted with hydroxy-, C 1-6 -alkyl; 3- alkoxy-, carboxy-, C 13 -alkoxycarbonyl, amino-, C 1-6 -alkylamino-, di-C 1-6 -alkyl-amino-C 2-4 -alkanoylamino-, N-C 1-6 -alkyl-C 3-6 -alkanoylamino - pyrrolidine, piperidine, hexamethylenimino, morpholine, piperazine, 4- (C 1-3 -alkyl) -piperazine, 4- (C 1-4 -alkanoyl) piperazine, 4-benzoyl-piperazine or imidazolyl group, said cycloalkyleneimino rings, C 1-5 -alkylamino- or di- (C 15 -alkyl) -amino groups may be additionally substituted with C 1-6 -alkyl. 5- alkyl, C 3 . 7 -cycloalkyl, hydroxy-, C1-7. 3- alkoxy-, carboxy-, C 1-6 -alkyloxy-; 3- alkoxycarbonyl, aminocarbonyl, C1-6alkoxycarbonyl; 3- alkylaminocarbonyl or di-C 1-3 -alkyl) aminocarbonyl, phenyl-C 1-6 alkyl; 3 may be an alkyl or phenyl group, which may optionally be in the phenyl core

-Ί mono- alebo disubstituovaná atómami fluóru, chlóru, brómu alebo jódu, CV3alkylovou alebo kyanoskupinou, pričom substituenty môžu byť rovnaké alebo rôzne, alebo alebo metylová skupina susediaca s atómom dusíka v uvedených cykloalkyléniminokruhoch môže byť nahradená karbonylovou alebo sulfonylovou skupinou, a uvedené monosubstituované fenylové skupiny môžu byť dodatočne substituované atómom fluóru, chlóru alebo brómu, alebo metylovou skupinou, osobitne tie zlúčeniny všeobecného vzorca I, v ktorých-Ί mono- or disubstituted by fluorine, chlorine, bromine or iodine atoms, C 3-6 alkyl or cyano, wherein the substituents may be the same or different, or the methyl group adjacent to the nitrogen atom in said cycloalkyleneimino rings may be replaced by a carbonyl or sulfonyl group; monosubstituted phenyl groups may be additionally substituted with a fluorine, chlorine or bromine atom or a methyl group, especially those compounds of formula I in which:

X je atóm kyslíka,X is an oxygen atom,

R1 je atóm vodíka, C^-alkoxy-karbonylová skupina,R 1 is hydrogen, C 1-4 -alkoxycarbonyl,

R2 je karboxy-, C^-alkoxy-karbonylová alebo aminokarbonylová skupina, v ktorej aminočasť môže byť substituovaná jednou alebo dvoma C1.3-alkylovými skupinami a substituenty môžu byť rovnaké alebo rôzne,R 2 is a carboxy-, C 1-4 -alkoxy-carbonyl or aminocarbonyl group in which the amino moiety may be substituted with one or two C 1 . The 3- alkyl groups and substituents may be the same or different,

R3 je fenylová skupina voliteľne substituovaná atómom fluóru, chlóru alebo brómu, metylovou, kyano-, alebo aminometylovou skupinou,R 3 is a phenyl group optionally substituted by a fluorine, chlorine or bromine atom, a methyl, cyano, or aminomethyl group,

R4 je atóm vodíka alebo metylová skupina a R5je atóm vodíka,R 4 is a hydrogen atom or a methyl group and R 5 is a hydrogen atom,

C15-alkylová skupina voliteľne substituovaná karboxy- alebo C1.3-alkoxykarbonylovou skupinou alebo benzylová skupina,C 15 alkyl group optionally substituted by carboxyl or C first 3- alkoxycarbonyl or benzyl,

C3.7-cykloalkylová skupina voliteľne substituovaná metylovou skupinou, indanylová, pyridylová, oxazolylová, tiazolylová alebo imidazolylová skupina voliteľne substituovaná metylovou skupinou, na ktorej cez dva susedné atómy uhlíka môže byť dodatočne nakondenzované fenylové jadro, metylfenylová skupina voliteľne substituovaná atómom fluóru, chlóru alebo brómu, metoxy-, karboxy-, C^-alky loxy karbonylovou, nitro- alebo aminosulfonylovou skupinou, alebo dimetoxyfenylová skupina, pyrolidinylová alebo piperidinylová skupina pripojená cez atóm uhlíka, ktorá je na atóme dusíka substituovaná C^-alkylovou skupinou, fenylová skupina, ktorá je substituovaná trifluórmetoxyskupinou, atómom fluóru, chlóru, brómu alebo jódu,C 3 . 7- cycloalkyl optionally substituted by methyl, indanyl, pyridyl, oxazolyl, thiazolyl or imidazolyl optionally substituted by methyl, on which two adjacent carbon atoms can be additionally fused to a phenyl core, methylphenyl optionally substituted by methoxy, fluorine, chlorine, chlorine carboxy-, C 1-6 -alkyloxycarbonyl, nitro- or aminosulfonyl, or dimethoxyphenyl, pyrrolidinyl or piperidinyl attached via a carbon atom which is substituted on the nitrogen atom by a C 1-6 -alkyl group, a phenyl group which is substituted by a trifluoromethoxy group , fluorine, chlorine, bromine or iodine,

-8C^-alkoxyskupinou, ktorá v polohe 2 alebo 3 môže byť substituovaná amino-, C13alkylamino-, di-(C1.3-alkyl)-amino-, fenyl-C^-alkylamino-, /\/-(C1.3-alkyl)-fenyl-C1.3alkylamino-, pyrolidínovou alebo piperidínovou skupinou, fenyl-Cva-alkylamino-Cvg-alkylovou skupinou, ktorá vo fenylovom jadre môže byť substituovaná atómom fluóru, chlóru, brómu alebo jódu, C^-alkylovou, C^-alkoxyalebo trifluórmetylovou skupinou a dodatočne na atóme dusíka amínu môže byť substituovaná C^-alkylovou skupinou, v ktorej atómy vodíka od polohy 2 môžu byť celkom alebo čiastočne nahradené atómami fluóru,-8C-alkoxy, which in the 2 or 3 may be substituted with amino, C13 alkylamino, di- (C first 3-alkyl) -amino-, phenyl-C ^ -alkylamino, / \ / - ( C first 3-alkyl) -phenyl-C first 3 alkylamino-, pyrrolidine- or piperidine-group, phenyl-C 1-8 -alkylamino-C 1-8 -alkyl, which in the phenyl ring may be substituted by fluorine, chlorine, bromine or iodine, C 1-6 -alkyl, C 1-6 -alkoxy or trifluoromethyl and additionally on the amine nitrogen atom may be substituted by a C 1-4 alkyl group in which the hydrogen atoms from the 2-position may be replaced, in whole or in part, by fluorine atoms,

C15-alkylovou, fenylovou, imidazolylovou, C3.7-cykloalkylovou, C^-alkoxy-C^alkoxy-, fenyl-C^g-alkoxy-, karboxy-C13-a lky levou, C^-alkoxykarbonyl-C^alkylovou, karboxy-, C1_3-alkoxykarbonylovou, aminokarbonylovou, (\3-alkylamin0karbonylovou, di-íCvg-alkylJ-aminokarbonylovou, fenyl-C1.3-alkylaminokarbonylovou, AHC^-alkyO-fenyl-C^-alkylaminokarbonylovou, piperazínkarbonylovou, N-(C^.3alkyl)-piperazínkarbonylovou, nitro-, amino-, C^-alkylamino-, di-ÍC^-alkylj-amino-, pyrolidínovou, piperidínovou, morfolínovou, C2J(-alkanoylamino-, A/-(C1.3-alkyl)-C2^talkanoylamino-, benzoylamino- alebo /V-tC^-alkylj-benzoylaminoskupinou, A/-(C1.3-alkyl)-C2.4-alkanoylaminoskupinou, ktorá je v alkylovej časti dodatočne substituovaná karboxy- alebo (\3-alkoxykarbonylovou skupinou,C 15 -alkyl, phenyl, imidazolyl, C 3 . 7 -cycloalkyl, C ^ -alkoxy-C ^ alkoxy, phenyl-C ^ g-alkoxy, carboxy-C 13 alpha lky left, C ^ -alkoxycarbonyl-C ^ alkyl, carboxy, C 1 _ 3 alkoxycarbonyl , aminocarbonyl, (\ 3-alkylamin0karbonylovou, di-alkyl is íCvg-aminocarbonyl, phenyl-C1. 3 -alkylaminokarbonylovou, AHC ^ -alkyl and phenyl-C ^ -alkylaminokarbonylovou, piperazinecarbonyl, N- (C ^. 3 alkyl) - piperazinecarbonyl, nitro, amino, C ^ -alkylamino, di-IC -alkylj-amino, pyrrolidino, piperidino, morpholino, C 2 J (-alkanoylamino-, A / - (C first 3 -alkyl) -C 2 ^ t alkanoylamino, benzoylamino, or / V-t C ^ -alkylj-benzoylamino, A / - (C first 3 -alkyl) -C second -alkanoylaminoskupinou 4, which is additionally substituted by alkyl or carboxy (\ 3-alkoxycarbonyl,

C^j-alkylaminokarbonylovou alebo di^C^-alkylj-aminokarbonylovou skupinou, v ktorých alkylová časť je dodatočne substituovaná di-(C1.3-alkyl)-aminoskupinou, aleboC ^ J-alkylaminocarbonyl and di ^ C ^ -alkylj-aminocarbonyl, wherein the alkyl moiety is additionally substituted by di (C first 3 alkyl) amino, or

W-íC^-alkylj-Cva-alkylsulfonylamino- alebo /V-ÍC^-alkylJ-fenylsulfonylaminoskupinou, v ktorých alkylová časť môže byť dodatočne substituovaná kyano-, karboxy-, Cvg-alkoxykarbonylovou, C1_3-alkylamino-, di-íC^-alkylJ-amino-, aminokarbonylovou, Cvs-alkylaminokarbonylovou, di-(C1.3-alkyl)-aminokarbonylovou, piperidínkarbonylovou alebo 2-[di-(C1.3-alkylamino)]-etylaminokarbonylovou skupinou, fenylová skupina voliteľne substituovaná (\3-alkyl0v0u skupinou, v ktorej alkylová časť je substituovaná hydroxy-, C13-alkoxy-, karboxy-, C13-alkoxy-karbonylovou, amino-, C^-alkylamino-, dHC^-alkylJ-amino-, CM-alkanoylamíno-, N-(C1.3-alkyl)C2.4-alkanoylamino-, pyrolidínovou, dehydropyrolidínovou, piperidínovou, dehydro-9piperidínovou, 3-hydroxypiperidínovou, 4-hydroxypiperidínovou, hexametylénimino-, morfolínovou, tiomorfolínovou, piperazínovou, 4-(C1.3-alkyl)-piperazínovou, 4-fenylpiperazínovou, 4-(C2J}-alkanoyl)-piperazínovou, 4-benzoyl-piperazínovou alebo imidazolylovou skupinou, pričom uvedené nasýtené cykloalkyléniminokruhy, C^-alkylamino- alebo di-íC^salkyl)-aminoskupiny môžu byť dodatočne substituované jednou alebo dvoma Ον5alkylovými skupinami, C3.7-cykloalkylovou, hydroxy-, C^-alkoxy-, karboxy-, C.,.3alkoxy karbonylovou, aminokarbonylovou, C^-alkylaminokarbonylovou alebo di(C^s-alkyO-aminokarbonylovou skupinou, fenyl-C^-alkylovou alebo fenylovou skupinou, ktorá vo fenylovom jadre môže byť dodatočne mono- alebo disubstituovaná atómami fluóru, chlóru, brómu alebo jódu, C^-alkylovými alebo kyanoskupinami, pričom substituenty môžu byť rovnaké alebo rôzne, alebo metylénskupina susediaca s atómom dusíka v uvedených cykloalkyléniminokruhoch môže byť nahradená karbonylovou alebo sulfonylovou skupinou, a uvedené monosubstituované fenylové skupiny môžu byť dodatočne substituované atómom fluóru, chlóru alebo brómu, metylovou, amino-, C13alkylamino- alebo di-íC^-alkylj-aminoskupinou, alebo na jednom z uvedených nesubstituovaných cykloalkyléniminokruhoch môže byť cez dva susedné atómy uhlíka nakondenzované fenylové jadro voliteľne substituované jednou alebo dvoma Cvs-alkoxyskupinami, ich izoméry a ich soli.N-IC--alkylj CVA-alkylsulfonylamino, or / V-IC -alkylJ-phenylsulfonylamino, wherein the alkyl moiety may additionally be substituted by cyano, carboxy, CVG-alkoxycarbonyl, C 1 _ 3 -alkylamino, di- IC -alkylJ-amino, aminocarbonyl, Cys-alkylaminocarbonyl, di (C first 3 alkyl) -aminokarbonylovou, piperidinocarbonyl or 2- [di- (C first 3 -alkylamino)] - ethylaminocarbonyl group, a phenyl group optionally substituted with a (3-alkyl) group in which the alkyl moiety is substituted with hydroxy, C 13 -alkoxy-, carboxy-, C 13 -alkoxy-carbonyl, amino-, C 1-6 -alkylamino-, C 1-6 -alkyl-1-amino-, C M -alkanoylamino-, N- (C first 3 alkyl) C 2nd -alkanoylamino- 4, pyrrolidino, dehydropyrolidínovou, piperidine, dehydro-9piperidínovou, 3-hydroxypiperidine, 4-hydroxypiperidine, hexametylénimino-, morpholino, thiomorpholino, piperazino 4- (C first 3 -alkyl) -piperazine, 4-phenyl piperazine, 4- (C 2 J} alkanoyl) -piperazine, 4-benzoyl l-piperazino or imidazolyl group wherein said saturated cykloalkyléniminokruhy, C ^ -alkylamino or di-IR ^ alkyl) amino group may be additionally substituted with one or two Ο ν5 alkyl, C 3. 7- cycloalkyl, hydroxy, C 1-6 -alkoxy, carboxy-, C 1-6 -alkyl- 3 alkoxy carbonyl, aminocarbonyl, C 1-6 -alkylaminocarbonyl or di (C 1-6 -alkyl-O-aminocarbonyl, phenyl-C 1-6 -alkyl or phenyl which may additionally be mono- or disubstituted in the phenyl ring by fluorine, chlorine, bromine or iodine, C 1-4 -alkyl or cyano, wherein the substituents may be the same or different, or the methylene adjacent to the nitrogen in said cycloalkyleneimino rings may be replaced by a carbonyl or sulfonyl group, and said monosubstituted phenyl groups may be additionally substituted by a fluorine, chlorine or bromine atom the methyl, amino, C 13 alkylamino- or di-C 1-6 -alkyl-amino, or at one of the above unsubstituted cycloalkyleneiminocycles, the fused phenyl ring optionally substituted by one or two C 1-6 -alkoxy groups, their isomers and salts thereof may be substituted via two adjacent carbon atoms .

Osobitne výhodné zlúčeniny uvedeného všeobecného vzorca I sú tie, v ktorých X je atóm kyslíka,Particularly preferred compounds of formula I are those wherein X is an oxygen atom,

R1 je atóm vodíka,R 1 is a hydrogen atom,

R2 je karboxy-, C^-alkoxy-karbonylová alebo aminokarbonylová skupina, v ktorej aminočasť môže byť substituovaná jednou alebo dvoma C1.3-alkylovými skupinami a substituenty môžu byť rovnaké alebo rôzne,R 2 is a carboxy-, C 1-4 -alkoxy-carbonyl or aminocarbonyl group in which the amino moiety may be substituted with one or two C 1 . The 3- alkyl groups and substituents may be the same or different,

R3 je fenylová skupina voliteľne substituovaná metylovou skupinou,R 3 is a phenyl group optionally substituted with a methyl group,

R4 je atóm vodíka alebo metylová skupina aR 4 is a hydrogen atom or a methyl group; and

-10R5je atóm vodíka,10R 5 is a hydrogen atom,

C13-alkylová skupina, benzylová skupina alebo metylová alebo etylová skupina substituovaná karboxy- alebo C^-alkoxy-karbonylovou skupinou,A C 13 -alkyl group, a benzyl group or a methyl or ethyl group substituted by a carboxy- or C 1-6 -alkoxy-carbonyl group,

C3.7-cykloalkylová skupina voliteľne substituovaná metylovou skupinou, indanylová, pyridylová, oxazolylová, tiazolylová alebo imidazolylová skupina voliteľne substituovaná metylovou skupinou, na ktorej cez dva susedné atómy uhlíka môže byť dodatočne nakondenzované fenylové jadro, metylfenylová skupina voliteľne substituovaná atómom fluóru, chlóru alebo brómu, metoxy-, karboxy-, C.,.3-alkyloxykarbonylovou, nitro- alebo aminosulfonylovou skupinou, alebo dimetoxyfenylová skupina,C 3 . 7- cycloalkyl optionally substituted by methyl, indanyl, pyridyl, oxazolyl, thiazolyl or imidazolyl optionally substituted by methyl, on which two adjacent carbon atoms can be additionally fused to a phenyl core, methylphenyl optionally substituted by methoxy, fluorine, chlorine, chlorine -, carboxy-, C.,. 3- alkyloxycarbonyl, nitro- or aminosulfonyl, or dimethoxyphenyl,

3-pyrolidinylová alebo 4-piperidinylová skupina, ktorá je na atóme dusíka substituovaná C^-alkylovou skupinou, fenylová skupina, ktorá je substituovaná trifluórmetoxy-, benzyloxy, kyano- alebo nitroskupinou, atómom fluóru, chlóru, alebo brómu,A 3-pyrrolidinyl or 4-piperidinyl group which is substituted on the nitrogen atom by a C 1-6 -alkyl group, a phenyl group which is substituted by a trifluoromethoxy, benzyloxy, cyano or nitro group, a fluorine, chlorine or bromine atom,

C^-alkoxyskupinou, pričom etoxy- a n-propoxyskupina môže byť na konci substituovaná dimetylamino-, dietylamino-, /V-etyl-metylamino-, /V-benzyl-metylamino- alebo piperidínovou skupinou, fenyl-C1.3-alkylamino-C1_3-alkylovou skupinou, ktorá vo fenylovom jadre môže byť substituovaná atómom fluóru, chlóru, brómu alebo jódu, metylovou, metoxy- alebo trifluórmetylovou skupinou a dodatočne a atóme dusíka aminoskupiny môže byť substituovaná C^-alkyl- alebo 2,2,2-trifluóretylovou skupinou,C 1-4 -alkoxy, wherein the ethoxy and n-propoxy group may be terminally substituted by dimethylamino-, diethylamino-, N -ethyl-methylamino-, N -benzyl-methylamino- or piperidine, phenyl-C 1 . 3 -alkylamino-C 1 _ 3 -alkyl group which the phenyl nucleus may be substituted by F, Cl, Br, I, methyl, methoxy or trifluoromethyl group and additionally a nitrogen atom of the amino group is optionally substituted Cl alkyl, or 2,2,2-trifluoroethyl,

C.,.4-alkylovou, fenylovou, imidazolylovou, cyklohexylovou, metoxymetylovou, karboxymetylovou, C V3-a lkoxy karbony l-metylovou, karboxy-, C13-alkoxykarbonylovou, aminokarbonylovou, C^-alkylaminokarbonylovou, di-(C.,_3-alkyl)aminokarbonylovou, fenyl-C^-alkylaminokarbonylovou, /\/-(C1.3-alkyl)-fenyl-Cl.3alkylaminokarbonylovou, piperazínkarbonylovou, /V-íC^-alkyQ-piperazínkarbonylovou, amino-, C^-alkylamino-, di-íC^-alkylJ-amino-, pyrolidínovou, piperidínovou, morfolínovou, C^-alkanoylamino-, /V-íC^-alkyO-C^-alkanoylamino-, benzoylamino- alebo A/-(C1_3-alkyl)-benzoylaminoskupinou,C.,. 4 -alkyl, phenyl, imidazolyl, cyclohexyl, methoxymethyl, carboxymethyl, C V3-a lkoxy-carbonyl methyl, carboxy, C 13 alkoxycarbonyl, aminocarbonyl, C ^ -alkylaminokarbonylovou, di (C., _ 3 alkyl) aminocarbonyl, phenyl-C ^ -alkylaminokarbonylovou, / \ / - (C1. 3 alkyl) -phenyl-C l. 3- alkylaminocarbonyl, piperazinecarbonyl, N, N-alkyl-N-piperazinecarbonyl, amino-, N-alkylamino-, di-N-alkyl-amino, pyrrolidine, piperidine, morpholine, N-alkanoylamino, N, N-C ^ C ^ -alkyl--alkanoylamino-, benzoylamino or A / - (C 1 _ 3 alkyl) -benzoylaminoskupinou.

-11 A/-(C1.3-alkyl)-C2^-alkanoylaminoskupinou, ktorá je v alkylovej časti dodatočne substituovaná karboxy- alebo C1.3-alkoxykarbonylovou skupinou, C^-alkylaminokarbonylovou alebo di-(C1.3-alkyl)-aminokarbonylovou skupinou, v ktorých alkylová časť je dodatočne substituovaná di-(C1.3-alkyl)-aminoskupinou, alebo /V-(C1.3-alkyl)-C1.3-alkylsulfonylamino- alebo /V-CC^-alkylj-fenylsulfonylaminoskupinou, v ktorých alkylová časť môže byť dodatočne substituovaná kyano-, karboxy-, C^-alkoxykarbonylovou, C^-alkylamino-, di-(C1.3-alkyl)-amino-, aminokarbonylovou, C^-alkylaminokarbonylovou, di-CC^-alkylj-aminokarbonylovou, piperidínkarbonylovou alebo 2-[di-(C1.3-alkylamino)]-etylaminokarbonylovou skupinou, fenylová skupina voliteľne substituovaná C^-alkylovou skupinou, v ktorej alkylová časť je substituovaná hydroxy-, C13-alkoxy-, karboxy-, C^-alkoxy-karbonylovou, amino-, C^-alkylamino-, di-íC^-alkylj-amino-, C^-alkanoylamino-, N-íC^-alkyl)C2_4-alkanoylamino-, pyrolidínovou, dehydropyrolidínovou, piperidínovou, dehydropiperidínovou, 4-hydroxypiperidínovou, hexametylénimino-, morfolínovou, tiomorfolínovou, piperazínovou, 4-(C1.3-alkyl)-piperazínovou, 4-fenyl-piperazínovou, 4(C2^-alkanoyl)-piperazínovou, 4-benzoyl-piperazínovou alebo imidazolylovou skupinou, pričom uvedené nasýtené cykloalkyléniminokruhy, môžu byť dodatočne substituované fenylovou skupinou alebo jednou alebo dvoma metylovými skupinami, uvedené C^-alkylamino- a di-íC^-alkylj-aminoskupiny môžu byť dodatočne substituované jednou alebo dvoma C^-alkylovými skupinami, cyklohexylovou, hydroxy-, C13-alkoxy-, karboxy-, C^-alkoxykarbonylovou, aminokarbonylovou, C^alkylaminokarbonylovou alebo di-CC^-alkylj-aminokarbonylovou skupinou, fenylC^-alkylovou alebo fenylovou skupinou, ktorá vo fenylovom jadre môže byť voliteľne substituovaná atómom fluóru, chlóru, brómu alebo jódu, metylovou alebo kyanoskupinou, alebo metylová skupina susediaca s atómom dusíka v uvedených cykloalkyléniminokruhoch môže byť nahradená karbonylovou alebo sulfonylovou skupinou, a-11 A / - (C first 3 alkyl) 2, -C ^ -alkanoylaminoskupinou which is additionally substituted by alkyl or carboxy-C first 3 alkoxycarbonyl group, a C ^ -alkylaminokarbonylovou or di- (C first 3 alkyl) -aminokarbonylovou group in which the alkyl moiety is additionally substituted by di (C first 3 -alkyl) -amino, and / or N (C first 3 alkyl) -C first 3 -alkylsulfonylamino- or / V-CC ^ -alkylj-phenylsulfonylamino, wherein the alkyl moiety may additionally be substituted by cyano, carboxy, C ^ alkoxycarbonyl, C ^ -alkylamino, di (C first 3 alkyl) amino, aminocarbonyl, C ^ -alkylaminokarbonylovou, di-CC ^ -alkylj-aminocarbonyl, piperidinocarbonyl or 2- [di- (C first 3 -alkylamino)] - ethylaminocarbonyl group, a phenyl group optionally substituted with C ^ -alkyl, wherein the alkyl moiety is substituted with hydroxy-, C 13 -alkoxy-, carboxy-, C 1-6 -alkoxy-carbonyl, amino-, C 1-6 -alkylamino-, di-C 1-6 -alkyl-amino-, C 1-6 -alkanoylamino-, IR-N-alkyl) C2 _4-alkanoylamino, pyrrolidino, dehydropyrolidínovou, piperidine, dehydropiperidínovou, 4-hydroxypiperidine, hexametylénimino-, morpholino, thiomorpholino, piperazino, 4- (C first 3 -alkyl) -piperazine, 4- phenyl-piperazine, 4 (2 C ^ alkanoyl) -piperazine, 4-benzoyl-piperazino or imidazolyl group, wherein the saturated cycloalkyleneimino rings, may be additionally substituted with phenyl or with one or two methyl groups, said C 1-6 -alkylamino- and di-C 1-6 -alkyl-amino groups may be additionally substituted with one or two C 1-6 -alkyl groups, cyclohexyl, hydroxy- 13- alkoxy-, carboxy-, C 1-4 -alkoxycarbonyl, aminocarbonyl, C 1-4 alkylaminocarbonyl or di-C 1-4 -alkyl-aminocarbonyl, phenyl C 1-4 -alkyl or phenyl, which in the phenyl ring may be optionally substituted by fluorine, chlorine, bromine or iodine, methyl or cyano, or a methyl group adjacent to the nitrogen atom in said cycloalkyleneimino rings may be replaced by a carbonyl or sulfonyl group, and

-12uvedené monosubstituované fenylové skupiny môžu byť dodatočne substituované atómom fluóru, chlóru alebo brómu, metylovou, amino-, Cvg-alkylamino- alebo di(C13-alkyl)-aminoskupinou, alebo na jednom z uvedených nesubstituovaných cykloalkyléniminokruhoch môže byť cez dva susedné atómy uhlíka nakondenzované fenylové jadro voliteľne substituované jednou alebo dvoma C^-alkoxyskupinami, ich izoméry a ich soli.-12uvedené monosubstituted phenyl groups may additionally be substituted by F, Cl, Br, methyl, amino, CVG-alkylamino or di (C 13 alkyl) amino, or one of the said unsubstituted cykloalkyléniminokruhoch may be through two adjacent carbon atoms a fused phenyl ring optionally substituted with one or two C 1-6 alkoxy groups, their isomers and salts thereof.

Osobitne výhodné zlúčeniny uvedeného všeobecného vzorca I sú tie, v ktorých X je atóm kyslíka,Particularly preferred compounds of formula I are those wherein X is an oxygen atom,

R1 je atóm vodíka,R 1 is a hydrogen atom,

R2 je karboxy- alebo aminokarbonylová skupina, v ktorej aminočasť môže byť substituovaná jednou alebo dvoma C^-alkylovými skupinami a substituenty môžu byť rovnaké alebo rôzne,R 2 is a carboxy- or aminocarbonyl group in which the amino moiety may be substituted by one or two C 1-6 -alkyl groups and the substituents may be the same or different,

R3 je fenylová skupina voliteľne substituovaná metylovou skupinou,R 3 is a phenyl group optionally substituted with a methyl group,

R4 je atóm vodíka aR 4 is hydrogen and

R5 je atóm vodíka,R 5 is a hydrogen atom,

3-pyrolidinylová alebo 4-piperidinylová skupina, ktoré sú na atóme dusíka substituované C13-alkylovou skupinou, fenylová skupina, ktorá je substituovaná C^-alkoxyskupinou, pričom etoxy- a n-propoxyskupina môže byť na konci substituovaná dimetylamino-, dietylamino-, /V-etyl-metylamino-, /V-benzylmetylamino- alebo piperidínovou skupinou, fenyl-C1.3-alkylamino-C1.3-alkylovou skupinou, ktorá vo fenylovom jadre môže byť substituovaná atómom fluóru, chlóru, brómu alebo jódu, metylovou, metoxy- alebo trifluórmetylovou skupinou a dodatočne a atóme dusíka aminoskupiny môže byť substituovaná C15-alkyl- alebo 2,2,2-trifluóretylovou skupinou, fenylová skupina voliteľne substituovaná Cv3-alkýlovou skupinou, v ktorej alkylová časť je substituovaná hydroxy-, C13-alkoxy-, karboxy-, C1.3-alkoxykarbonylovou, amino-, C^-alkylamino-, di-CC^-alkylj-amino-, C^-alkanoylamino-, N-íC^-alkyl)C^-alkanoylamino-, py rolidí novou, dehydropyrolidínovou, piperidínovou, dehydro-13piperidínovou, 4-hydroxypiperidínovou, hexametylénimino-, morfolínovou, tiomorfolínovou, piperazínovou, 4-(C1.3-alkyl)-piperazínovou, 4-fenyl-piperazínovou, 4(C2^-alkanoyl)-piperazínovou, 4-benzoyl-piperazí novou alebo imidazolylovou skupinou, pričom uvedené nasýtené cykloalkyléniminokruhy, môžu byť dodatočne substituované fenylovou skupinou alebo jednou alebo dvoma metylovými skupinami, uvedené C^-alkylamino- a di-CC^-alkylj-aminoskupiny môžu byť dodatočne substituované jednou alebo dvoma C^-alkylovými skupinami, cyklohexylovou, hydroxy-, C13-alkoxy-, karboxy-, C^-alkoxykarbonylovou, aminokarbonylovou, C^alkylaminokarbonylovou alebo di-ÍC^-alkylJ-aminokarbonylovou skupinou, fenylC13-alkylovou alebo fenylovou skupinou, ktorá vo fenylovom jadre môže byť voliteľne substituovaná atómom fluóru, chlóru, brómu alebo jódu, metylovou alebo kyanoskupinou, alebo metylová skupina susediaca s atómom dusíka v uvedených cykloalkyléniminokruhoch môže byť nahradená karbonylovou alebo sulfonylovou skupinou, a uvedené monosubstituované fenylové skupiny môžu byť dodatočne substituované atómom fluóru, chlóru alebo brómu, metylovou, amino-, C^-alkylamino- alebo di(C^-alkylj-aminoskupinou, alebo na jednom z uvedených nesubstituovaných cykloalkyléniminokruhoch môže byť cez dva susedné atómy uhlíka nakondenzované fenylové jadro voliteľne substituované jednou alebo dvoma Cvg-alkoxyskupinami, ich izoméry a ich soli.A 3-pyrrolidinyl or 4-piperidinyl group which is substituted on the nitrogen atom by a C 13 -alkyl group, a phenyl group which is substituted by a C 1-6 -alkoxy group, wherein the ethoxy and n-propoxy group may be terminally substituted by dimethylamino-, diethylamino-, N-ethyl-methylamino-, N-benzylmethylamino- or piperidine, phenyl-C 1 . 3 -alkylamino-C first A 3- alkyl group which in the phenyl ring may be substituted by a fluorine, chlorine, bromine or iodine atom, a methyl, methoxy or trifluoromethyl group, and in addition and by an amino nitrogen atom may be substituted by a C 15 -alkyl- or 2,2,2-trifluoroethyl group , phenyl optionally substituted by C v3 -alkyl, wherein the alkyl moiety is substituted by hydroxy, C 13 -alkoxy, carboxy, C first 3- alkoxycarbonyl, amino-, C 1-4 -alkylamino-, di-C 1-4 -alkyl-amino-, C 1-4 -alkanoylamino-, N-C 1-4 -alkyl) C 1-4 -alkanoylamino-, pyrrolidine, dehydropyrrolidine, piperidine, dehydro-13piperidínovou, 4-hydroxypiperidine, hexametylénimino-, morpholino, thiomorpholino, piperazino, 4- (C first 3 -alkyl) -piperazine, 4-phenyl-piperazine, 4 (2 C ^ alkanoyl) -piperazine, 4-benzoyl piperazinyl or imidazolyl, wherein said saturated cycloalkyleneimino rings may be additionally substituted with phenyl or with one or two methyl groups, said C 1-6 -alkylamino- and di-C 1-6 -alkyl-amino groups may be additionally substituted with one or two C 1-6 -alkylamino groups; alkyl groups, cyclohexyl, hydroxy-, C 13 -alkoxy-, carboxy-, C 1-4 -alkoxycarbonyl, aminocarbonyl, C 1-4 -alkylaminocarbonyl or di-C 1-6 -alkyl-4-aminocarbonyl, phenylC 13 -alkyl or phenyl groups which in the phenyl core can be optional not substituted by a fluorine, chlorine, bromine or iodine atom, a methyl or cyano group, or a methyl group adjacent to a nitrogen atom in said cycloalkyleneimino rings may be replaced by a carbonyl or sulfonyl group, and said monosubstituted phenyl groups may be additionally substituted by fluorine, chlorine or chlorine , amino-, C 1-6 -alkylamino- or di (C 1-6 -alkyl) -amino, or on one of said unsubstituted cycloalkyleneimino rings, the fused phenyl ring optionally substituted by one or two C 1-6 -alkoxy groups, their isomers and salts thereof may be via two adjacent carbon atoms .

Osobitne výhodné sú uvedené zlúčeniny, v ktorých zvyšok R2 je v polohe 5, zvlášť nasledovné zlúčeniny:Especially preferred are the compounds in which R 2 is in the 5-position, especially the following compounds:

(a) 3-Z-[1 -(4-aminometyl-fenylamino)-1 -fenyl-metylén]-5-amido-2-indolinón, (b) 3-Z-[1-(1-fenylamino)-1-fenyl-metylén]-5-amido-2-indolinón, (c) 3-Z-[1 -(4-bróm-fenylamino)-1 -fenyl-metylén]-5-amido-2-indolinón, (d) 3-Z-[1-(4-dimetylamino-metyl)-fenylamino)-1-fenyl-metylén]-5-amido-2-indolinón, (e) 3-Z-[1-(4-pyrolidínmetyl-fenylamino)-1-fenyl-metylén]-5-amido-2-indolinón, (f) 3-Z-[1-(4-piperidínmetyl-fenylamino)-1-fenyl-metylén]-5-amido-2-indolinón,(a) 3-Z- [1- (4-aminomethyl-phenylamino) -1-phenyl-methylene] -5-amido-2-indolinone, (b) 3-Z- [1- (1-phenylamino) -1] -phenyl-methylene] -5-amido-2-indolinone, (c) 3-Z- [1- (4-bromo-phenylamino) -1-phenyl-methylene] -5-amido-2-indolinone, (d) 3-Z- [1- (4-dimethylamino-methyl) -phenylamino) -1-phenyl-methylene] -5-amido-2-indolinone, (e) 3-Z- [1- (4-pyrrolidinomethyl-phenylamino)] -1-phenyl-methylene] -5-amido-2-indolinone, (f) 3-Z- [1- (4-piperidinomethyl-phenylamino) -1-phenyl-methylene] -5-amido-2-indolinone,

-14(g) 3-Z-[1 -(4-hexametyléniminometyl-fenylamino)-1 -fenyl-metylén]-5-amido-2indolinón, (h) 3-Z-[1-(4-benzyl-piperidín)-metyl)-fenylamino)-1-fenyl-metylén]-5-amido-2indolinón, (i) 3-Z-[1 -(4-(/V-butyl-aminometyl)-fenylamino)-1 -fenyl-metylén]-5-amido-2-indolinón, (j) 3-Z-[ 1 -(4-(/V-(fenyl-metyl)-aminometyl)-fenylamino)-1 -fenyl-metylén]-5-amido-2indolinón, (k) 3-Z-[1 -(4-(A/-metyl-A/-benzyl-amino-metyl)-fenylamino)-1 -fenyl-metylén]-5-amido2-indolinón, (l) 3-Z-[1-(4-piperidín-metyl-fenylamino)-1-fenyl-metylén]-5-dimetylkarbamoyl-2indolinón, (m) 3-Z-[1 -(4-piperidín-metyl-fenylamino)-1 -fenyl-metylén]-5-dietylkarbamoyl-2indolinón, (n) 3-Z-[ 1 -(4-(3-dietylamino-propoxy)-fenylamino)-1 -fenyl-metylén]-5-amido-2indolinón, a ich soli.-14 (g) 3-Z- [1- (4-hexamethyleniminomethyl-phenylamino) -1-phenyl-methylene] -5-amido-2-indolinone, (h) 3-Z- [1- (4-benzyl-piperidine)] (methyl) -phenylamino) -1-phenyl-methylene] -5-amido-2-indolinone; (i) 3-Z- [1- (4- (N-butyl-aminomethyl) -phenylamino) -1-phenyl-methylene] ] -5-amido-2-indolinone, (j) 3-Z- [1- (4- (N - (phenylmethyl) aminomethyl) phenylamino) -1-phenylmethylene] -5-amido- 2-indolinone, (k) 3-Z- [1- (4- (N-methyl-N-benzyl-amino-methyl) -phenylamino) -1-phenyl-methylene] -5-amido-2-indolinone, (1) 3-Z- [1- (4-piperidin-methyl-phenylamino) -1-phenyl-methylene] -5-dimethylcarbamoyl-2-indolinone, (m) 3-Z- [1- (4-piperidin-methyl-phenylamino) - 1-phenyl-methylene] -5-diethylcarbamoyl-2-indolinone, (n) 3-Z- [1- (4- (3-diethylamino-propoxy) -phenylamino) -1-phenyl-methylene] -5-amido-2-indolinone, and salts thereof.

Vynález poskytuje aj spôsoby prípravy (v podstate známe aj z literatúry) zlúčenín podľa vynálezu, ktoré zahrnujú: a) Reakciu zlúčeniny všeobecného vzorca IIThe invention also provides processes for the preparation (essentially known from the literature) of the compounds of the invention, comprising: a) Reaction of a compound of formula II

R3 R 3

v ktoromin which

X, R2 a R3 boli definované vyššie,X, R 2 and R 3 are as defined above,

R6 je atóm vodíka, ochranná skupina pre atóm dusíka laktámovej skupiny alebo väzba na tuhú fázu aR 6 is a hydrogen atom, a protecting group for a nitrogen atom of a lactam group or a solid phase bond; and

- 15Z1 je atóm halogénu, hydroxy-, alkoxy- alebo aralkoxyskupina, napríklad atóm chlóru alebo brómu, metoxy-, etoxy- alebo benzyloxyskupina, s amínom všeobecného vzorca Hl (IN) v ktorom- 15Z 1 is a halogen atom, a hydroxy-, alkoxy- or aralkoxy group, for example a chlorine or bromine atom, a methoxy-, ethoxy- or benzyloxy group, with an amine of the general formula H 1 (IN) in which:

R4 a R5 boli určené vyššie, a v prípade potreby následné odštiepenie použitej ochrannej skupiny atómu dusíka laktámovej skupiny alebo tuhej fázy.R 4 and R 5 have been defined above and, if necessary, subsequent cleavage of the nitrogen protecting group of the lactam group or solid phase used.

Ochranná skupina atómu dusíka laktámovej skupiny môže byť napríklad acetylová, benzoylová, etoxykarbonylová, terc-butylkarbonylová alebo benzyloxykarbonylová skupina a tuhá fáza môže byť Rinkova alebo Sieberova živica.The nitrogen protecting group of the lactam group may be, for example, acetyl, benzoyl, ethoxycarbonyl, tert-butylcarbonyl or benzyloxycarbonyl and the solid phase may be a Rink or Sieber resin.

Reakcia sa výhodne uskutoční v rozpúšťadle ako je napríklad dimetylformamid, toluol, acetonitril, tetrahydrofurán, dimetylsulfoxid, metylénchlorid alebo ich zmesi, voliteľne v prítomnosti inertnej zásady ako je napríklad trietylamín, /V-etyldiizopropylamín alebo hydrouhličitan sodný pri teplote 20 až 175 °C, pričom jedna ochranná skupina sa môže v dôsledku amidizácie zároveň odštiepiť.The reaction is preferably carried out in a solvent such as dimethylformamide, toluene, acetonitrile, tetrahydrofuran, dimethylsulfoxide, methylene chloride, or mixtures thereof, optionally in the presence of an inert base such as triethylamine, N-ethyldiisopropylamine or sodium bicarbonate at 20 to 175 ° C. one protecting group can also be cleaved off as a result of amidization.

Ak Z1 v zlúčenine všeobecného vzorca II je atóm halogénu, potom reakcia prebieha výhodne v prítomnosti inertnej zásady pri teplote medzi 20 až 120 °C.When Z 1 in the compound of formula (II) is a halogen atom, the reaction is preferably carried out in the presence of an inert base at a temperature of between 20 and 120 ° C.

Ak Z1 v zlúčenine všeobecného vzorca II je hydroxy-, alkoxy- alebo aralkoxyskupina, potom reakcia prebieha výhodne pri teplote 20 až 200 °C.When Z 1 in the compound of formula (II) is a hydroxy-, alkoxy- or aralkoxy group, the reaction is preferably carried out at a temperature of 20 to 200 ° C.

Voliteľne potrebné následné odštiepenie použitej ochrannej skupiny sa uskutoční výhodne buď hydrolyticky vo vodnom alebo alkoholovom rozpúšťadle ako je napríklad metanol/voda, etanol/voda, izopropanol/voda, tetrahydrofurán/voda, dioxán/voda, dimetylformamid/voda, metanol alebo etanol v prítomnosti alkalickej zásady ako je napríklad hydroxid lítny, hydroxid sodný alebo hydroxid draselný pri teplote medzi 0 až 100 °C, výhodne pri teplote medzi 10 až 50 °C,Optionally, the subsequent cleavage of the protecting group used is preferably carried out either hydrolytically in an aqueous or alcoholic solvent such as methanol / water, ethanol / water, isopropanol / water, tetrahydrofuran / water, dioxane / water, dimethylformamide / water, methanol or ethanol in the presence of alkaline. bases such as lithium hydroxide, sodium hydroxide or potassium hydroxide at a temperature between 0 to 100 ° C, preferably at a temperature between 10 to 50 ° C,

-16alebo výhodne amidizáciou s primárnou alebo sekundárnou organickou zásadou ako je napríklad amoniak, metylamín, butylamín, dimetylamín alebo piperidin v rozpúšťadle ako je napríklad metanol, etanol, dimetylformamid a ich zmesi alebo v nadbytku použitého amínu pri teplote medzi 0 a 100 °C, výhodne pri teplote 10 až °C.-16 or preferably by amidization with a primary or secondary organic base such as ammonia, methylamine, butylamine, dimethylamine or piperidine in a solvent such as methanol, ethanol, dimethylformamide and mixtures thereof or in excess of the amine used at a temperature between 0 and 100 ° C, preferably at 10 ° C.

Odštiepenie použitej tuhej fázy sa uskutoční výhodne pomocou kyseliny trifluóroctovej a vody v prítomnosti dialkylsulfidu ako je napríklad dimetylsulfid pri teplote medzi 0 až 35 °C, výhodne pri izbovej teplote.The cleavage of the solid phase used is preferably carried out with trifluoroacetic acid and water in the presence of a dialkyl sulfide such as dimethyl sulfide at a temperature between 0 to 35 ° C, preferably at room temperature.

b) Zlúčeniny všeobecného vzorca I, ktoré obsahujú aminometylovú skupinu a X je atóm kyslíka sa pripravia:(b) Compounds of formula I which contain an aminomethyl group and X is an oxygen atom are prepared by:

redukciou zlúčeniny všeobecného vzorca IVreducing the compound of formula IV

(IV) v ktorom(IV) in which

R1 až R4 boli určené vyššie, aR 1 to R 4 are defined above, and

R7 je ako R5 určené vyššie s tým, že R5 obsahuje kyanoskupinu.R 7 is as R 5 as defined above, provided that R 5 contains a cyano group.

Redukcia sa uskutočňuje výhodne pomocou katalytickej hydratácie s vodíkom v prítomnosti katalyzátora ako je napríklad paládium/uhlie alebo platina v rozpúšťadle ako ne napríklad metanol, etanol, etylester kyseliny octovej, dimetylformamid, dimetylformamid/acetón alebo ľadová kyselina octová, voliteľne za pridania kyseliny ako je napríklad kyselina chlorovodíková pri teplote medzi 0 až 50 °C, avšak výhodne pri izbovej teplote, a pri tlaku vodíka 102 až 7.102 kPa (1 až 7 barov), výhodne však pri 3.102 až 5.102 kPa (3 až 5 baroch).The reduction is preferably carried out by catalytic hydration with hydrogen in the presence of a catalyst such as palladium / carbon or platinum in a solvent such as, for example, methanol, ethanol, ethyl acetate, dimethylformamide, dimethylformamide / acetone or glacial acetic acid, optionally with an acid such as hydrochloric acid at temperatures between 0 DEG and 50 DEG C., but preferably at room temperature and at a hydrogen pressure of 10 2 to 7.10 2 kPa (1-7 bar), but preferably at 3.10 2 to 5.10 2 kPa (3-5 bar).

-17Ak sa podľa vynálezu získa zlúčenina všeobecného vzorca I, ktorá obsahuje alkoxykarbonylovú skupinu, potom je možné prekonvertovať ju pomocou hydrolýzy na zodpovedajúcu karboxyzlúčeninu, alebo zlúčenina všeobecného vzorca I, ktorá obsahuje amino- alebo alkylaminoskupinu, potom je možné prekonvertovať ju pomocou alkylácie alebo redukčnej alkylácie na zodpovedajúcu alkylamino- alebo dialkylaminozlúčeninu, alebo zlúčenina všeobecného vzorca I, ktorá obsahuje amino- alebo alkylaminoskupinu, potom je možné prekonvertovať ju pomocou acylácie na zodpovedajúcu acylovú zlúčeninu, alebo zlúčenina všeobecného vzorca I, ktorá obsahuje karboxyskupinu, potom je možné prekonvertovať ju esterifikáciou alebo amidizáciou na zodpovedajúcu esterovú alebo aminokarbonylovú zlúčeninu.If a compound of formula (I) containing an alkoxycarbonyl group is obtained according to the invention, then it can be converted by hydrolysis to the corresponding carboxy compound, or a compound of formula (I) containing an amino or alkylamino group, then converted by alkylation or reductive alkylation. to the corresponding alkylamino- or dialkylamino compound, or a compound of formula I containing an amino- or alkylamino group, then it can be converted by acylation to the corresponding acyl compound, or a compound of formula I containing a carboxy group, then converted by esterification or amidization to the corresponding ester or aminocarbonyl compound.

Následná hydrolýza sa uskutočňuje výhodne vo vodnom rozpúšťadle ako je napríklad voda, izopropanol/voda, tetrahydrofurán/voda alebo dioxán/voda, v prítomnosti kyseliny ako je napríklad kyselina trifluóroctová, kyselina chlorovodíková alebo kyselina sírová, alebo v prítomnosti alkalickej zásady ako je napríklad hydroxid lítny, hydroxid sodný alebo hydroxid draselný pri teplote medzi 0 až 100 °C, výhodne pri teplote medzi 10 až 50 °C.The subsequent hydrolysis is preferably carried out in an aqueous solvent such as water, isopropanol / water, tetrahydrofuran / water or dioxane / water, in the presence of an acid such as trifluoroacetic acid, hydrochloric acid or sulfuric acid, or in the presence of an alkaline base such as lithium hydroxide. , sodium hydroxide or potassium hydroxide at a temperature between 0 to 100 ° C, preferably at a temperature between 10 to 50 ° C.

Následná redukčná alkylácia sa uskutočňuje výhodne vo vhodnom rozpúšťadle ako je napríklad metanol, metanol/voda, metanol/voda/amoniak, etanol, éter, tetrahydrofurán, dioxán alebo dimetylformamid voliteľne za pridania kyseliny ako je napríklad kyselina chlorovodíková v prítomnosti katalytický aktívneho vodíka, napríklad vodíka v prítomnosti Raneyovho niklu, platiny alebo paládia/uhlia, alebo v prítomnosti hydridu kovu ako je napríklad hydrid sodno-boritý, hydrid borito-lítny alebo hydrid lítno-hlinitý pri teplote medzi 0 až 100 °C, výhodne pri teplote medzi 20 až 80 °C.Subsequent reductive alkylation is preferably carried out in a suitable solvent such as methanol, methanol / water, methanol / water / ammonia, ethanol, ether, tetrahydrofuran, dioxane or dimethylformamide optionally with the addition of an acid such as hydrochloric acid in the presence of catalytically active hydrogen, e.g. in the presence of Raney nickel, platinum or palladium / coal, or in the presence of a metal hydride such as sodium borohydride, lithium boron hydride or lithium aluminum hydride at a temperature between 0 to 100 ° C, preferably at a temperature between 20 to 80 ° C.

Následná alkylácia sa uskutočňuje s pomocou alkylačného činidla ako je napríklad alkylhalogenid alebo dialkylsulfát, napríklad metyljodid, dimetylsulfát alebo propylbromid, vhodne v rozpúšťadle ako je napríklad metanol, etanol, metylénchlorid, tetrahydrofurán, toluol, dioxán, dimetylsulfoxid alebo dimetylformamid, voliteľne v prítomnosti anorganickej alebo terciámej organickej zásadySubsequent alkylation is carried out with an alkylating agent such as an alkyl halide or dialkyl sulfate, for example methyl iodide, dimethyl sulfate or propyl bromide, suitably in a solvent such as methanol, ethanol, methylene chloride, tetrahydrofuran, toluol, dioxane, dimethylsulfoxide or dimethylformamide, optionally in organic bases

-18ako je napríklad trietylamín, /V-etyl-diizopropylamín alebo dimetylaminopyridín, výhodne pri teplote medzi 20 °C a teplotou varu použitého rozpúšťadla.For example, triethylamine, N-ethyl-diisopropylamine or dimethylaminopyridine, preferably at a temperature between 20 ° C and the boiling point of the solvent used.

Následná acylácia sa uskutočňuje v rozpúšťadle ako je napríklad metylénchlorid, dietyléter, tetrahydrofurán, toluol, dioxán, acetonitril, dimetylsulfoxid alebo dimetylformamid, voliteľne v prítomnosti anorganickej alebo terciárnej organickej zásady, výhodne pri teplote medzi 20 °C a teplotou varu použitého rozpúšťadla. Pritom sa acylácia uskutočňuje so zodpovedajúcou kyselinou, výhodne v prítomnosti dehydratačného činidla, napríklad v prítomnosti izobutylesteru kyseliny chlórmravčej, tetraetylesteru kyseliny ortouhličitej, trimetylesteru kyseliny ortooctovej, 2,2-dimetoxypropánu, tetrametoxysilánu, tionylchloridu, trimetylchlórsilánu, chloridu fosforitého, oxidu fosforečného, Λ/,ΛΓ-dicyklohexylkarbodiimidu, /V,/V’-dicyklohexylkarbodiimidu//V-hydroxysukcinimidu, Λ/,/V’-dicyklohexylkarbodiimidu/1-hydroxy-benzotriazolu, 2-(1 H-benzotriazol-1-yl)-1,1,3,3-tetrametyluróniumtetrafluórboritanu, 2-(1 H-benzotriazol-1 -y l)-1,1,3,3-tetrametylurónium-tetrafluórboritanu/1-hydroxy-benzotriazolu, Λ/,Λ/’-karbonyldiimidazolu alebo trifenylfosfínu/chloridu uhličitého, a voliteľne za pridania zásady ako je napríklad pyridín, 4dimetylaminopyridín, /V-metyl-morfolín alebo trietylamín, vhodne pri teplote medzi 0 až 150 °C, výhodne pri teplote medzi 0 až 100 °C, a acylácia so zodpovedajúcou reaktívnou zlúčeninou ako je napríklad ich anhydrid, ester, imidazolid alebo halogenid voliteľne v prítomnosti terciárnej organickej zásady ako je napríklad trietylamín, /V-etyl-diizopropylamín alebo /V-metyl-morfolín pri teplote medzi 0 až 150 °C, výhodne pri teplote medzi 50 až 100 °C.Subsequent acylation is carried out in a solvent such as methylene chloride, diethyl ether, tetrahydrofuran, toluene, dioxane, acetonitrile, dimethylsulfoxide or dimethylformamide, optionally in the presence of an inorganic or tertiary organic base, preferably at a temperature between 20 ° C and the boiling point of the solvent used. The acylation is carried out with the corresponding acid, preferably in the presence of a dehydrating agent, for example in the presence of isobutyl chloroformate, tetraethyl carbonate, trimethyl orthoacetate, 2,2-dimethoxypropane, tetramethoxysilane, thionyl chloride, trimethylchloride, trimethylchloride, ΛΓ-dicyclohexylcarbodiimide, N, N'-dicyclohexylcarbodiimide, N -hydroxysuccinimide, N, N'-dicyclohexylcarbodiimide / 1-hydroxy-benzotriazole, 2- (1H-benzotriazol-1-yl) -1,1, 3,3-tetramethyluronium tetrafluoroborate, 2- (1H-benzotriazol-1-yl) -1,1,3,3-tetramethyluronium tetrafluoroborate / 1-hydroxy-benzotriazole, Λ /, Λ / - carbonyldiimidazole or triphenylphosphine / carbon tetrachloride , and optionally with the addition of a base such as pyridine, 4-dimethylaminopyridine, N-methylmorpholine or triethylamine, suitably at a temperature between 0 to 150 ° C, preferably at a temperature between 0 to 100 ° C, and acyla cia with a corresponding reactive compound such as their anhydride, ester, imidazole or halide optionally in the presence of a tertiary organic base such as triethylamine, N-ethyl-diisopropylamine or N-methyl-morpholine at a temperature between 0 to 150 ° C, preferably at a temperature between 50 and 100 ° C.

Následná esterifikácia alebo amidizácia sa uskutočňuje vhodne reakciou reaktívneho zodpovedajúceho derivátu kyseliny uhličitej so zodpovedajúcim alkoholom alebo amínom podľa uvedeného opisu.Subsequent esterification or amidization is conveniently carried out by reacting a reactive corresponding carbonic acid derivative with the corresponding alcohol or amine as described above.

Pri uvedených reakciách sa prítomné reaktívne skupiny, ako je napríklad karboxy-, amino-, alkylamino- alebo iminoskupina, môžu počas reakcie voliteľne chrániť obvyklými ochrannými skupinami, ktoré sa po reakcii opäť odštiepia.In the above reactions, the reactive groups present, such as, for example, carboxy, amino, alkylamino or imino, may optionally be protected during the reaction by conventional protecting groups which are cleaved again after the reaction.

Ochranný zvyšok pre karboxylovú skupinu môže byť trimetylsilylová, metylová, etylová, ŕerc-butylová, benzylová alebo tetrahydropyranylová skupina, aThe protecting group for the carboxyl group may be trimethylsilyl, methyl, ethyl, tert-butyl, benzyl or tetrahydropyranyl, and

-19ochranný zvyšok pre amino-, alkylamino- alebo iminoskupinu môže byť acetylová, trifluóracetylová, benzoylová, etoxykarbonylová, terc-butoxykarbonylová, benzyloxykarbonylová, benzylová, metoxybenzylová aiebo 2,4-dimetoxybenzylová skupina a pre aminoskupinu dodatočne aj ftalylová skupina.The protecting group for the amino, alkylamino or imino group may be acetyl, trifluoroacetyl, benzoyl, ethoxycarbonyl, tert-butoxycarbonyl, benzyloxycarbonyl, benzyl, methoxybenzyl or 2,4-dimethoxybenzyl group, and additionally phthalyl for the amino group.

Voliteľné následné odštiepenie použitej ochrannej skupiny sa uskutočňuje napríklad hydrolyticky vo vodnom rozpúšťadle ako je napríklad voda, izopropanol/voda, tetrahydrofurán/voda alebo dioxán/voda, v prítomnosti kyseliny ako je napríklad kyselina trifluóroctová, kyselina chlorovodíková alebo kyselina sírová, alebo v prítomnosti alkalickej zásady ako je napríklad hydroxid lítny, hydroxid sodný aiebo hydroxid draselný pri teplote medzi 0 až 100 °C, výhodne pri teplote medzi 10 až 50 °C.The optional subsequent cleavage of the protecting group used is carried out, for example, hydrolytically in an aqueous solvent such as water, isopropanol / water, tetrahydrofuran / water or dioxane / water, in the presence of an acid such as trifluoroacetic acid, hydrochloric acid or sulfuric acid, or in the presence of an alkaline base. such as lithium hydroxide, sodium hydroxide or potassium hydroxide at a temperature between 0 to 100 ° C, preferably at a temperature between 10 to 50 ° C.

Odštiepenie benzylového, metoxybenzylového alebo benzyloxykarbonylového zvyšku sa uskutočňuje napríklad hydrogenolyticky, napríklad s vodíkom v prítomnosti katalyzátora ako je napríklad paládium/uhlie v rozpúšťadle ako je napríklad metanol, etanol, etylester kyseliny octovej, dimetylformamid, dimetylformamid/acetón alebo ľadová kyselina octová, voliteľne za pridania kyselina ako je kyselina chlorovodíková alebo ľadová kyselina octová pri teplote medzi 0 až 50 °C, výhodne však pri izbovej teplote, a pri tlaku vodíka 102 až 7.102 kPa (1 až 7 barov), výhodne však pri 3.102 až 5.102 kPa (3 až 5 baroch).The cleavage of the benzyl, methoxybenzyl or benzyloxycarbonyl radical is carried out, for example, hydrogenolytically, for example with hydrogen in the presence of a catalyst such as palladium / carbon in a solvent such as methanol, ethanol, ethyl acetate, dimethylformamide, dimethylformamide / acetone or glacial acetic acid. an acid such as hydrochloric acid or glacial acetic acid at a temperature between 0 to 50 ° C, preferably at room temperature, and at a hydrogen pressure of 10 2 to 7.10 2 kPa (1 to 7 bar), preferably at 3.10 2 to 5.10 2 kPa (3 to 5 bar).

Odštiepenie metoxybenzylovej skupiny sa môže uskutočniť aj v prítomnosti oxidačného činidla ako je napríklad amóniumnitrát ceričitý v rozpúšťadle ako je napríklad metylénchlorid, acetonitril alebo acetonitril/voda pri teplote medzi 0 až 50 °C, výhodne však pri izbovej teplote.The cleavage of the methoxybenzyl group may also be carried out in the presence of an oxidizing agent such as cerium ammonium nitrate in a solvent such as methylene chloride, acetonitrile or acetonitrile / water at a temperature between 0 to 50 ° C, preferably at room temperature.

Odštiepenie 2,4-dimetoxybenzylového zvyšku sa však uskutočňuje výhodne v kyseline trifluóroctovej v prítomnosti anizolu.However, the cleavage of the 2,4-dimethoxybenzyl residue is preferably carried out in trifluoroacetic acid in the presence of anisole.

Odštiepenie terc-butylového alebo ŕerc-butyloxykarbonylového zvyšku sa uskutočňuje výhodne vystavením účinku kyseliny ako je napríklad kyselina trifluóroctová alebo kyselina chlorovodíková s použitím rozpúšťadla ako je napríklad metylénchlorid, dioxán, ester kyseliny octovej alebo éter.The cleavage of the tert-butyl or tert-butyloxycarbonyl moiety is preferably effected by exposure to an acid such as trifluoroacetic acid or hydrochloric acid using a solvent such as methylene chloride, dioxane, acetic acid ester or ether.

Odštiepenie ftalylového zvyšku sa uskutočňuje výhodne v prítomnosti hydrazínu alebo primárneho amínu ako je napríklad metylamín, etylamín alebo n-20butylamín v rozpúšťadle ako je napríklad metanol, etanol, izopropanol, toluol/voda alebo dioxán pri teplote medzi 20 až 50 °C.The cleavage of the phthalyl residue is preferably carried out in the presence of hydrazine or a primary amine such as methylamine, ethylamine or n-20-butylamine in a solvent such as methanol, ethanol, isopropanol, toluene / water or dioxane at a temperature between 20-50 ° C.

Ďalej je možné získané chirálne zlúčeniny všeobecného vzorca I rozdeliť na ich enantioméry a/alebo diastereoméry.Furthermore, the obtained chiral compounds of the formula I can be separated into their enantiomers and / or diastereomers.

Takto sa dajú napríklad získané zlúčeniny všeobecného vzorca I, ktoré sa vyskytujú v racemátoch, rozdeliť s použitím známych spôsobov (pozri Allinger N.L. a Eliel E.L. v „Topics in Stereochemistry“, zväzok 6, Wiley Interscience, 1971) na optické antipódy, a zlúčeniny všeobecného vzorca I s aspoň 2 asymetrickými atómami uhlíka sa dajú na základe fyzikálno-chemických rozdielov rozdeliť s použitím známych spôsobov, napríklad chromatograficky a/alebo trakčnou kryštalizáciou, na diastereoméry, ktoré, ak sú v racemickej forme, sa môžu následne rozdeliť uvedeným spôsobom na enantioméry.Thus, for example, the obtained compounds of the formula I which occur in the racemates can be separated into optical antipodes using known methods (see Allinger NL and Eliel EL in "Topics in Stereochemistry", Volume 6, Wiley Interscience, 1971), and compounds of the general formula of the formula I with at least 2 asymmetric carbon atoms can be separated into diastereomers by known methods, for example by chromatography and / or traction crystallization, based on physicochemical differences, which, if in a racemic form, can subsequently be separated into the enantiomers in that manner.

Rozdelenie enantiomérov sa uskutočňuje výhodne delením v kolóne na chirálne fázy alebo kryštalizáciou z opticky aktívneho rozpúšťadla alebo reakciou s opticky aktívnou látkou, ktorá s racemickou zlúčeninou tvorí soli alebo deriváty ako sú napríklad estery alebo amidy, osobitne kyseliny a ich aktivované deriváty alebo alkoholy, a rozdelenie týmto spôsobom získanej zmesi diastereomérnych solí alebo derivátov, napríklad na základe rozdielnej rozpustnosti, pričom z čistých diastereomérnych solí alebo derivátov sa pôsobením vhodných činidiel môžu uvoľniť voľné antipódy. Osobitne užitočné opticky aktívne kyseliny sú napríklad D- a L-formy kyseliny vínnej, kyseliny dibenzoylvínnej, kyseliny di-o-tolylvínnej, kyseliny jablčnej, kyseliny mandľovej, kyseliny gáforsulfónovej, kyseliny glutamínovej, kyseliny /V-acetylglutamínovej, kyseliny asparágovej, kyseliny /V-acetyl-asparágovej alebo kyseliny chinovej. Opticky aktívny alkohol môže byť napríklad (+) alebo (-)mentol a opticky aktívny acylový zvyšok v amidoch môže byť napríklad (+) alebo (-)-mentyloxykarbonylový zvyšok.The resolution of the enantiomers is preferably carried out by column separation into chiral phases or by crystallization from an optically active solvent or by reaction with an optically active substance which forms salts or derivatives such as esters or amides, especially acids and their activated derivatives or alcohols, with the racemic compound. mixtures of diastereomeric salts or derivatives obtained in this way, for example because of different solubilities, whereby free antipodes can be released from the pure diastereomeric salts or derivatives by treatment with suitable agents. Particularly useful optically active acids are, for example, the D- and L-forms of tartaric acid, dibenzoyltartaric acid, di-o-tolyltartaric acid, malic acid, mandelic acid, camphorsulfonic acid, glutamic acid, N-acetylglutamic acid, aspartic acid, V acetyl aspartic or quinic acid. The optically active alcohol may be, for example, (+) or (-) menthol, and the optically active acyl residue in the amides may be, for example, a (+) or (-) - mentyloxycarbonyl radical.

Okrem toho možno získané zlúčeniny vzorca I prekonvertovať na ich soli, osobitne pre farmaceutické použitie na ich farmaceutický prijateľné soli s anorganickými alebo organickými kyselinami. Kyseliny môžu byť napríklad kyselina chlorovodíková, kyselina bromovodíková, kyselina sírová, kyselinaIn addition, the compounds of formula I obtained can be converted into their salts, especially for pharmaceutical use, into their pharmaceutically acceptable salts with inorganic or organic acids. The acids may be, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, acid

-21 fosforečná, kyselina fumarová, kyselina jantárová, kyselina mliečna, kyselina citrónová, kyselina vínna, kyselina maleinová alebo kyselina metánsulfónová.-21 phosphoric acid, fumaric acid, succinic acid, lactic acid, citric acid, tartaric acid, maleic acid or methanesulfonic acid.

Okrem toho sa takýmto spôsobom získané nové zlúčeniny vzorca I, ak obsahujú karboxyskupinu, dajú v prípade potreby následne prekonvertovať na ich soli s anorganickými alebo organickými zásadami, osobitne pre farmaceutické použitie na ich fyziologicky prijateľné soli. Zásady môžu byť napríklad hydroxid sodný, hydroxid draselný, cyklohexylamín, etanolamín, dietanolamín a trietanolamín.In addition, the novel compounds of the formula I obtained in this way, if they contain a carboxy group, can be subsequently converted, if necessary, into their salts with inorganic or organic bases, especially for pharmaceutical use, into their physiologically acceptable salts. The bases may be, for example, sodium hydroxide, potassium hydroxide, cyclohexylamine, ethanolamine, diethanolamine and triethanolamine.

Zlúčeniny použité ako východiskové produkty všeobecného vzorca I až VIII sú čiastočne známe z literatúry, alebo sa získavajú spôsobmi známymi z literatúry, alebo budú opísané v príkladoch.The compounds used as starting products of formulas (I) to (VIII) are partly known from the literature, or are obtained by methods known from the literature, or will be described in the examples.

Ako je to uvedené už na začiatku, nové zlúčeniny všeobecného vzorca I, v ktorých R1 je vodík alebo zvyšok prekurzora, majú cenné farmakologické vlastnosti, osobitne inhibičné účinky na rôzne kinázy a komplexy cyklín/CDK, na proliferáciu kultivovaných ľudských nádorových buniek, a taktiež po ústnom podaní na rast nádorov v nahých myšiach, ktoré boli predtým infikované ľudskými nádorovými bunkami.As indicated at the outset, the novel compounds of formula I, wherein R 1 is hydrogen or a prodrug group have valuable pharmacological properties, particularly inhibitory effects on various kinases and cyclin / CDK complexes, on the proliferation of cultivated human tumor cells, and also after oral administration to tumor growth in nude mice previously infected with human tumor cells.

Napríklad u zlúčenín uvedených v tabuľke 1 sa nasledovným spôsobom testovali ich biologické vlastnosti:For example, the compounds listed in Table 1 were tested for their biological properties as follows:

Test 1Test 1

Inhibícia enzýmu cyklín/CDK, aktivita in vitroInhibition of the enzyme cyclin / CDK, in vitro activity

Hmyzie bunky High Five™ (BTI-TN-5B1-4), ktoré sa infikovali vysokým titrom rekombinantného bakulovírusu, sa použili na produkciu aktívnych ľudských holoenzýmov cyklín/CDK. S použitím bakulovírusového vektoru, ktorý obsahoval dva promótory (promótor podporujúci polyhedrín, promótor podporujúci P10) sa exprimovali v tej istej bunke GST-značené cyklíny (napríklad cyklín D1 alebo cyklín D3) so zodpovedajúcou His6-značenou CDK podjednotkou (napríklad pre CDK4 alebo CDK6). Aktívny holoenzým sa izoloval afinitnou chromatografiou na glutatióne/Sepharose. Rekombinantný GST-značené pRB (aa 379 až 928) saHigh Five ™ insect cells (BTI-TN-5B1-4) infected with high titer recombinant baculovirus were used to produce active human cyclin / CDK holoenzymes. Using a baculovirus vector containing two promoters (polyhedrin-promoting promoter, P10-promoter), GST-labeled cyclins (e.g., cyclin D1 or cyclin D3) were expressed in the same cell with the corresponding His 6 -labeled CDK subunit (e.g., for CDK4 or CDK6). ). The active holoenzyme was isolated by glutathione / Sepharose affinity chromatography. Recombinant GST-labeled pRB (aa 379-928) was

-22vyprodukoval v E. coli a vyčistil sa afinitnou chromatografiou na glutatióne/Sepharose.-22 produced in E. coli and purified by glutathione / Sepharose affinity chromatography.

Substráty, ktoré sa použili pre kinázové testy, záviseli od špecifických kináz. Histón H1 (Sigma) sa použil ako substrát pre cyklín E/CDK2, cyklín A/CDK2, cyklín B/CDK1 a pre v-cyklín/CDK6. GST-značený pRB (aa 379 až 928) sa použil ako substrát pre cyklín D1/CDK4, cyklín D3/CDK4, cyklín D1/CDK6 a pre cyklín D3/CDK6.The substrates used for kinase assays were dependent on specific kinases. Histone H1 (Sigma) was used as a substrate for cyclin E / CDK2, cyclin A / CDK2, cyclin B / CDK1, and v-cyclin / CDK6. GST-labeled pRB (aa 379-928) was used as a substrate for cyclin D1 / CDK4, cyclin D3 / CDK4, cyclin D1 / CDK6, and cyclin D3 / CDK6.

Lyzáty s rekombinantnými hmyzími bunkami infikovanými bakulovírusom alebo aj rekombinantné kinázy (získané čistením z lyzátov) sa inkubovali 45 minút pri 30 °C spolu s rádioaktívne značeným ATP v prítomnosti vhodného substrátu s rôznymi koncentráciami inhibítora v 1%-nom roztoku DMSO (dimetylsulfoxidu). Substrátové proteíny s asociovanou rádioaktivitou sa vyzrážali s 5%-nou TCA (kyselinou trichlóroctovou) v hydrofóbnych PVDF viacjamkových mikrotitračných platničkách (Millipore) alebo s 0,5%-ným roztokom kyseliny fosforečnej na filtroch Whatman P81. Po pridaní scintilačného roztoku sa rádioaktivita merala v kvapalnom scintilačnom počítači 1450 Microbeta firmy Wallace. Pre každú koncentráciu látky sa uskutočnili dve merania; pre inhibíciu enzýmu sa vypočítali hodnoty IC50.Lysates with recombinant baculovirus-infected insect cells or even recombinant kinases (obtained from lysate purification) were incubated for 45 minutes at 30 ° C together with radiolabeled ATP in the presence of a suitable substrate at various inhibitor concentrations in 1% DMSO (dimethylsulfoxide). Substrate proteins with associated radioactivity were precipitated with 5% TCA (trichloroacetic acid) in hydrophobic PVDF multiwell microtiter plates (Millipore) or with a 0.5% phosphoric acid solution on Whatman P81 filters. After addition of the scintillation solution, radioactivity was measured in a 1450 Microbeta liquid scintillation counter from Wallace. Two measurements were performed for each substance concentration; for enzyme inhibition was calculated the IC 50th

Test 2Test 2

Inhibícia proliferácie kultivovaných ľudských nádorových buniekInhibition of proliferation of cultured human tumor cells

Bunky nádorovej bunkovej línie SK-UT-1B odvodené z leiomyosarkómu (získané z American Type Culture Collection (ATCC) sa kultivovali v minimálnom esenciálnom médiu s neesenciálnymi aminokyselinami (Gibco) doplnenom pyruvátom sodným (1 mmol), glutamínom (2 mmol) a 10%-ným fetálnym hovädzím sérom (Gibco) a pozbierali sa v logaritmickej fáze rastu. Potom sa bunky SK-UT-1B umiestnili vo viacjamkových platničkách typu Cytostar® (Amersham) s hustotou 4000 buniek na jamku a inkubovali sa cez noc v inkubátore. K bunkám sa pridali rôzne koncentrácie zlúčenín (rozpustené v DMSO; koncová koncentrácia <1%). Po 48 hodinách inkubácie sa do každej jamky pridal 14C-tymidín (Amersham) aLeiomyosarcoma-derived tumor cell line SK-UT-1B (obtained from the American Type Culture Collection (ATCC)) was cultured in minimal essential medium with non-essential amino acids (Gibco) supplemented with sodium pyruvate (1 mmol), glutamine (2 mmol) and 10% fetal bovine serum (Gibco) and harvested in logarithmic growth phase, then SK-UT-1B cells were plated in Cytostar® type multi-well plates (Amersham) at 4000 cells per well and incubated overnight in an incubator. various concentrations of compounds (dissolved in DMSO; final concentration < 1%) were added After 48 hours incubation, 14 C-thymidine (Amersham) was added to each well.

-23platnička sa inkubovala ďalších 24 hodín. Množstvo 14C-tymidínu, ktoré sa v prítomnosti inhibítora inkorporovalo do nádorových buniek a znamená počet buniek v S-fáze, sa odmerala v kvapalnom scintilačnom počítači 1450 Microbeta firmy Wallace. Vypočítali sa hodnoty IC50 pre inhibíciu proliferácie (= inhibícia inkorporovaného 14C-tymidínu) s korekciou na základné žiarenie pozadia. Všetky merania sa uskutočnili dvakrát.The plate was incubated for an additional 24 hours. The amount of 14 C-thymidine which was incorporated into the tumor cells in the presence of the inhibitor and represents the number of cells in the S-phase was measured in a 1450 Microbeta liquid scintillation counter from Wallace. IC 50 values for inhibition of proliferation (= inhibition of incorporated 14 C-thymidine) corrected for background background radiation were calculated. All measurements were performed in duplicate.

Test 3Test 3

Účinky in vivo na nahých myšiach s nádormiIn vivo effects on nude tumor-bearing mice

Samčím a/alebo samičím nahým myšiam (NMRI nu/nu; 25 až 35 g; N = 10 až 20) sa podkožné injikovalo 10® buniek [SK-UT-1B alebo buniek z nemalobunkového pľúcneho nádoru NCI-H460 (získané z ATCC) v objeme 0,1 ml; alebo sai podkožné implantovali malé zhluky buniek SK-UT-1B alebo NCI-H460. Jeden až tri týždne po injikovaní prípadne implantovaní sa ústne pomocou sondy podával kinázový inhibítor denne po dobu 2 až 4 týždňov. Veľkosť nádorov sa merala trikrát týždenne pomocou digitálneho meradla. Účinok kinázového inhibítoru na rast nádoru sa určoval ako percento inhibície v porovnaní s kontrolnou skupinou, ktoréi dostávala placebo.Male and / or female nude mice (NMRI nu / nu; 25-35 g; N = 10-20) were injected subcutaneously with 10® cells [SK-UT-1B or non-small cell lung tumor NCI-H460 (obtained from ATCC) in a volume of 0.1 ml; or small clusters of SK-UT-1B or NCI-H460 cells were implanted subcutaneously. One to three weeks after injection or implantation, a kinase inhibitor was administered orally daily with a probe for 2 to 4 weeks. Tumor size was measured three times a week using a digital scale. The effect of kinase inhibitor on tumor growth was determined as a percentage of inhibition compared to the control group receiving placebo.

Nasledujúca tabuľka obsahuje zistené výsledky Testu 2 in vitro.The following table shows the results of Test 2 in vitro.

Zlúčenina (Príklad č.) Compound (Example #) Inhibícia proliferácie buniek SK-UT-1B IC50 [μΜ]Inhibition of SK-UT-1B IC 50 Cell Proliferation [μΜ] 4(2) 4 (2) 0,17 0.17 4(14) 4 (14) 0,18 0.18 4(62) 4 (62) 0,05 0.05 4(53) 4 (53) 0,01 0.01 4(54) 4 (54) 0,03 0.03 4(60) 4 (60) 0,03 0.03 4(120) 4 (120) 0,04 0.04 4(122) 4 (122) 0,04 0.04 4(94) 4 (94) 0,03 0.03 3(3) 3 (3) 0,01 0.01 3(7) 3 (7) 0,01 0.01 4(129) 4 (129) 0,04 0.04

-24Na základe svojich biologických vlastností sú nové zlúčeniny všeobecného vzorca I, ich izoméry a ich fyziologicky prijateľné soli vhodné na liečbu ochorení, pre ktoré je charakteristické nadmerné alebo anomálne množenie buniek.Because of their biological properties, the novel compounds of formula (I), their isomers and their physiologically acceptable salts are useful in the treatment of diseases characterized by excessive or anomalous cell proliferation.

K takýmto ochoreniam patria (bez nároku na úplnosť): infekcie vírusového pôvodu (napríklad HIV a Kaposiho sarkóm); zápaly a autoimúnne choroby (napríklad kolitída, artritída, Alzheimerova choroba, glomerulonefritída a hojenie rán); bakteriálne, plesňové a/alebo parazitárne infekcie; leukémie, lymfómy a solídne nádory; choroby kože (napríklad psoriáza); choroby kostí; kardiovaskulárne choroby (napríklad restenóza a hypertrofia). Ďalej sú užitočné ako ochrana proliferujúcich buniek (napríklad buniek vlasov, čreva, krvi a progenitorových buniek) pred poškodením DNA žiarením, UV svetlom a/alebo cytostatickou liečbou.Such diseases include, but are not limited to: infections of viral origin (e.g., HIV and Kaposi's sarcoma); inflammation and autoimmune diseases (e.g., colitis, arthritis, Alzheimer's disease, glomerulonephritis and wound healing); bacterial, fungal and / or parasitic infections; leukemias, lymphomas and solid tumors; skin diseases (e.g., psoriasis); bone diseases; cardiovascular diseases (e.g. restenosis and hypertrophy). Furthermore, they are useful for protecting proliferating cells (e.g., hair, intestine, blood and progenitor cells) from DNA damage by radiation, UV light and / or cytostatic treatment.

Nové zlúčeniny možno použiť na krátkodobú alebo dlhodobú liečbu uvedených ochorení a voliteľne aj v kombinácii s inými štandardnými zlúčeninami ako sú napríklad ostatné cytostatiká.The novel compounds can be used for the short or long term treatment of said diseases and optionally also in combination with other standard compounds such as other cytostatics.

Na dosiahnutie zodpovedajúceho účinku požadované dávkovanie je pri vnútrožilovom podávaní vhodne 0,1 až 30 mg/kg, výhodne 0,3 až 10 mg/kg, a pri ústnom podávaní 0,1 až 100 mg/kg, výhodne 0,3 až 30 mg/kg, a to 1- až 4-krát denne. Pre tieto účely sa zlúčeniny všeobecného vzorca I pripravené podľa tohto vynálezu, voliteľne v kombinácii s inými účinnými látkami, spolu s jedným alebo viacerými inertnými obvyklými nosičmi a/alebo riedidlami, ako je napríklad kukuričný škrob, mliečny cukor, trstinový cukor, mikrokryštalická celulóza, stearan horečnatý, polyvinylpyrolidón, kyselina citrónová, kyselina vínna, voda, voda/etanol, voda/glycerín, voda/sorbit, voda/polyetylénglykol, propylénglykol, cetylstearylalkohol, karboxymetylcelulóza alebo mastné látky, ako napríklad tuk alebo ich vhodné zmesi, môžu začleniť do obvyklých galenických prípravkov ako sú napríklad tablety, dražé, kapsuly, prášky, suspenzie, čapíky alebo roztoky na injekcie alebo infúzie.To achieve a corresponding effect, the desired dosage is suitably 0.1 to 30 mg / kg, preferably 0.3 to 10 mg / kg, and 0.1 to 100 mg / kg, preferably 0.3 to 30 mg, for intravenous administration. / kg, 1 to 4 times a day. For this purpose, the compounds of the formula I prepared according to the invention, optionally in combination with other active ingredients, together with one or more inert customary carriers and / or diluents such as corn starch, milk sugar, cane sugar, microcrystalline cellulose, stearate magnesium, polyvinylpyrrolidone, citric acid, tartaric acid, water, water / ethanol, water / glycerin, water / sorbitol, water / polyethylene glycol, propylene glycol, cetyl stearyl alcohol, carboxymethylcellulose or fatty substances such as fat or suitable mixtures thereof may be incorporated into conventional galenic preparations such as tablets, dragees, capsules, powders, suspensions, suppositories or solutions for injection or infusion.

Nasledovné príklady majú vynález podrobnejšie vysvetliť.The following examples are intended to explain the invention in more detail.

-25Prikladv uskutočnenia vynálezuExemplary embodiments of the invention

Príprava 1Preparation 1

Metylester kyseliny 1-acetyl-2-indolinón-5-karboxylovej1-Acetyl-2-indolinone-5-carboxylic acid methyl ester

10,5 g metylesteru kyseliny 2-indolinón-5-karboxylovej (pripravenej analogicky podľa Ogawu a spol., Chem. Pharm. Bull 36, 2253 - 2258 (1988)) sa mieša v 30 ml acetanhydridu 4 hodiny pri 140 °C. Nechá sa potom vychladnúť, prileje sa ľadová voda a zrazenina sa odsaje. Produkt sa ešte raz premyje vodou, potom sa pozbiera v metylénchloride, nad síranom sodným sa vysuší a skoncentruje.10.5 g of 2-indolinone-5-carboxylic acid methyl ester (prepared analogously to Ogaw et al., Chem. Pharm. Bull 36, 2253-2258 (1988)) is stirred in 30 ml of acetic anhydride for 4 hours at 140 ° C. It is then allowed to cool, ice water is added and the precipitate is filtered off with suction. The product was washed once more with water, then collected in methylene chloride, dried over sodium sulfate and concentrated.

Výťažok: 11 g (86 % teoretickej hodnoty)Yield: 11 g (86% of theory)

Rf: 0,63 (silikagél; metylénchlorid/metanol = 50:1) Rf: 0.63 (silica gel; methylene chloride / methanol = 50: 1)

Príprava 2Preparation 2

Metylester kyseliny 1 -acetyl-3-(1 -etoxy-1 -fenyl-metylén)-2-indolinón-5-karboxylovej g metylesteru kyseliny 1-acetyl-2-indolinón-5-karboxylovej sa mieša v 110 ml acetanhydridu a 30 ml trietylesteru kyseliny ortobenzoovej 2 hodiny pri 100 °C. Potom sa zmes odparí, zvyšok sa premyje éterom a odsaje sa.1-Acetyl-3- (1-ethoxy-1-phenyl-methylene) -2-indolinone-5-carboxylic acid methyl ester 1-acetyl-2-indolinone-5-carboxylic acid methyl ester is stirred in 110 ml acetic anhydride and 30 ml triethyl orthobenzoate for 2 hours at 100 ° C. The mixture is evaporated, the residue is washed with ether and filtered off with suction.

Výťažok: 11,5 g (67 % teoretickej hodnoty)Yield: 11.5 g (67% of theory)

Rf: 0,55 (silikagél; metylénchlorid/petroléter/ester kyseliny octovej = 4:5:1) Rf: 0.55 (silica gel, methylene chloride / petroleum ether / ethyl acetate = 4: 5: 1)

Príprava 3Preparation

28,0 g Rinkovej živice (MBHA-živica, Novobiochem) sa nechá nabobtnať v 330 ml dimetylformamidu. Potom sa pridá 330 ml 30%-ného piperidínu v dimetylformamide a trepe sa 7 minút, aby sa odštiepila ochranná skupina FMOC. Potom sa živica niekoľkokrát premyje dimetylformamidom. Pridá sa 7,3 g kyseliny 2indolinón-5-karboxylovej, 5,6 g hydroxybenzotriazolu, 13,3 g O-(benzotriazol-l-yl)Λ/,Λ/,Λ/',Λ/’-tetrametyl-urónium-tetrafluoroboritanu a 5,7 ml W-etyl-diizopropylamínu v28.0 g of Rink resin (MBHA resin, Novobiochem) was swelled in 330 ml of dimethylformamide. Then 330 ml of 30% piperidine in dimethylformamide is added and shaken for 7 minutes to cleave the FMOC protecting group. The resin is then washed several times with dimethylformamide. 7.3 g of 2-indolinone-5-carboxylic acid, 5.6 g of hydroxybenzotriazole, 13.3 g of O- (benzotriazol-1-yl) Λ /, Λ /, Λ /,, Λ / tetramethyluronium- tetrafluoroborate and 5.7 ml of N-ethyl-diisopropylamine v

-26300 ml dimetylformamidu a trepe sa 1 hodinu. Roztok sa odsaje a živica sa premyje päťkrát s 300 ml dimetylformamidu a trikrát s 300 ml metylénchloridu. Vysuší sa prebublávaním dusíka cez živicu.-26300 ml of dimethylformamide and shaken for 1 hour. The solution is filtered off with suction and the resin is washed five times with 300 ml of dimethylformamide and three times with 300 ml of methylene chloride. It is dried by bubbling nitrogen through the resin.

Výťažok: 28 g naplnenej živiceYield: 28 g filled resin

Príprava 4 g živice pripravenej podľa prípravy 3 sa mieša 1 hodinu pri 80 °C s 15 ml acetanhydridu. Potom sa pridá 15 ml trietylesteru kyseliny ortobenzoovej a trepe sa ďalšie 3 hodiny pri 110 °C. Potom sa živica odsaje a premyje sa dimetylformamidom, metanolom a napokon metylénchloridom.PREPARATION 4 g of the resin prepared according to preparation 3 are stirred for 1 hour at 80 DEG C. with 15 ml of acetic anhydride. 15 ml of triethyl orthobenzoate are then added and the mixture is shaken for a further 3 hours at 110 ° C. The resin is then filtered off with suction and washed with dimethylformamide, methanol and finally methylene chloride.

Výťažok: 7 g vlhkej živiceYield: 7 g wet resin

Príprava 5Preparation

4-(Etylamino-metyl)-nitrobenzén g nitrobenzylbromidu sa rozpustí v 25 ml etanolu, zmieša sa s 25 ml 10%ného roztoku etylamínu v etanole a 2 hodiny sa ohrieva do spätného toku. Potom sa roztok odparí, zvyšok sa pozbiera v metylénchloride a premyje sa zriedeným lúhom sodným. Napokon sa organická fáza skoncentruje.4- (Ethylamino-methyl) -nitrobenzene g of nitrobenzyl bromide was dissolved in 25 ml of ethanol, treated with 25 ml of a 10% solution of ethylamine in ethanol and heated at reflux for 2 hours. Then the solution is evaporated, the residue is taken up in methylene chloride and washed with dilute sodium hydroxide solution. Finally, the organic phase is concentrated.

Výťažok: 2,3 g (46 % teoretickej hodnoty)Yield: 2.3 g (46% of theory)

Rf: 0,2 (silikagél; metylénchlorid/metanol = 9:1) Rf: 0.2 (silica gel, methylene chloride / methanol = 9: 1)

Analogicky sa pripravuje:Similarly prepared:

4-[/V-(4-chlórfenyl-metyl)-amino-metyl]-nitrobenzén4 - [/ V- (4-chloro-phenyl-methyl) amino-methyl] nitrobenzene

4-(/V-cyklohexyl-amino-metyl)-nitrobenzén4 - (/ V-cyclohexyl-amino-methyl) -nitrobenzene

4-(/V-izopropyl-amino-metyl)-nitrobenzén4 - (/ V-isopropyl-amino-methyl) -nitrobenzene

4-(/V-butyl-amino-metyl)-nitrobenzén4 - (/ V-butyl-methyl-amino) nitrobenzene

4-(/V-metoxykarbonyl-metyl-amino-metyl)-nitrobenzén4 - (/ V-methoxycarbonyl-methyl-amino-methyl) -nitrobenzene

4-(/V-(fenyl-metyl)-amino-metyl)-nitrobenzén4 - (/ V- (phenyl-methyl) aminomethyl) nitrobenzene

4-(pyrolidín-metyl)-nitrobenzén4- (pyrrolidin-methyl) -nitrobenzene

-274-(morfolín-metyl)-nitrobenzén-274- (morpholino-methyl) -nitrobenzene

4-(p i pe rid í n-metyl)-nitrobenzén4- (piperidin-methyl) -nitrobenzene

4-(hexametylénimino)-nitrobenzén4- (hexamethyleneimino) -nitrobenzene

4-(4-hydroxy-piperidín-metyl)-nitrobenzén4- (4-hydroxy-piperidino-methyl) -nitrobenzene

4-(4-metyl-piperidín-metyl)-nitrobenzén4- (4-methyl-piperidino-methyl) -nitrobenzene

4-(4-ety l-piperid í n-metyl)-nitrobenzén4- (4-Ethyl-piperidin-methyl) -nitrobenzene

4-(4-izopropyl-piperidín-metyl)-nitrobenzén4- (4-Isopropyl-piperidin-methyl) -nitrobenzene

4-(4-feny l-piperid í n-mety l)-n itrobenzén4- (4-Phenyl-piperidin-methyl) -nitrobenzene

4-(4-benzyl-piperid í n-mety l)-n itrobenzén4- (4-Benzyl-piperidin-methyl) -nitrobenzene

4-(4-etoxykarbonyl-piperid í n-metyl)-n itrobenzén4- (4-ethoxycarbonyl-piperidin-methyl) -n-itrobenzene

4-(dimetylamino-metyl)-nitrobenzén4- (dimethylamino-methyl) -nitrobenzene

4-(dipropylamino-metyl)-nitrobenzén4- (dipropylamino-methyl) -nitrobenzene

4-(4-ŕerc-butyloxykarbonyl-piperazín-metyl)-nitrobenzén4- (4-tert-butyloxycarbonyl-piperazine-methyl) -nitrobenzene

3- (dimetylamino-metyl)-nitrobenzén3- (dimethylamino-methyl) -nitrobenzene

4- (2-dietylamino-etyl)-nitrobenzén4- (2-diethylamino-ethyl) -nitrobenzene

4-(2-morfolinyl-etyl)-nitrobenzén4- (2-morpholinyl-ethyl) -nitrobenzene

4-(2-pyrolidinyl-etyl)-nitrobenzén4- (2-pyrrolidinyl-ethyl) -nitrobenzene

4-(2-piperid iny l-ety l)-n itrobenzyl4- (2-Piperidinyl-1-ethyl) -n-itrobenzyl

4-(N-etyl-/\/-benzyl-amino-metyl)-nitrobenzén4- (N-ethyl - / \ / - benzyl-amino-methyl) -nitrobenzene

4-(A/-propyl-/V-benzyl-amino-metyl)-nitrobenzén4 (A / -propyl / V-benzyl-amino-methyl) -nitrobenzene

4-[/V-metyl-/\/-(4-chlórfenylmetyl)-amino-metyl])-nitrobenzén4 - [/ V-methyl - / \ / - (4-chlorophenyl methyl) aminomethyl]) - nitrobenzene

4-[/V-metyl-/V-(4-brómfenylmetyl)-amino-metyl]-nitrobenzén4 - [/ V-methyl- / V- (4-bromophenyl-methyl) amino-methyl] nitrobenzene

4-[A/-metyl-A/-(3-chlórfenylmetyl)-amino-metyl]-nitrobenzén4 [A / -methyl-A / - (3-chlorophenylmethyl) amino-methyl] nitrobenzene

4-[/V-metyl-/\/-(3,4-dimetoxyfenylmetyl)-amino-metyl]-nitrobenzén4 - [/ V-methyl - / \ / - (3,4-dimethoxyphenylmethyl) amino-methyl] nitrobenzene

4-[W-metyl-A/-(4-metoxyfenylmetyl)-amino-metyl]-nitrobenzén4- [N-methyl-A / - (4-methoxyphenyl-methyl) amino-methyl] nitrobenzene

4-[/V-2,2,2-trifluóretyl-/V-(fenylmetyl)-amino-metyl]-nitrobenzén4 - [/ V-2,2,2-trifluóretyl- / N- (phenylmethyl) amino-methyl] nitrobenzene

4-[/V-2,2,2-trifluóretyl-/\/-(4-chlórfenylmetyl)-amino-metyl]-nitrobenzén4 - [/ V-2,2,2-trifluoro-ethyl - / \ / - (4-chlorophenyl methyl) amino-methyl] nitrobenzene

Príprava 6Preparation 6

4-(/V-etyl-/V-ŕerc-butoxykarbonyl-amino-metyl)-nitrobenzén4 - (/ V-ethyl- / V-tert-butoxycarbonylamino-methyl) -nitrobenzene

-282,2 g 4-(etylamino-metyl)-nitrobenzénu sa rozpustí v 50 ml esteru kyseliny octovej a mieša sa s 2,6 g d i-ŕerc-butyl-d i karbonátom 30 minút pri izbovej teplote. Potom sa roztok premyje vodou a skoncentruje sa.-282.2 g of 4- (ethylamino-methyl) -nitrobenzene are dissolved in 50 ml of acetic acid ester and stirred with 2.6 g of di-tert-butyl di-carbonate for 30 minutes at room temperature. The solution was washed with water and concentrated.

Výťažok: 3,4 gYield: 3.4 g

Rf: 0,9 (silikagél; metylénchlorid/metanol = 9:1) Rf: 0.9 (silica gel, methylene chloride / methanol = 9: 1)

Analogicky sa pripravuje:Similarly prepared:

4-[A/-(4-chlórfenyl-metyl)-/\/-ŕezTC-butoxykarbonyl-amino-metyl)-nitrobenzén4- [A / - (4-chloro-phenyl-methyl) - / \ / - ŕezTC-butoxycarbonylamino-methyl) -nitrobenzene

4-(A/-cyklohexyl-/V-ŕerc-butoxykarbonyl-amino-metyl)-nitrobenzén4 (A / -cyclohexyl / N-tert-butoxycarbonyl-methyl-amino) nitrobenzene

4-(/V-izopropyl-/\/-ŕerc-butoxykarbonyl-amino-metyl)-nitrobenzén4 - (/ V-isopropyl - / \ / - t-butoxycarbonyl-methyl-amino) nitrobenzene

4-(/V-butyl-/V-ŕerc-butoxykarbonyl-amino-metyl)-nitrobenzén4 - (/ V-butyl / V-tert-butoxycarbonylamino-methyl) -nitrobenzene

4-(/V-metoxykarbonyl-metyl-/V-ŕerc-butoxykarbonyl-amino-metyl)-nitrobenzén4 - (/ V-methoxycarbonyl-methyl- / V-tert-butoxycarbonylamino-methyl) -nitrobenzene

4-(/V-(fenyl-metyl)-/V-ŕerc-butoxykarbonyl-amino-metyl)-nitrobenzén4 - (/ V- (phenyl-methyl) - / V-tert-butoxycarbonylamino-methyl) -nitrobenzene

Príprava 7Preparation 7

4-(A/-etyl-/\/-ŕerc-butoxykarbonyl-amino-metyl)-anilín4 (A / ethyl - / \ / - t-butoxycarbonyl-methyl-amino) -aniline

6,4 g 4-(A/-etyl-A/-ŕerc-butoxykarbonyl-amino-metyi)-nitrobenzénu sa rozpustí v 60 ml metanolu a hydratuje sa 3 hodiny s 1,5 g Raneyovho niklu pri izbovej teplote. Potom sa katalyzátor odfiltruje a roztok sa skoncentruje.6.4 g of 4- (N-ethyl-N-tert-butoxycarbonyl-amino-methyl) -nitrobenzene are dissolved in 60 ml of methanol and hydrated with 1.5 g of Raney nickel for 3 hours at room temperature. The catalyst was then filtered off and the solution was concentrated.

Výťažok: 4,78 gYield: 4.78 g

R,: 0,7 (silikagél; metylénchlorid/metanol 50:1)Rf: 0.7 (silica gel; methylene chloride / methanol 50: 1)

Analogicky sa pripravuje:Similarly prepared:

4-[A/-(4-chlórfenyl-metyl)-/V-ŕerc-butoxykarbonyl-amino-metyl]-anilín4- [A / - (4-chloro-phenyl-methyl) - / V-t-butoxycarbonyl-methyl-amino] -aniline

4-(A/-cyklohexyl-/V-ŕerc-butoxykarbonyl-amino-metyl)-anilín4 (A / -cyclohexyl / N-tert-butoxycarbonyl-methyl-amino) -aniline

4-(A/-izopropyl-/V-ŕerc-butoxykarbonyl-amino-metyl)-anilín4 (A / -izopropyl- / N-tert-butoxycarbonyl-methyl-amino) -aniline

4-(/V-butyl-/\/-terc-butoxykarbonyl-amino-metyl)-anilín4 - (/ V-butyl - / \ / - t-butoxycarbonyl-methyl-amino) -aniline

4-(/\/-metoxykarbonyl-metyl-/\/-ŕerc-butoxykarbonyl-amino-metyl)-anilín4 - (/ \ / - methoxycarbonyl-methyl - / \ / - t-butoxycarbonyl-methyl-amino) -aniline

4-(A/-(fenyl-metyl)-/\/-ŕezTC-butoxykarbonyl-amino-metyl)-anilín4 (A / - (phenylmethyl) - / \ / - ŕezTC-butoxycarbonylamino-methyl) -aniline

4-(pyrolidín-metyl)-anilín4- (pyrrolidin-methyl) -aniline

-294-(morfolín-metyl)-anilín-294- (morpholino-methyl) -aniline

4-(piperidín-metyl)-anilín4- (piperidin-methyl) -aniline

4-(hexametylénimino-metyl)-anilín4- (hexamethyleneimino-methyl) -aniline

4-(4-hydroxy-piperidín-metyl)-anilín4- (4-hydroxy-piperidino-methyl) -aniline

4-(4-metyl-piperidín-metyl)-anilín4- (4-methyl-piperidino-methyl) -aniline

4-(4-etyl-piperidín-metyl)-anilín4- (4-ethyl-piperidino-methyl) -aniline

4-(4-izopropyl-piperidín-metyl)-anilín4- (4-Isopropyl-piperidin-methyl) -aniline

4-(4-fenyl-piperidín-metyl)-anilín4- (4-phenyl-piperidino-methyl) -aniline

4-(4-benzyl-piperidín-metyl)-anilín4- (4-benzyl-piperidin-methyl) -aniline

4-(4-etoxykarbonyl-piperidín-metyl)-anilín4- (4-ethoxycarbonyl-piperidino-methyl) -aniline

4-(2-morfolinyl-etyl)-anilín4- (2-morpholinyl-ethyl) -aniline

4-(2-pyrolidnyl-etyl)-anilín4- (2-ethyl-pyrolidnyl) aniline

4-(2-piperidinyl-etyl)-anilín4- (2-piperidinyl-ethyl) -aniline

4-(/V-etyl-/V-benzyl-amino-metyl)-anilín4 - (/ V-ethyl- / V-benzyl-methyl-amino) -aniline

4-(A/-propyl-/V-benzyl-amino-metyl)-anilín4 (A / -propyl / V-benzyl-methyl-amino) -aniline

4-[A/-metyl-W-(4-chlórfenylmetyl)-amino-metyl]-anilín4 [A / -methyl-N- (4-chlorophenylmethyl) amino-methyl] aniline

4-[A/-metyl-A/-(4-brómfenylmetyl)-amino-metyl]-anilín4 [A / -methyl-A / - (4-bromophenyl-methyl) amino-methyl] aniline

4-[/V-metyl-A/-(3-chlórfenylmetyl)-amino-metyl]-anilín4 - [/ V-methyl-A / - (3-chlorophenylmethyl) amino-methyl] aniline

4-[A/-metyl-A/-(3,4-dimetoxyfenylmetyl)-amino-metyl]-anilín4 [A / -methyl-A / - (3,4-dimethoxyphenylmethyl) amino-methyl] aniline

4-[A/-metyl-/V-(4-metoxyfenylmetyl)-amino-metyl]-anilín4 [A / methyl / V- (4-methoxyphenyl-methyl) amino-methyl] aniline

4-[/V-2,2,2-trifluóretyl-/V-(fenylmetyl)-amino-metyl]-anilín4 - [/ V-2,2,2-trifluóretyl- / N- (phenylmethyl) amino-methyl] aniline

4-[N-2,2,2-trifluóretyl-/V-(4-chlórfenylmetyl)-amino-rnetyl]-anilín4- [N-2,2,2-trifluóretyl- / N- (4-chlorophenylmethyl) amino-methyl] aniline

Príprava koncových produktovPreparation of end products

Príklad 1Example 1

Metylester kyseliny 3-Z-[1-(1-metyl-piperidín-4-yl-amino)-1-fenyl-metylén]-2indolinón-5-karboxylovej3-Z- [1- (1-Methyl-piperidin-4-yl-amino) -1-phenyl-methylene] -2-indolinone-5-carboxylic acid methyl ester

11,5 g metylesteru kyseliny 1-acetyl-3-(1-etoxy-1-fenyl-metylén)-2-indolinón 5-karboxylovej sa rozpustí v 115 ml metylénchloridu a mieša sa s 10,8 g 4-amino-/V11.5 g of 1-acetyl-3- (1-ethoxy-1-phenyl-methylene) -2-indolinone 5-carboxylic acid methyl ester are dissolved in 115 ml of methylene chloride and stirred with 10.8 g of 4-amino- N

-30metylpiperidínu 5 hodín pri izbovej teplote. Potom sa pridá 20 ml metanolového amoniaku a nechá sa stáť cez noc. Roztok sa odparí a zvyšok sa premyje éterom. Výťažok: 11,9 g (97 % teoretickej hodnoty)-30-methylpiperidine for 5 hours at room temperature. Then 20 ml of methanolic ammonia are added and allowed to stand overnight. The solution was evaporated and the residue was washed with ether. Yield: 11.9 g (97% of theory)

R,: 0,20 (silikagél; metylénchlorid/metanol = 9:1)R f: 0.20 (silica gel; methylene chloride / methanol = 9: 1)

C23H25N3O3C23H25N3O3

Hmotnostné spektrum: m/z = 391 (M*)Mass Spectrum: m / z = 391 (M &lt; + &gt;)

Analogicky sa pripraví:Analogously prepare:

(1) Metylester kyseliny 3-Z-[1-(4-(piperidín-metyl)-fenylamino)-1-fenyl-metylén]-2indolinón-5-karboxylovej(1) 3-Z- [1- (4- (Piperidin-methyl) -phenylamino) -1-phenyl-methylene] -2-indolinone-5-carboxylic acid methyl ester

R,: 0,4 (silikagél; metylénchlorid/metanol = 9:1)Rf: 0.4 (silica gel; methylene chloride / methanol = 9: 1)

C29H29N3O3C29H29N3O3

Hmotnostné spektrum: m/z = 467 (M+) (2) Metylester kyseliny 3-Z-[1-(4-(/V-fenylmetyl-/\/-metylamÍno-metyl)-fenyl-amino)-1fenyl-metylén]-2-indolinón-5-karboxylovej ^32^9^03Mass spectrum: m / z = 467 (M + ) (2) 3-Z- [1- (4- (N-Phenylmethyl-N-methylamino-methyl) -phenylamino) -1-phenyl-methylene acid methyl ester -2-indolinone-5-carboxylic acid

Hmotnostné spektrum: m/z = 503 (M+) (3) Metylester kyseliny 3-Z-[1-(4-(dimetylamino-metyl)-fenylamino)-1-fenyl-metylén]2-indolinón-5-karboxylovejMass spectrum: m / z = 503 (M + ) (3) 3-Z- [1- (4- (dimethylamino-methyl) -phenylamino) -1-phenyl-methylene] 2-indolinone-5-carboxylic acid methyl ester

C26H25N3O3 2 C 6 H 5 N 3 O 3 2

Hmotnostné spektrum: m/z = 427 (M+) (4) Metylester kyseliny 3-Z-[1-(3-(dimetylamino-metyl)-fenylamino)-1-fenyl-metylén]2-indolinón-5-karboxylovej θ2βΗ25^3θ3Mass spectrum: m / z = 427 (M + ) (4) 3-Z- [1- (3- (dimethylamino-methyl) -phenylamino) -1-phenyl-methylene] 2-indolinone-5-carboxylic acid methyl ester θ2β225 ^ 3θ3

Hmotnostné spektrum: m/z = 427 (M+) (5) Metylester kyseliny 3-Z-[1-(4-chlór-fenylamino)-1-fenyl-metylén]-2-indolinón-5karboxylovejMass spectrum: m / z = 427 (M + ) (5) 3-Z- [1- (4-Chloro-phenylamino) -1-phenyl-methylene] -2-indolinone-5-carboxylic acid methyl ester

-31 (6) Metylester kyseliny 3-Z-(1-fenylamino-12-fenyl-metylén)-2-indolinón-5karboxylovej-31 (6) 3-Z- (1-Phenylamino-12-phenyl-methylene) -2-indolinone-5-carboxylic acid methyl ester

Príklad 2Example 2

Kyselina 3-Z-[1-(1-metyl-piperidín-4-yl-amino)-1-fenyl-metylén]-2-indolinón-5karboxylová3-Z- [1- (1-Methyl-piperidin-4-yl-amino) -1-phenyl-methylene] -2-indolinone-5-carboxylic acid

11,9 g metylesteru kyseliny 3-Z-[1-(1-metyl-piperidín-4-yl-amino)-1-fenylmetylénJ-2-indolinón-5-karboxylovej sa ohrieva do spätného toku 4 hodiny v 300 ml metanolu a 150 ml 1 N lúhu sodného. Potom sa neutralizuje so 150 ml 1 N kyseliny chlorovodíkovej a skoncentruje sa dosucha. Zvyšok sa niekoľkokrát premyje vodou a vysuší sa.11.9 g of 3-Z- [1- (1-methyl-piperidin-4-ylamino) -1-phenylmethylene] -2-indolinone-5-carboxylic acid methyl ester was heated to reflux in 300 ml of methanol for 4 hours and 150 ml of 1 N sodium hydroxide solution. It is then neutralized with 150 ml of 1 N hydrochloric acid and concentrated to dryness. The residue was washed several times with water and dried.

Výťažok: 86 % teoretickej hodnotyYield: 86% of theory

R,: 0,17 (silikagél; metylénchlorid/metanol = 4:1)Rf: 0.17 (silica gel; methylene chloride / methanol = 4: 1)

C22H23N3O3C22H23N3O3

Hmotnostné spektrum: m/z = 377 (M+)Mass Spectrum: m / z = 377 (M &lt; + &gt; )

Analogicky sa pripraví:Analogously prepare:

(1) Kyselina 3-Z-[1-(4-(piperidín-metyl)-fenylamino)-1-fenyl-metylén]-2-indolinón-5karboxylová(1) 3-Z- [1- (4- (Piperidin-methyl) -phenylamino) -1-phenyl-methylene] -2-indolinone-5-carboxylic acid

Rf: 0,15 (silikagél; metylénchlorid/metanol = 9:1) Rf: 0.15 (silica gel; methylene chloride / methanol = 9: 1)

C28H27N3O3C28H27N3O3

Hmotnostné spektrum: m/z = 453 (M+) (2) Kyselina 3-Z-[1 -(4-(A/-fenylmetyl-A/-metylamino-metyl)-fenyl-amino)-1 -fenylmetylén)-2-indolinón-5-karboxylováMass Spectrum: m / z = 453 (M + ) (2) 3-Z- [1- (4- (N-Phenylmethyl-N-methylamino-methyl) -phenylamino) -1-phenylmethylene) - 2-indolinone-5-carboxylic acid

C32H27N3O3C32H27N3O3

Hmotnostné spektrum: m/z = 489 (M+) (3) Kyselina 3-Z-[1 -(4-(dimetylamino-metyl)-fenylamino)-1 -fenyl-metylén]-2indolinón-5-karboxylováMass Spectrum: m / z = 489 (M &lt; + &gt; ) (3) 3-Z- [1- (4- (dimethylamino-methyl) -phenylamino) -1-phenyl-methylene] -2-indolinone-5-carboxylic acid

-32θ25^23^3θ3-32θ25 ^ 23 ^ 3θ3

Hmotnostné spektrum: m/z = 413 (M+) (4) Kyselina 3-Z-[1 -(3-(dimetylamino-metyl)-fenylamino)-1 -fenyl-metylén)-2indolinón-5-karboxylová θ25^23^3θ3Mass Spectrum: m / z = 413 (M + ) (4) 3-Z- [1- (3- (dimethylamino-methyl) -phenylamino) -1-phenyl-methylene) -2-indolinone-5-carboxylic acid ^ 3θ3

Hmotnostné spektrum: m/z = 413 (M+) (5) Kyselina 3-Z-[ 1 -(4-chlór-fenylamino)-1 -fenyl-metylén]-2-indolinón-5-karboxylová (6) Kyselina 3-Z-[1 -fenylamino-1 -fenyl-metylén)-2-indolinón-5-karboxylováMass Spectrum: m / z = 413 (M + ) (5) 3-Z- [1- (4-chloro-phenylamino) -1-phenyl-methylene] -2-indolinone-5-carboxylic acid (6) Acid 3 -Z- [1-Phenylamino-1-phenyl-methylene) -2-indolinone-5-carboxylic acid

Príklad 3Example 3

3-Z-[ 1 -(1 -metyl-piperid í η-4-y l-amino)-1 -fenyl-metylén]-5-dimety lkarbamoyl-2indolinón g kyseliny 3-Z-[1-(1-metyl-piperidín-4-yl-amino)-1-fenyl-metylén]-2-indoliηόη-5-karboxylovej sa ohrievajú s 5 ml tionylchloridu 2 hodiny do spätného toku. Potom sa odparí a zvyšok sa premyje éterom. 0,5 g tohto kyslého chloridu sa bez ďalšieho čistenia pozbiera do v 5 ml metylénchloridu a zmieša sa s 0,5 ml dimetylamínu v 5 ml metylénchloridu a mieša sa cez noc pri izbovej teplote. Produkt sa chromatografuje cez kolónu silikagélu a metylénchloridu/metanolu/amoniaku (4:1:0,1).3-Z- [1- (1-methyl-piperidin-4-yl-amino) -1-phenyl-methylene] -5-dimethylcarbamoyl-2-indolinone g 3-Z- [1- (1-methyl) -piperidin-4-yl-amino) -1-phenyl-methylene] -2-indole-5-carboxylic acid was heated to reflux with 5 ml of thionyl chloride for 2 hours. It is then evaporated and the residue is washed with ether. 0.5 g of this acid chloride is taken up in 5 ml of methylene chloride without further purification and mixed with 0.5 ml of dimethylamine in 5 ml of methylene chloride and stirred overnight at room temperature. The product is chromatographed over a column of silica gel and methylene chloride / methanol / ammonia (4: 1: 0.1).

Výťažok: 50 % teoretickej hodnotyYield: 50% of theory

Rf: 0,14 (silikagél; metylénchlorid/metanol = 9:1) Rf: 0.14 (silica gel; methylene chloride / methanol = 9: 1)

C24H28N4O2C24H28N4O2

Hmotnostné spektrum: m/z = 404 (M+)Mass Spectrum: m / z = 404 (M &lt; + &gt; )

Analogicky sa pripravujú nasledovné zlúčeniny:The following compounds are prepared analogously:

(1) 3-Z-[1-(1-metyl-piperidín-4-yl-amino)-1-fenyl-metylén]-5-metylkarbamoyl-2indolinón(1) 3-Z- [1- (1-methyl-piperidin-4-ylamino) -1-phenyl-methylene] -5-methylcarbamoyl-2-indolinone

Výťažok: 49 % teoretickej hodnotyYield: 49% of theory

-33Rf: 0,19 (silikagél; metylénchlorid/metanol = 4:1) θ23^26^4θ2-33R f : 0.19 (silica gel; methylene chloride / methanol = 4: 1) θ23 ^ 26 ^ 4θ2

Hmotnostné spektrum: m/z = 390 (M+) (2) 3-Z-[1-(1-metyl-piperidín-4-yl-amino)-1-fenyl-metylén]-5-karbamoyl-2-indolinón Výťažok: 58 % teoretickej hodnotyMass Spectrum: m / z = 390 (M &lt; + &gt; ) (2) 3-Z- [1- (1-methyl-piperidin-4-ylamino) -1-phenyl-methylene] -5-carbamoyl-2-indolinone Yield: 58% of theory

Rf: 0,15 (silikagél; metylénchlorid/metanol = 4:1) Rf: 0.15 (silica gel; methylene chloride / methanol = 4: 1)

C22H24N4O2C22H24N4O2

Hmotnostné spektrum: m/z = 376 (M+) (3) 3-Z-[1-(4-piperidino-metyl-fenylamino)-1-fenyl-metylén]-5-dimetylkarbamoyl-2indolinónMass Spectrum: m / z = 376 (M &lt; + &gt; ) (3) 3-Z- [1- (4-piperidinomethyl-phenylamino) -1-phenyl-methylene] -5-dimethylcarbamoyl-2-indolinone

Pripraví sa z kyseliny 3-Z-[1-(4-piperidín-metyl-fenylamino)-1-fenyl-metylén]2-indolinón-5-karboxylovej alebo sa 0,64 g kyseliny Z-[1 -(4-piperidín-metylfenylamino)-1-fenyl-metylén]-2-indolinón-5-karboxylovej, 0,34 g dimetylamínhydrochloridu, 0,9 g O-benzotriazol-1-yl-/V,/\/,/\/’,/\/-tetrametylurónium-tetrafluórboritanu, 0,4 g 1-hydroxy-1H-benzotriazolu a 2,9 g diizopropylénetylamínu sa mieša v 20 ml dimetylformamidu 20 hodín pri izbovej teplote. Potom sa skoncentruje a zvyšok sa suspenduje vo vode. Zrazenina sa odsaje.Prepared from 3-Z- [1- (4-piperidin-methyl-phenylamino) -1-phenyl-methylene] 2-indolinone-5-carboxylic acid or with 0.64 g of Z- [1- (4-piperidine) (methylphenylamino) -1-phenylmethylene] -2-indolinone-5-carboxylic acid, 0.34 g of dimethylamine hydrochloride, 0.9 g of O-benzotriazol-1-yl- (N, N, N ') N-tetramethyluronium tetrafluoroborate, 0.4 g of 1-hydroxy-1 H -benzotriazole and 2.9 g of diisopropylene ethylamine are stirred in 20 ml of dimethylformamide for 20 hours at room temperature. It is then concentrated and the residue is suspended in water. The precipitate is filtered off with suction.

Výťažok: 600 mg (88 % teoretickej hodnoty)Yield: 600 mg (88% of theory)

Rf: 0,2 (silikagél; metylénchlorid/etanol = 9:1) Rf: 0.2 (silica gel, methylene chloride / ethanol = 9: 1)

C30H32N4O2C30H32N4O2

Hmotnostné spektrum: m/z = 481 (M+H)+ (4) 3-Z-[1 -(4-piperidín-metyl-fenylamino)-1 -fenyl-metylén]-5-metylkarbamoyl-2indolinónMass Spectrum: m / z = 481 (M + H) + (4) 3-Z- [1- (4-piperidin-methyl-phenylamino) -1-phenyl-methylene] -5-methylcarbamoyl-2-indolinone

Pripraví sa z kyseliny 3-Z-[1-(4-piperidín-metyl-fenylamino)-1-fenyl-metylén]2-indolinón-5-karboxylovej a metylamínu analogicky s príkladom 3 (3).Prepared from 3-Z- [1- (4-piperidin-methyl-phenylamino) -1-phenyl-methylene] -2-indolinone-5-carboxylic acid and methylamine in analogy to Example 3 (3).

Rf: 0,2 (silikagél; metylénchlorid/etanol = 9:1) θ29^30^4θ2 Rf: 0.2 (silica gel, methylene chloride / ethanol = 9: 1) θ29 ^ 30 ^ 4θ2

Hmotnostné spektrum: m/z = 467 (M+H)+ Mass spectrum: m / z = 467 (M + H) &lt; + &gt; .

-34(5) 3-Ζ-[ 1 -(4-piperidín-metyl-fenylamino)-1 -fenyl-metylén]-5-metyletylkarbamoyl-2indolinón-34 (5) 3- Ζ- [1- (4-piperidin-methyl-phenylamino) -1-phenyl-methylene] -5-methylethylcarbamoyl-2-indolinone

Pripraví sa z kyseliny 3-Z-[1-(4-piperidín-metyl-fenylamino)-1-fenyl-metylén] 2-indolinón-5-karboxylovej a metyl-etylamínu analogicky s príkladom 3 (3).Prepared from 3-Z- [1- (4-piperidin-methyl-phenylamino) -1-phenyl-methylene] -2-indolinone-5-carboxylic acid and methyl-ethylamine in analogy to Example 3 (3).

Rf: 0,55 (silikagél; metylénchlorid/etanol = 9:1) θ3ΐΗ34Ν4Ο2 Rf: 0.55 (silica gel; methylene chloride / ethanol = 9: 1) θ3ΐΗ3 4 Ν 2 Ο 4

Hmotnostné spektrum: m/z = 495 (M+H)+ (6) 3-Z-[ 1 -(4-piperidín-metyl-fenylamino)-1 -fenyl-metylén]-5-propylkarbamoyl-2indolinónMass Spectrum: m / z = 495 (M + H) + (6) 3- Z- [1- (4-piperidin-methyl-phenylamino) -1-phenyl-methylene] -5-propylcarbamoyl-2-indolinone

Pripraví sa z kyseliny 3-Z-[1-(4-piperidín-metyl-fenylamino)-1-fenyl-metylén] 2-indolinón-5-krabónovej a propylamínu analogicky s príkladom 3 (3).Prepared from 3-Z- [1- (4-piperidine-methyl-phenylamino) -1-phenyl-methylene] -2-indolinone-5-boxic acid and propylamine in analogy to Example 3 (3).

Rf: 0,31 (silikagél; metylénchlorid/etanol = 9:1) θ31^34Ν4Ο2 Rf: 0.31 (silica gel; methylene chloride / ethanol = 9: 1) θ31 ^ Ν 3 4 4 2 Ο

Hmotnostné spektrum: m/z = 495 (M+H)+ (7) 3-Z-[1-(4-piperidín-metyl-fenylamino)-1-fenyl-metylén]-5-dietylkarbamoyl-2indolinónMass Spectrum: m / z = 495 (M + H) + (7) 3-Z- [1- (4-piperidin-methyl-phenylamino) -1-phenyl-methylene] -5-diethylcarbamoyl-2-indolinone

Pripraví sa z kyseliny 3-Z-[1-(4-piperidín-metyl-fenylamino)-1-fenyl-metylén] 2-indolinón-5-karboxylovej a dietylamínu analogicky s príkladom 3 (3).Prepared from 3-Z- [1- (4-piperidin-methyl-phenylamino) -1-phenyl-methylene] -2-indolinone-5-carboxylic acid and diethylamine in analogy to Example 3 (3).

Rf: 0,55 (silikagél; metylénchlorid/etanol = 9:1) θ32^36^4θ2 Rf: 0.55 (silica gel; methylene chloride / ethanol = 9: 1) θ32 ^ 36 ^ 4 θ2

Hmotnostné spektrum: m/z = 509 (M+H)+ (8) 3-Z-[ 1 -(4-(/V-fenylmetyl-/V-metyl-aminometyl)-fenylamino)-1 -fenyl-metylén]-5metylkarbamoyl-2-indolinón (9) 3-Z-[1 -(4-(/V-fenylmetyl-/\/-metyl-aminometyl)-fenylamino)-1 -fenyl-metylén]-5dimetylkarbamoyl-2-indolinón (10) 3-Z-[ 1 -(4-(/V-fenylmetyl-A/-metyl-aminometyl)-fenylamino)-1 -fenyl-metylén]-5dietylkarbamoyl-2-indolinónMass Spectrum: m / z = 509 (M + H) + (8) 3-Z- [1- (4- (N-phenylmethyl- N -methyl-aminomethyl) -phenylamino) -1-phenyl-methylene] -5-methylcarbamoyl-2-indolinone (9) 3-Z- [1- (4- (N-phenylmethyl-1H-methyl-aminomethyl) -phenylamino) -1-phenyl-methylene] -5-dimethylcarbamoyl-2-indolinone ( 10) 3-Z- [1- (4- (N-phenylmethyl-N-methyl-aminomethyl) -phenylamino) -1-phenyl-methylene] -5-diethylcarbamoyl-2-indolinone

-35(11) 3-Z-[1 -(4-(/V-fenylmetyl-A/-rnetyl-aminometyl)-fenylamino)-1 -fenyl-metylén]-5propylkarbamoyl-2-indolinón (12) 3-Z-[1-(4-(/V-fenylmetyl-/V-metyl-aminometyl)-fenylamino)-1-fenyl-metylén]-5dipropylkarbamoyl-2-indolinón (13) 3-Z-[1-(4-(dimetylamino-metyl)-fenylamino)-1-fenyl-metylén]-5-metylkarbamoyl 2-indolinón (14) 3-Z-[1-(4-(dimetylamino-metyl)-fenylamino)-1-fenyl-nnetylén]-5dimetylkarbamoyl-2-indolinón (15) 3-Z-[1 -(4-(dimetylamino-metyl)-fenylamino)-1 -fenyl-metylén]-5-dietylkarbamoyl 2-indolinón (16) 3-Z-[1-(4-(dimetylamino-metyl)-fenylamino)-1-fenyl-metylén]-5propylkarbamoyl-2-indolinón (17) 3-Z-[1-(4-(dimetylamino-metyl)-fenylamino)-1-fenyl-metylén]-5dipropylkarbamoyl-2-indolinón (18) 3-Z-[ 1 -(3-(dimetylamino-metyl)-fenylamino)-1 -fenyl-metylén]-5-metylkarbamoyl 2-indolinón (19) 3-Z-[1-(3-(dimetylamino-metyl)-fenylamino)-1-fenyl-metylén]-5dimetylkarbamoyl-2-indolinón (20) 3-Z-[ 1 -(3-(dimetylamino-metyl)-fenylamino)-1 -fenyl-metylén]-5-dietylkarbamoyl 2-indolinón (21) 3-Z-[ 1 -(3-(dimetylamino-metyl)-fenylamino)-1 -fenyl-metylén]-5propylkarbamoyl-2-indolinón (22) 3-Z-[1 -(3-(dimetylamino-metyl)-fenylamino)-1 -fenyl-metylén]-5dipropylkarbamoyl-2-indolinón (23) 3-Z-[ 1 -(4-chlór-fenylamino)-1 -fenyl-metylén]-5-metylkarbamoyl-2-indolinón (24) 3-Z-[ 1 -(4-chlór-fenylamino)-1 -fenyl-metylén]-5-dimetylkarbamoyl-2-indolinón (25) 3-Z-[1 -(4-chlór-fenylamino)-1 -fenyl-metylén]-5-dietylkarbamoyl-2-indolinón (26) 3-Z-[1 -(4-chlór-fenylamino)-1 -fenyl-metylén]-5-propylkarbamoyl-2-indolinón (27) 3-Z-[ 1 -(4-chlór-fenylamino)-1 -fenyl-metylén]-5-dipropylkarbamoyl-2-indolinón (28) 3-Z-(1-fenylamino-1-fenyl-metylén)-5-metylkarbamoyl-2-indolinón (29) 3-Z-(1-fenylamino-1-fenyl-metylén)-5-dimetylkarbamoyl-2-indolinón-35 (11) 3-Z- [1- (4- (N-phenylmethyl-N-methyl-aminomethyl) -phenylamino) -1-phenyl-methylene] -5-propylcarbamoyl-2-indolinone (12) 3-Z - [1- (4- (N-phenylmethyl- N -methyl-aminomethyl) -phenylamino) -1-phenyl-methylene] -5-dipropylcarbamoyl-2-indolinone (13) 3-Z- [1- (4- ( dimethylamino-methyl) -phenylamino) -1-phenyl-methylene] -5-methylcarbamoyl 2-indolinone (14) 3-Z- [1- (4- (dimethylamino-methyl) -phenylamino) -1-phenyl-methylene] - 5-Dimethylcarbamoyl-2-indolinone (15) 3-Z- [1- (4- (dimethylamino-methyl) -phenylamino) -1-phenyl-methylene] -5-diethylcarbamoyl 2-indolinone (16) 3-Z- [1- (4- (dimethylamino-methyl) -phenylamino) -1-phenyl-methylene] -5-propylcarbamoyl-2-indolinone (17) 3-Z- [1- (4- (dimethylamino-methyl) -phenylamino) -1-phenyl- methylene] -5-dipropylcarbamoyl-2-indolinone (18) 3-Z- [1- (3- (dimethylamino-methyl) -phenylamino) -1-phenyl-methylene] -5-methylcarbamoyl 2-indolinone (19) 3-Z- [1- (3- (dimethylamino-methyl) -phenylamino) -1-phenyl-methylene] -5-dimethylcarbamoyl-2-indolinone (20) 3-Z- [1- (3- (dimethylamino-methyl) -phenylamino) -1] phenyl-methylene] -5-diethylcarbamoyl 2-indolinone (21) 3-Z- [1- (3- (dimethylamino-methyl) -phenylamino) -1-phenyl-methylene] -5-propylcarbamoyl-2-indolinone (22) 3-Z- [1- (3- (dimethylamino-methyl) -phenylamino) -1-phenyl-methylene] -5-dipropylcarbamoyl-2-indolinone (23) 3- Z- [1- (4-chloro-phenylamino) -1-phenyl-methylene] -5-methylcarbamoyl- 2-indolinone (24) 3-Z- [1- (4-chloro-phenylamino) -1-phenyl-methylene] -5-dimethylcarbamoyl-2-indolinone (25) 3-Z- [1- (4-chloro- phenylamino) -1-phenyl-methylene] -5-diethylcarbamoyl-2-indolinone (2S) 3-Z- [1- (4-chloro-phenylamino) -1-phenyl-methylene] -5-propylcarbamoyl-2-indolinone ( 27) 3-Z- [1- (4-chloro-phenylamino) -1-phenyl-methylene] -5-dipropylcarbamoyl-2-indolinone (28) 3-Z- (1-phenylamino-1-phenyl-methylene) - 5-Methylcarbamoyl-2-indolinone (2 S) 3-Z- (1-phenylamino-1-phenylmethylene) -5-dimethylcarbamoyl-2-indolinone

-36(30) 3-Z-(1-fenylamino-1-fenyl-metylén)-5-dietylkarbamoyl-2-indolinón (31) 3-Z-(1-fenylamino-1-fenyl-metylén)-5-propylkarbamoyl-2-indolinón (32) 3-Z-(1-fenylamino-1-fenyl-metylén)-5-dipropylkarbamoyl-2-indolinón-36 (30) 3-Z- (1-phenylamino-1-phenyl-methylene) -5-diethylcarbamoyl-2-indolinone (31) 3-Z- (1-phenylamino-1-phenyl-methylene) -5-propylcarbamoyl -2-indolinone (32) 3-Z- (1-phenylamino-1-phenylmethylene) -5-dipropylcarbamoyl-2-indolinone

Príklad 4Example 4

3-Z-[1-(4-amino-fenylamino)-1-fenyl-metylén]-5-amido-2-indolinón3-Z- [1- (4-amino-phenylamino) -1-phenyl-methylene] -5-amido-2-indolinone

800 mg živice pripravenej podľa príkladu IV sa suspenduje v 4 ml metylénchloridu a trepe sa s 0,8 g 1,4-fenyléndiamínu 16 hodín pri izbovej teplote. Odfiltruje sa a živica sa niekoľkokrát premyje metylénchloridom, metanolom a dimetylformamidom. Potom sa na 2 hodiny pridajú 3 ml metanolového amoniaku, aby sa odstránila acetylová skupina. Nakoniec sa po ďalšom premytí pridajú 4 ml 10%-nej kyseliny trifluóroctovej v metylénchloride počas 90 minút, živica sa odlúči a roztok sa skoncentruje. Zvyšok sa pozbiera v malom objeme 1 N lúhu sodného a vyextrahuje sa metylénchloridom. Organická fáza sa nad síranom sodným vysuší a odparí sa.800 mg of the resin prepared according to Example IV are suspended in 4 ml of methylene chloride and shaken with 0.8 g of 1,4-phenylenediamine for 16 hours at room temperature. Filter and wash the resin several times with methylene chloride, methanol and dimethylformamide. Then 3 ml of methanolic ammonia are added for 2 hours to remove the acetyl group. Finally, after further washing, 4 ml of 10% trifluoroacetic acid in methylene chloride are added over 90 minutes, the resin is separated and the solution is concentrated. The residue was collected in a small volume of 1 N sodium hydroxide solution and extracted with methylene chloride. The organic phase is dried over sodium sulphate and evaporated.

Výťažok: 45 mg (30 % teoretickej hodnoty vo všetkých krokoch)Yield: 45 mg (30% of theory in all steps)

Rf: 0,26 (silikagél; metylénchlorid/metanol = 9:1) Rf: 0.26 (silica gel; methylene chloride / methanol = 9: 1)

C22H18N4O2 C 22 H 18 N 4 O 2

Hmotnostné spektrum: m/z = 370 (M+)Mass Spectrum: m / z = 370 (M &lt; + &gt; )

Analogicky sa pripravia nasledovné zlúčeniny:The following compounds are prepared analogously:

(1) 3-Z-[1-(3-amino-fenylamino)-1-fenyl-metylén]-5-amido-2-indolinón(1) 3-Z- [1- (3-Amino-phenylamino) -1-phenyl-methylene] -5-amido-2-indolinone

Výťažok: 24 % teoretickej hodnotyYield: 24% of theory

Rf: 0,44 (silikagél; metylénchlorid/metanol = 9:1) Rf: 0.44 (silica gel; methylene chloride / methanol = 9: 1)

C22H18N4O2 C 22 H 18 N 4 O 2

Hmotnostné spektrum: m/z = 370 (M+) (2) 3-Z-(1-fenylamino-1-fenyl-metylén)-5-amido-2-indolinónMass Spectrum: m / z = 370 (M + ) (2) 3-Z- (1-phenylamino-1-phenylmethylene) -5-amido-2-indolinone

Výťažok: 27 % teoretickej hodnotyYield: 27% of theory

Rf: 0,53 (silikagél; metylénchlorid/metanol = 9:1) Rf: 0.53 (silica gel; methylene chloride / methanol = 9: 1)

-37C22Hi7N3O2 -37C22Hi 7 N 3 O 2

Hmotnostné spektrum: m/z = 355 (M+) (3) 3-Z-[1 -(4-acetylamino-fenylamino)-1 -fenyl-metylén]-5-amido-2-indolinón Výťažok: 28 % teoretickej hodnotyMass spectrum: m / z = 355 (M + ) (3) 3-Z- [1- (4-acetylamino-phenylamino) -1-phenyl-methylene] -5-amido-2-indolinone Yield: 28% of theory

Rf: 0,35 (silikagél; metylénchlorid/metanol = 9:1) θ24^20^4θ3 Rf: 0.35 (silica gel; methylene chloride / methanol = 9: 1) θ24 H 20 N 4θ3

Hmotnostné spektrum: m/z = 412 (M+) (4) 3-Z-[1-(4-acetyl-/V-metyl-amino-fenylamino)-1-fenyl-metylén]-5-amido-2-indolinón Výťažok: 15 % teoretickej hodnotyMass Spectrum: m / z = 412 (M + ) (4) 3-Z- [1- (4-acetyl- N -methyl-amino-phenylamino) -1-phenyl-methylene] -5-amido-2- Indolinone Yield: 15% of theory

Rf: 0,36 (silikagél; metylénchlorid/metanol = 9:1) θ25^22^4θ3 Rf: 0.36 (silica gel; methylene chloride / methanol = 9: 1) θ25 ^ 22 ^ 4θ3

Hmotnostné spektrum: m/z = 426 (M+) (5) 3-Z-[1-(4-(2-amino-etyl)-fenylamino)-1-fenyl-metylén]-5-amido-2-indolinón Výťažok: 30 % teoretickej hodnotyMass Spectrum: m / z = 426 (M + ) (S) 3-Z- [1- (4- (2-amino-ethyl) -phenylamino) -1-phenyl-methylene] -5-amido-2-indolinone Yield: 30% of theory

R,: 0,04 (silikagél; metylénchlorid/metanol = 9:1)Rf: 0.04 (silica gel; methylene chloride / methanol = 9: 1)

C24H22N4O2 C 24 H 22 N 4 O 2

Hmotnostné spektrum: m/z = 398 (IVľ) (6) 3-Z-[1 -(4-metoxy-fenylamino)-1 -fenyl-metylén]-5-amido-2-indolinónMass Spectrum: m / z = 398 (M +) (6) 3-Z- [1- (4-methoxy-phenylamino) -1-phenyl-methylene] -5-amido-2-indolinone

Výťažok: 32 % teoretickej hodnotyYield: 32% of theory

Rf: 0,48 (silikagél; metylénchlorid/metanol = 9:1) Rf: 0.48 (silica gel; methylene chloride / methanol = 9: 1)

C23H19N3O3C23H19N3O3

Hmotnostné spektrum: m/z = 385 (M+) (7) 3-Z-[ 1 -(4-bifenylamino)-1 -fenyl-metylén]-5-amido-2-indolinónMass Spectrum: m / z = 385 (M &lt; + &gt; ) (7) 3-Z- [1- (4-biphenylamino) -1-phenylmethylene] -5-amido-2-indolinone

Výťažok: 22 % teoretickej hodnotyYield: 22% of theory

Rf: 0,51 (silikagél; metylénchlorid/metanol = 9:1) Rf: 0.51 (silica gel; methylene chloride / methanol = 9: 1)

C28H21N3O2 C 28 H 21 N 3 O 2

-38Hmotnostné spektrum: m/z = 431 (M*) (8) 3-Z-[ 1 -(3-pyridylamino)-1 -fenyl-metylén]-5-amido-2-indolinón Výťažok: 35 % teoretickej hodnoty-38 Mass spectrum: m / z = 431 (M +) (8) 3- Z- [1- (3-pyridylamino) -1-phenylmethylene] -5-amido-2-indolinone Yield: 35% of theory

Rf: 0,41 (silikagél; metylénchlorid/metanol = 9:1) Rf: 0.41 (silica gel; methylene chloride / methanol = 9: 1)

C21H16N4O2 C 21 H 16 N 4 O 2

Hmotnostné spektrum: m/z = 356 (M+) (9) 3-Z-[1 -(4-dimetylamino-fenylamino)-1 -fenyl-metylén]-5-amido-2-indolinón Výťažok: 19 % teoretickej hodnotyMass spectrum: m / z = 356 (M + ) (9) 3-Z- [1- (4-dimethylamino-phenylamino) -1-phenyl-methylene] -5-amido-2-indolinone Yield: 19% of theory

Rf: 0,49 (silikagél; metylénchlorid/metanol = 9:1) Rf: 0.49 (silica gel; methylene chloride / methanol = 9: 1)

C24H22N4O2C24H22N4O2

Hmotnostné spektrum: m/z = 398 (M+) (10) 3-Z-[1-(4-morfolín-fenylamino)-1-fenyl-metylén]-5-amido-2-indolinón Výťažok: 42 % teoretickej hodnotyMass spectrum: m / z = 398 (M + ) (10) 3-Z- [1- (4-morpholin-phenylamino) -1-phenyl-methylene] -5-amido-2-indolinone Yield: 42% of theory

Rf: 0,48 (silikagél; metylénchlorid/metanol = 9:1) θ26^24^4θ3 Rf: 0.48 (silica gel; methylene chloride / methanol = 9: 1) θ26 ^ 24 ^ 4θ3

Hmotnostné spektrum: m/z = 440 (M+) (11) 3-Z-[1-(4-ŕerc-butyl-fenylamino)-1-fenyl-metylén]-5-amido-2-indolinón Výťažok: 32 % teoretickej hodnotyMass Spectrum: m / z = 440 (M + ) (11) 3-Z- [1- (4-tert-butyl-phenylamino) -1-phenyl-methylene] -5-amido-2-indolinone Yield: 32% of theoretical value

Rf: 0,48 (silikagél; metylénchlorid/metanol = 9:1) Rf: 0.48 (silica gel; methylene chloride / methanol = 9: 1)

C26H25N3O2C26H25N3O2

Hmotnostné spektrum: m/z = 411 (M+) (12) 3-Z-[1-(2-amino-fenylamino)-1-fenyl-metylén]-5-amido-2-indolinón Výťažok: 28 % teoretickej hodnotyMass spectrum: m / z = 411 (M + ) (12) 3-Z- [1- (2-Amino-phenylamino) -1-phenyl-methylene] -5-amido-2-indolinone Yield: 28% of theory

Rf: 0,52 (silikagél; metylénchlorid/metanol = 9:1) Rf: 0.52 (silica gel; methylene chloride / methanol = 9: 1)

C22H18N4O2C22H18N4O2

Hmotnostné spektrum: m/z = 370 (M+)Mass Spectrum: m / z = 370 (M &lt; + &gt; )

-39(13) 3-Ζ-[ 1 -(4-benzyloxy-fenylamino)-1 -fenyl-metylén]-5-amido-2-indolinón Výťažok: 40 % teoretickej hodnoty-39 (13) 3-Ζ- [1- (4-benzyloxy-phenylamino) -1-phenyl-methylene] -5-amido-2-indolinone Yield: 40% of theory

Rf: 0,4 (silikagél; metylénchlorid/metanol = 9:1) θ29^23^3θ3 Rf: 0.4 (silica gel, methylene chloride / methanol = 9: 1) θ29 ^ 23 ^ 3θ3

Hmotnostné spektrum: m/z = 461 (M+) (14) 3-Z-[1-(4-bróm-fenylamino)-1-fenyl-metylén]-5-amido-2-indolinón Výťažok: 35 % teoretickej hodnotyMass spectrum: m / z = 461 (M + ) (14) 3-Z- [1- (4-Bromo-phenylamino) -1-phenyl-methylene] -5-amido-2-indolinone Yield: 35% of theory

Rf: 0,46 (silikagél; metylénchlorid/metanol = 9:1) θ22Ηΐ6θΓΝ3Ο2 Rf: 0.46 (silica gel; methylene chloride / methanol = 9: 1) θ22Ηΐ6θΓΝ 3 Ο 2

Hmotnostné spektrum: m/z = 433/435 (M+) (15) 3-Z-[ 1 -(4-metoxykarbonyl-fenylamino)-1 -fenyl-metylén]-5-amido-2-indolinón Výťažok: 34 % teoretickej hodnotyMass Spectrum: m / z = 433/435 (M + ) (15) 3- Z- [1- (4-Methoxycarbonyl-phenylamino) -1-phenyl-methylene] -5-amido-2-indolinone Yield: 34% of theoretical value

Rf: 0,36 (silikagél; metylénchlorid/metanol = 9:1) Rf: 0.36 (silica gel; methylene chloride / methanol = 9: 1)

C24H19N3O4 C 24 H 19 N 3 O 4

Hmotnostné spektrum: m/z = 413 (M+) (16) 3-Z-[1-(3-amido-fenylamino)-1-fenyl-metylén]-5-amido-2-indolinón Výťažok: 32 % teoretickej hodnotyMass spectrum: m / z = 413 (M + ) (16) 3-Z- [1- (3-amido-phenylamino) -1-phenyl-methylene] -5-amido-2-indolinone Yield: 32% of theory

Rf: 0,32 (silikagél; metylénchlorid/metanol = 9:1) Rf: 0.32 (silica gel; methylene chloride / methanol = 9: 1)

C23H18N4O3 C 23 H 18 N 4 O 3

Hmotnostné spektrum: m/z = 398 (M+) (17) 3-Z-[1-(3-metyl-fenylamino)-1-fenyl-metylén]-5-amido-2-indolinón Výťažok: 12 % teoretickej hodnotyMass spectrum: m / z = 398 (M + ) (17) 3-Z- [1- (3-methyl-phenylamino) -1-phenyl-methylene] -5-amido-2-indolinone Yield: 12% of theory

Rf: 0,5 (silikagél; metylénchlorid/metanol = 9:1) θ23^19^3θ2 Rf: 0.5 (silica gel, methylene chloride / methanol = 9: 1) θ23 ^ 19 ^ 3θ2

Hmotnostné spektrum: m/z = 369 (M+)Mass Spectrum: m / z = 369 (M &lt; + &gt; )

-40(18) 3-Z-[1 -(2-metyl-fenylamino)-1 -fenyl-metylén]-5-amido-2-indolinón Výťažok: 21 % teoretickej hodnoty-40 (18) 3-Z- [1- (2-methyl-phenylamino) -1-phenyl-methylene] -5-amido-2-indolinone Yield: 21% of theory

R,: 0,5 (silikagél; metylénchlorid/metanol = 9:1)Rf: 0.5 (silica gel; methylene chloride / methanol = 9: 1)

C23H19N3O2C23H19N3O2

Hmotnostné spektrum: m/z = 369 (M+) (19) 3-Z-[ 1 -(3-metoxy-fenylamino)-1 -fenyl-metylén]-5-amido-2-indolinón Rf: 0,49 (silikagél; metylénchlorid/metanol = 9:1)MS: m / z = 369 (M +) (19) 3-Z- [1 - (3-methoxy-phenylamino) -1-phenyl-methylene] -5-amido-2-indolinone Rf: 0.49 (silica gel; methylene chloride / methanol = 9: 1)

C23H19N3O3C23H19N3O3

Hmotnostné spektrum: m/z = 385 (M+) (20) 3-Z-[ 1 -(3-etoxykarbonyl-fenylamino)-1 -fenyl-metylén]-5-amido-2-indolinón Rf: 0,48 (silikagél; metylénchlorid/metanol = 9:1) ^25^21^04MS: m / z = 385 (M +) (20) 3-Z- [1 - (3-ethoxycarbonyl-phenylamino) -1-phenyl-methylene] -5-amido-2-indolinone Rf: 0.48 (silica gel; methylene chloride / methanol = 9: 1) ^ 25 ^ 21 ^ 04

Hmotnostné spektrum: m/z = 427 (IVľ) (21) 3-Z-[1-(3-nitro-fenylamino)-1-fenyl-metylén]-5-amido-2-indolinón Výťažok: 32 % teoretickej hodnotyMass Spectrum: m / z = 427 (M +) (21) 3-Z- [1- (3-nitro-phenylamino) -1-phenyl-methylene] -5-amido-2-indolinone Yield: 32% of theory

R,: 0,56 (silikagél; metylénchlorid/metanol = 9:1)Rf: 0.56 (silica gel; methylene chloride / methanol = 9: 1)

C22H16N4O4 C 22 H 16 N 4 O 4

Hmotnostné spektrum: m/z = 400 (M+) (22) 3-Z-[ 1 -(4-amido-fenylamino)-1 -fenyl-metylén]-5-amido-2-indolinón Výťažok: 26 % teoretickej hodnotyMass Spectrum: m / z = 400 (M + ) (22) 3-Z- [1- (4-amido-phenylamino) -1-phenyl-methylene] -5-amido-2-indolinone Yield: 26% of theory

Rf: 0,47 (silikagél; metylénchlorid/metanol = 9:1) θ23^18^4θ3 Rf: 0.47 (silica gel; methylene chloride / methanol = 9: 1) θ23 ^ 18 ^ 4θ3

Hmotnostné spektrum: m/z = 398 (IVľ) (23) 3-Z-[ 1 -(4-pyridylamino)-1 -fenyl-metylén]-5-amido-2-indolinón Výťažok: 15 % teoretickej hodnotyMass Spectrum: m / z = 398 (M +) (23) 3-Z- [1- (4-Pyridylamino) -1-phenylmethylene] -5-amido-2-indolinone Yield: 15% of theory

Rf: 0,42 (silikagél; metylénchlorid/metanol = 9:1) Rf: 0.42 (silica gel; methylene chloride / methanol = 9: 1)

-41 C21H16N4O2 -41 C 21 H 16 N 4 O 2

Hmotnostné spektrum: m/z = 356 (M+) (24) 3-Z-[1-(4-metyl-fenylamino)-1-fenyl-metylén]-5-amido-2-indolinón Výťažok: 45 % teoretickej hodnotyMass spectrum: m / z = 356 (M + ) (24) 3-Z- [1- (4-methyl-phenylamino) -1-phenyl-methylene] -5-amido-2-indolinone Yield: 45% of theory

Rf: 0,54 (silikagél; metylénchlorid/metanol = 9:1) Rf: 0.54 (silica gel; methylene chloride / methanol = 9: 1)

C23H19N3O2 C 23 H 19 N 3 O 2

Hmotnostné spektrum: m/z = 369 (M+) (25) 3-Z-[1-(4-etoxy-fenylamino)-1-fenyl-metylén]-5-amido-2-indolinón Výťažok: 40 % teoretickej hodnotyMass spectrum: m / z = 369 (M + ) (25) 3-Z- [1- (4-ethoxy-phenylamino) -1-phenyl-methylene] -5-amido-2-indolinone Yield: 40% of theoretical

R,: 0,51 (silikagél; metylénchlorid/metanol = 9:1) θ24Η21^3θ3Rf: 0.51 (silica gel; methylene chloride / methanol = 9: 1) θ2 4 Η21 ^ 3θ3

Hmotnostné spektrum: m/z = 399 (M+) (26) 3-Z-[1 -(3-bróm-fenylamino)-1 -fenyl-metylén]-5-amido-2-indolinón Výťažok: 41 % teoretickej hodnotyMass Spectrum: m / z = 399 (M + ) (26) 3-Z- [1- (3-bromo-phenylamino) -1-phenyl-methylene] -5-amido-2-indolinone Yield: 41% of theory

Rf: 0,53 (silikagél; metylénchlorid/metanol = 9:1) Rf: 0.53 (silica gel; methylene chloride / methanol = 9: 1)

C22HieBrN3O2 C 22 H ie BrN 3 O 2

Hmotnostné spektrum: m/z = 433/435 (M+) (27) 3-Z-[ 1 -(4-chlór-fenylamino)-1 -fenyl-metylén]-5-amido-2-indolinón Výťažok: 50 % teoretickej hodnotyMass spectrum: m / z = 433/435 (M + ) (27) 3- Z- [1- (4-chloro-phenylamino) -1-phenyl-methylene] -5-amido-2-indolinone Yield: 50% of theoretical value

R,: 0,49 (silikagél; metylénchlorid/metanol = 9:1) θ22Ηιβθ'Ν3Ο2 Rf: 0.49 (silica gel; methylene chloride / methanol = 9: 1) θ22Ηιβθ'Ν 3 Ο 2

Hmotnostné spektrum: m/z = 389/391 (M+) (28) 3-Z-[1-(4-izopropyl-fenylamino)-1-fenyl-metylén]-5-amido-2-indolinón Výťažok: 48 % teoretickej hodnotyMass spectrum: m / z = 389/391 (M + ) (28) 3- Z- [1- (4-isopropyl-phenylamino) -1-phenyl-methylene] -5-amido-2-indolinone Yield: 48% of theoretical value

Rf: 0,65 (silikagél; metylénchlorid/metanol = 9:1) ^25^23^302 Rf: 0.65 (silica gel; methylene chloride / methanol = 9: 1) ^ 25 ^ 23 ^ 302

-42Hmotnostné spektrum: m/z = 397 (IVľ) (29) 3-Z-[1 -(2-fluorenylamino)-1 -fenyl-metylén]-5-amido-2-indolinón-42Mass spectrum: m / z = 397 (MH +) (29) 3-Z- [1- (2-fluorenylamino) -1-phenylmethylene] -5-amido-2-indolinone

Výťažok: 43 % teoretickej hodnotyYield: 43% of theory

Rf: 0,58 (silikagél; metylénchlorid/metanol = 9:1) θ29^21^3θ2 Rf: 0.58 (silica gel; methylene chloride / methanol = 9: 1) θ29 ^ 21 ^ 3θ2

Hmotnostné spektrum: m/z = 443 (M+) (30) 3-Z-[1 -(4-(2-hydroxyetyl)-fenylamino)-1 -fenyl-metylén]-5-amido-2-indolinón Výťažok: 22 % teoretickej hodnotyMass spectrum: m / z = 443 (M + ) (30) 3-Z- [1- (4- (2-hydroxyethyl) phenylamino) -1-phenylmethylene] -5-amido-2-indolinone Yield: 22% of the theoretical value

Rf: 0,37 (silikagél; metylénchlorid/metanol = 9:1) θ24^21^3θ3 Rf: 0.37 (silica gel; methylene chloride / methanol = 9: 1) θ24 ^ 21 ^ 3θ3

Hmotnostné spektrum: m/z = 398 (M-H) (31) 3-Z-[1-(4-(4-imidazolyl)-fenylamino)-1-fenyl-metylén]-5-amido-2-indolinón Výťažok: 23 % teoretickej hodnotyMass Spectrum: m / z = 398 (MH) (31) 3-Z- [1- (4- (4-imidazolyl) phenylamino) -1-phenylmethylene] -5-amido-2-indolinone Yield: 23 % of the theoretical value

Rf: 0,5 (silikagél; metylénchlorid/metanol = 9:1) ^25^1 gN5O2 Rf: 0.5 (silica gel, methylene chloride / methanol = 9: 1) ^ 25 ^ 1 5 g of N 2 O

Hmotnostné spektrum: m/z = 421 (M+) (32) 3-Z-[1 -(4-etoxykarbonylmetyl-fenylamino)-1 -fenyl-metylén]-5-amido-2-indolinón θ26^23^3θ4Mass Spectrum: m / z = 421 (M &lt; + &gt; ) (32) 3-Z- [1- (4-ethoxycarbonylmethyl-phenylamino) -1-phenylmethylene] -5-amido-2-indolinone

Hmotnostné spektrum: m/z = 442 (M+H)+ (33) 3-Z-[1 -(4-bróm-3-metyl-fenylamino)-1 -fenyl-metylén]-5-amido-2-indolinón θ23^18θ^3θ2Mass Spectrum: m / z = 442 (M + H) + (33) 3- Z- [1- (4-bromo-3-methyl-phenylamino) -1-phenyl-methylene] -5-amido-2-indolinone θ23 18θ ^ ^ 3θ2

Hmotnostné spektrum: m/z = 447/449 (M+) (34) 3-Z-[1 -(4-cyklohexyl-fenylamino)-1 -fenyl-metylén]-5-amido-2-indolinón θ28^27^3θ2Mass spectrum: m / z = 447/449 (M + ) (34) 3- Z- [1- (4-cyclohexyl-phenylamino) -1-phenyl-methylene] -5-amido-2-indolinone 3θ2

Hmotnostné spektrum: m/z = 437 (M+)Mass Spectrum: m / z = 437 (M &lt; + &gt; )

-43(35) 3-Z-[1 -(4-bróm-2-metyl-fenylamino)-1 -fenyl-metylén]-5-amido-2-indolinón C23H18BrN3O2 -43 (35) 3-Z- [1- (4-bromo-2-methyl-phenylamino) -1-phenyl-methylene] -5-amido-2-indolinone C 23 H 18 BrN 3 O 2

Hmotnostné spektrum: m/z = 447/449 (M+) (36) 3-Z-[1 -amino-1 -fenyl-metylén]-5-amido-2-indolinónMass Spectrum: m / z = 447/449 (M &lt; + &gt; ) (36) 3-Z- [1-amino-1-phenyl-methylene] -5-amido-2-indolinone

Rf: 0,3 (silikagél; metylénchlorid/metanol = 9:1) ^16^13^302 Rf: 0.3 (silica gel, methylene chloride / methanol = 9: 1) ^ 16 ^ 13 ^ 302

Hmotnostné spektrum: m/z = 279 (M+) (37) 3-Z-[ 1 -cyklohexylamino-1 -fenyl-metylén]-5-amido-2-indolinón Rf: 0,55 (silikagél; metylénchlorid/metanol = 9:1)Mass spectrum: m / z = 279 (M + ) (37) 3-Z- [1-cyclohexylamino-1-phenyl-methylene] -5-amido-2-indolinone R f : 0.55 (silica gel; methylene chloride / methanol = 9: 1

C22H23N3O2 C 22 H 23 N 3 O 2

Hmotnostné spektrum: m/z = 361 (M+) (38) 3-Z-[ 1 -cyklopentylamino-1 -fenyl-metylén]-5-amido-2-indolinón Rf: 0,53 (silikagél; metylénchlorid/metanol = 9:1)Mass spectrum: m / z = 361 (M + ) (38) 3-Z- [1-cyclopentylamino-1-phenyl-methylene] -5-amido-2-indolinone R f : 0.53 (silica gel; methylene chloride / methanol = 9: 1

C21H21N3O2 C 21 H 21 N 3 O 2

Hmotnostné spektrum: m/z = 347 (M*) (39) 3-Z-[1-metylamino-1-fenyl-metylén]-5-amido-2-indolinónMass Spectrum: m / z = 347 (M +) (39) 3-Z- [1-methylamino-1-phenylmethylene] -5-amido-2-indolinone

R,: 0,5 (silikagél; metylénchlorid/metanol = 9:1)Rf: 0.5 (silica gel; methylene chloride / methanol = 9: 1)

Cl7HlsN3O2 Cl7HlsN 2 O 3

Hmotnostné spektrum: m/z = 293 (M+) (40) 3-Z-[1 -etylamino-1 -fenyl-metylén]-5-amido-2-indolinónMass Spectrum: m / z = 293 (M &lt; + &gt; ) (40) 3-Z- [1-ethylamino-1-phenylmethylene] -5-amido-2-indolinone

Rf: 0,52 (silikagél; metylénchlorid/metanol = 9:1) θΙβ^Ιϊ^θΣ Rf: 0.52 (silica gel; methylene chloride / methanol = 9: 1) θΙβ Ιϊ ^ ^ θΣ

Hmotnostné spektrum: m/z = 307 (M+) (41) 3-Z-[1-izopropylamino-1-fenyl-metylén]-5-amido-2-indolinónMass Spectrum: m / z = 307 (M &lt; + &gt; ) (41) 3-Z- [1-isopropylamino-1-phenyl-methylene] -5-amido-2-indolinone

Rf: 0,44 (silikagél; metylénchlorid/metanol = 9:1) Rf: 0.44 (silica gel; methylene chloride / methanol = 9: 1)

-44Ο19Η19Ν3Ο2-44Ο19Η19Ν3Ο2

Hmotnostné spektrum: m/z = 321 (M+) (42) 3-Z-[1 -dimetylamino-1 -fenyl-metylén]-5-amido-2-indolinón Rf: 0,39 (silikagél; metylénchlorid/metanol = 9:1) θ18^17^3θ2Mass spectrum: m / z = 321 (M + ) (42) 3-Z- [1-dimethylamino-1-phenyl-methylene] -5-amido-2-indolinone R f : 0.39 (silica gel; methylene chloride / methanol = 9: 1) θ18 ^ 17 ^ 3θ2

Hmotnostné spektrum: m/z = 307 (M+) (43) 3-Z-[1 -cyklpropylamino-1 -fenyl-metylén]-5-amido-2-indolinón Rf: 0,47 (silikagél; metylénchlorid/metanol = 9:1)Mass spectrum: m / z = 307 (M + ) (43) 3-Z- [1-cyclopropylamino-1-phenylmethylene] -5-amido-2-indolinone R f : 0.47 (silica gel; methylene chloride / methanol = 9: 1

O19H17N3O2O19H17N3O2

Hmotnostné spektrum: m/z = 319 (M+) (44) 3-Z-[ 1 -cykloheptylamino-1 -fenyl-metylén]-5-amido-2-indolinón Rf: 0,58 (silikagél; metylénchlorid/metanol = 9:1) θ23^25^3θ2Mass spectrum: m / z = 319 (M + ) (44) 3-Z- [1-cycloheptylamino-1-phenyl-methylene] -5-amido-2-indolinone R f : 0.58 (silica gel; methylene chloride / methanol = 9: 1) θ23 ^ 25 ^ 3θ2

Hmotnostné spektrum: m/z = 375 (M+) (45) 3-Z-[1-cyklobutylamino-1-fenyl-metylén]-5-amido-2-indolinón R,: 0,49 (silikagél; metylénchlorid/metanol = 9:1)Mass spectrum: m / z = 375 (M + ) (45) 3-Z- [1-cyclobutylamino-1-phenyl-methylene] -5-amido-2-indolinone R f: 0.49 (silica gel; methylene chloride / methanol = 9: 1

C20H19N3O2C20H19N3O2

Hmotnostné spektrum: m/z = 333 (M+) (46) 3-Z-[ 1 -(4-metylcyklohexylamino)-1 -fenyl-metylén]-5-amido-2-indolinón Rf: 0,67 (silikagél; metylénchlorid/metanol = 9:1)MS: m / z = 333 (M +) (46) 3-Z- [1 - (4-methylcyclohexylamine) -1-phenyl-methylene] -5-amido-2-indolinone Rf: 0.67 (silica gel ; methylene chloride / methanol = 9: 1)

Ο23^25^3θ2Ο23 ^ 25 ^ 3θ2

Hmotnostné spektrum: m/z = 375 (M+) (47) 3-Z-[1-(1-(R,S)-indanylamino)-1-fenyl-metylén]-5-amido-2-indolinón R,: 0,59 (silikagél; metylénchlorid/metanol = 9:1)Mass Spectrum: m / z = 375 (M &lt; + &gt; ) (47) 3-Z- [1- (1- (R, S) -indanylamino) -1-phenylmethylene] -5-amido-2-indolinone R, : 0.59 (silica gel; methylene chloride / methanol = 9: 1)

O25H21N3O2O25H21N3O2

-45Hmotnostné spektrum: m/z = 395 (IVľ) (48) 3-Z-[ 1 -(metoxykarbonylmetylamino)-l -fenyl-metylén]-5-amido-2-indolinón R,: 0,46 (silikagél; metylénchlorid/metanol = 9:1)Mass spectrum: m / z = 395 (MH +) (48) 3-Z- [1- (methoxycarbonylmethylamino) -1-phenylmethylene] -5-amido-2-indolinone R f: 0.46 (silica gel; methylene chloride) / methanol = 9: 1)

CigHiyN 3O4 CigHiyN 3 O 4

Hmotnostné spektrum: m/z = 351 (M+) (49) 3-Z-[1-((2-metoxykarbonyl-etyl)-amino)-1-fenyl-metylén]-5-amido-2-indolinón Rf: 0,45 (silikagél; metylénchlorid/metanol = 9:1)Mass spectrum: m / z = 351 (M + ) (49) 3-Z- [1 - ((2-methoxycarbonyl-ethyl) -amino) -1-phenyl-methylene] -5-amido-2-indolinone R f : 0.45 (silica gel; methylene chloride / methanol = 9: 1)

C20H19N3O4 C 20 H 19 N 3 O 4

Hmotnostné spektrum: m/z = 365 (M+) (50) 3-Z-[1-(4-aminometyl-fenylamino)-1-fenyl-metylén]-5-amido-2-indolinón Výťažok: 32 % teoretickej hodnotyMass spectrum: m / z = 365 (M + ) (50) 3-Z- [1- (4-Aminomethyl-phenylamino) -1-phenyl-methylene] -5-amido-2-indolinone Yield: 32% of theory

R,: 0,46 (silikagél; metylénchlorid/metanol = 9:1)Rf: 0.46 (silica gel; methylene chloride / methanol = 9: 1)

C23H20N4O2C23H20N4O2

Hmotnostné spektrum: m/z = 384 (M+) (51) 3-Z-[1 -(4-pyrolidínmetyl-fenylamino)-1-fenyl-metylén]-5-amido-2-indolinón Výťažok: 60 % teoretickej hodnotyMass spectrum: m / z = 384 (M + ) (51) 3-Z- [1- (4-pyrrolidinomethyl-phenylamino) -1-phenyl-methylene] -5-amido-2-indolinone Yield: 60% of theoretical

Rf: 0,07 (silikagél; metylénchlorid/metanol = 9:1) Rf: 0.07 (silica gel; methylene chloride / methanol = 9: 1)

C27H26N4O2C27H26N4O2

Hmotnostné spektrum: m/z = 438 (M+) (52) 3-Z-[1 -(4-morfolínmetyl-fenylamino)-1 -fenyl-metylén]-5-amido-2-indolinón Výťažok: 65 % teoretickej hodnotyMass spectrum: m / z = 438 (M + ) (52) 3-Z- [1- (4-Morpholinomethyl-phenylamino) -1-phenyl-methylene] -5-amido-2-indolinone Yield: 65% of theory

Rf: 0,46 (silikagél; metylénchlorid/metanol = 9:1) θ27^26^4θ3 Rf: 0.46 (silica gel; methylene chloride / methanol = 9: 1) θ27 ^ 26 ^ 4θ3

Hmotnostné spektrum: m/z = 454 (M+)Mass Spectrum: m / z = 454 (M &lt; + &gt; )

-46(53) 3-Z-[1-(4-piperidínmetyl-fenylamino)-1-fenyl-metylén]-5-amido-2-indolinón Výťažok: 60 % teoretickej hodnoty-46 (53) 3-Z- [1- (4-Piperidinomethyl-phenylamino) -1-phenyl-methylene] -5-amido-2-indolinone Yield: 60% of theory

Rf: 0,08 (silikagél; metylénchlorid/metanol = 9:1) θ28^28^4θ2 Rf: 0.08 (silica gel; methylene chloride / methanol = 9: 1) θ28 ^ 28 ^ 4θ2

Hmotnostné spektrum: m/z = 452 (M+) (54) 3-Z-[1 -(4-hexametyléniminometyl-fenylamino)-1 -fenyl-metylén]-5-amido-2indolinón-trifluóracetátMass Spectrum: m / z = 452 (M + ) (54) 3- Z- [1- (4-Hexamethyleniminomethyl-phenylamino) -1-phenyl-methylene] -5-amido-2-indolinone trifluoroacetate

C29H30N4O2C29H30N4O2

Hmotnostné spektrum: m/z = 466 (M+) (55) 3-Z-[1-(4-(4-hydroxy-piperidínmetyl)-fenylamino)-1-fenyl-metylén]-5-amido-2indolinón ^28^28^403Mass Spectrum: m / z = 466 (M + ) (55) 3- Z- [1- (4- (4-Hydroxy-piperidinomethyl) -phenylamino) -1-phenyl-methylene] -5-amido-2-indolinone ^ 28 ^ 28 ^ 403

Hmotnostné spektrum: m/z = 468 (M+) (56) 3-Z-[1-(4-(4-metyl-piperidínmetyl)-fenylamino)-1-fenyl-metylén]-5-amido-2indolinón θ29^30^4θ2Mass spectrum: m / z = 468 (M + ) (56) 3-Z- [1- (4- (4-methyl-piperidinomethyl) -phenylamino) -1-phenyl-methylene] -5-amido-2-indolinone 30 ^ 4θ2

Hmotnostné spektrum: m/z = 466 (M+) (57) 3-Z-[1 -(4-(4-etyl-piperidínmetyl)-fenylamino)-1 -fenyl-metylén]-5-amido-2indolinónMass Spectrum: m / z = 466 (M &lt; + &gt; ) (57) 3-Z- [1- (4- (4-ethyl-piperidinomethyl) phenylamino) -1-phenylmethylene] -5-amido-2-indolinone

C30H32N4O2C30H32N4O2

Hmotnostné spektrum: m/z = 480 (IVľ) (58) 3-Z-[1 -(4-(4-izopropyl-piperidínmetyl)-fenylamino)-1 -fenyl-metylén]-5-amido-2 indolinón θ31^34Ν402Mass Spectrum: m / z = 480 (M +) (58) 3-Z- [1- (4- (4-Isopropyl-piperidinomethyl) -phenylamino) -1-phenyl-methylene] -5-amido-2 indolinone 34Ν 4 02

Hmotnostné spektrum: m/z = 494 (IVľ)Mass Spectrum: m / z = 494 (M +)

-47(59) 3-Z-[1 -(4-(4-fenyl-piperid ínmetyInitro-fenylamino)-1 -fenyl-metylén]-5-amido-2indolinón θ34^32^4θ2-47 (59) 3-Z- [1- (4- (4-phenyl-piperidinomethylnitro-phenylamino) -1-phenyl-methylene] -5-amido-2-indolinone

Hmotnostné spektrum: m/z = 528 (IVľ) (60) 3-Z-[1 -(4-(4-benzyl-piperidínmetyl)-fenylamino)-1 -fenyl-metylén]-5-amido-2indolinón θ35^34^4θ2Mass Spectrum: m / z = 528 (M +) (60) 3-Z- [1- (4- (4-Benzyl-piperidinomethyl) -phenylamino) -1-phenyl-methylene] -5-amido-2-indolinone ^ 4θ2

Hmotnostné spektrum: m/z = 542 (IVľ) (61) 3-Z-[1-(4-(4-etoxykarbonyl-piperidínmetyl)-fenylamino)-1-fenyl-metylén]-5amido-2-indolinón θ31^32^4θ4Mass Spectrum: m / z = 542 (M +) (61) 3-Z- [1- (4- (4-Ethoxycarbonyl-piperidinomethyl) -phenylamino) -1-phenyl-methylene] -5-amido-2-indolinone ^ 4θ4

Hmotnostné spektrum: m/z = 524 (IVľ) (62) 3-Z-[ 1 -(4-dimetylaminometyl-fenylamino)-1 -fenyl-metylén]-5-amido-2-indolinón C25H24N4O2 Mass Spectrum: m / z = 524 (M +) (62) 3-Z- [1- (4-dimethylaminomethyl-phenylamino) -1-phenyl-methylene] -5-amido-2-indolinone C 25 H 24 N 4 O 2

Hmotnostné spektrum: m/z = 412 (IVľ) (63) 3-Z-[ 1 -(4-dipropylaminometyl-fenylamino)-1 -fenyl-metylén]-5-amido-2-indolinón C29H32N4O2Mass Spectrum: m / z = 412 (MH +) (63) 3-Z- [1- (4-Dipropylaminomethyl-phenylamino) -1-phenyl-methylene] -5-amido-2-indolinone C29H32N4O2

Hmotnostné spektrum: m/z = 468 (IVľ) (64) 3-Z-[1 -(4-piperazinylmetyl-fenylamino)-1 -fenyl-metylén]-5-amido-2-indolinón C27H27N5O2 Mass spectrum: m / z = 468 (MH +) (64) 3-Z- [1- (4-piperazinylmethyl-phenylamino) -1-phenyl-methylene] -5-amido-2-indolinone C 27 H 27 N 5 O 2

Hmotnostné spektrum: m/z = 453 (IVľ) (65) 3-Z-[1 -(3-dimetylaminometyl-fenylamino)-1 -fenyl-metylén]-5-amido-2-indolinón ^25^24^402Mass Spectrum: m / z = 453 (MH +) (65) 3-Z- [1- (3-dimethylaminomethyl-phenylamino) -1-phenyl-methylene] -5-amido-2-indolinone ^ 25 ^ 24 ^ 402

Hmotnostné spektrum: m/z = 412 (M+)Mass Spectrum: m / z = 412 (M &lt; + &gt; )

-48(66) 3-Ζ-[ 1 -(4-(2-dietylamino-etyl)-fer»ylamino)-1 -fenyl-metylén]-5-amido-2-indolinón cäna-48 (66) 3- Ζ- [1- (4- (2-diethylamino-ethyl) -phenylamino) -1-phenyl-methylene] -5-amido-2-indolinone

Hmotnostné spektrum: m/z = 454 (M+) (67) 3-Z-[1-(4-(2-morfolín-etyl)-fenylamino)-1-fenyl-metylén]-5-amido-2-indolinón θ28^28^4θ3Mass Spectrum: m / z = 454 (M &lt; + &gt; ) (67) 3-Z- [1- (4- (2-morpholin-ethyl) -phenylamino) -1-phenyl-methylene] -5-amido-2-indolinone θ28 ^ 28 ^ 4θ3

Hmotnostné spektrum: m/z = 468 (M+) (68) 3-Z-[1 -(4-(2-pyrolidinyl-etyl)-fenylamino)-1 -fenyl-metylén]-5-amido-2-indolinón C28H28N4O2Mass Spectrum: m / z = 468 (M + ) (68) 3- Z - [1- (4- (2-pyrrolidinyl-ethyl) -phenylamino) -1-phenyl-methylene] -5-amido-2-indolinone C28H28N4O2

Hmotnostné spektrum: m/z = 452 (M+) (69) 3-Z-[1-(4-(2-piperidinyl-etyl)-fenylamino)-1-fenyl-metylén]-5-amido-2-indolinón θ29^30^4θ2Mass Spectrum: m / z = 452 (M + ) (69) 3- [1- (4- (2-piperidinyl-ethyl) -phenylamino) -1-phenyl-methylene] -5-amido-2-indolinone θ29 ^ 30 ^ 4θ2

Hmotnostné spektrum: m/z = 466 (M+) (70) 3-Z-[1 -(2-tiazolylamino)-1 -fenyl-metylén]-5-amido-2-indolinónMass Spectrum: m / z = 466 (M &lt; + &gt; ) (70) 3-Z- [1- (2-thiazolylamino) -1-phenylmethylene] -5-amido-2-indolinone

Výťažok: 30 % teoretickej hodnotyYield: 30% of theory

Rf: 0,48 (silikagél; metylénchlorid/metanol = 9:1) Rf: 0.48 (silica gel; methylene chloride / methanol = 9: 1)

C19H14N4O2SC 19 H 14 N 4 O 2 S

Hmotnostné spektrum: m/z = 362 (M+) (71) 3-Z-[1-(benzimidazol-2-ylamino)-1-fenyl-metylén]-5-amido-2-indolinón Výťažok: 29 % teoretickej hodnotyMass Spectrum: m / z = 362 (M + ) (71) 3-Z- [1- (benzimidazol-2-ylamino) -1-phenylmethylene] -5-amido-2-indolinone Yield: 29% of theory

Rf: 0,44 (silikagél; metylénchlorid/metanol = 9:1) Rf: 0.44 (silica gel; methylene chloride / methanol = 9: 1)

C23H17N5O2 C 23 H 17 N 5 O 2

Hmotnostné spektrum: m/z = 395 (M+) (72) 3-Z-[1 -(5-metyl-izoxazol-3-yl-amino)-1 -fenyl-metylén]-5-amido-2-indolinón Výťažok: 39 % teoretickej hodnotyMass Spectrum: m / z = 395 (M &lt; + &gt; ) (72) 3-Z- [1- (5-methyl-isoxazol-3-yl-amino) -1-phenyl-methylene] -5-amido-2-indolinone Yield: 39% of theory

Rf: 0,43 (silikagél; metylénchlorid/metanol = 9:1) Rf: 0.43 (silica gel; methylene chloride / methanol = 9: 1)

-49C21H18N4O3 -49C 21 H 18 N 4 O 3

Hmotnostné spektrum: m/z = 374 (M+) (73) 3-Z-[ 1 -benzylamino-1 -fenyl-metylén]-5-amido-2-indolinónMass Spectrum: m / z = 374 (M &lt; + &gt; ) (73) 3-Z- [1-benzylamino-1-phenyl-methylene] -5-amido-2-indolinone

Rf: 0,63 (silikagél; metylénchlorid/metanol = 9:1) θ23^19^3θ2 Rf: 0.63 (silica gel; methylene chloride / methanol = 9: 1) θ23 ^ 19 ^ 3θ2

Hmotnostné spektrum: m/z = 369 (M+) (74) 3-Z-[ 1 -(4-(1 -imidazolyl-metyl)-fenylamino)-1 -fenyl-metylén]-5-amido-2-indolinón Rf: 0,45 (silikagél; metylénchlorid/metanol = 9:1)Mass Spectrum: m / z = 369 (M &lt; + &gt; ) (74) 3-Z- [1- (4- (1-imidazolylmethyl) phenylamino) -1-phenylmethylene] -5-amido-2-indolinone Rf: 0.45 (silica gel; methylene chloride / methanol = 9: 1)

C26H22N5O2 C 26 H 22 N 5 O 2

Hmotnostné spektrum: m/z = 436 (M+) (75) 3-Z-[ 1 -(4-((2-dietylamino-etyl)-aminokarbonyl)-fenylamino)-1 -fenyl-metylén]-5amido-2-indolinón-trifluóracetátMass Spectrum: m / z = 436 (M &lt; + &gt; ) (75) 3-Z- [1- (4 - ((2-diethylamino-ethyl) -aminocarbonyl) -phenylamino) -1-phenyl-methylene] -5-amido-2 -indolinón trifluoroacetate

Výťažok: 27 % teoretickej hodnotyYield: 27% of theory

Rf: 0,05 (silikagél; metylénchlorid/metanol = 9:1) Rf: 0.05 (silica gel; methylene chloride / methanol = 9: 1)

C29H31N5O3C29H31N5O3

Hmotnostné spektrum: m/z = 497 (M+) (76) 3-Z-[1-(4-acetylaminometyl-fenylamino)-1-fenyl-metylén]-5-amido-2-indolinón Rf: 0,4 (silikagél; metylénchlorid/metanol = 9:1)MS: m / z = 497 (M +) (76) 3-Z- [1- (4-acetylamino-phenylamino) -1-phenyl-methylene] -5-amido-2-indolinone Rf value: 0.4 (silica gel; methylene chloride / methanol = 9: 1)

C25H22N4O3 C 2 5H 22 N 4 O 3

Hmotnostné spektrum: m/z = 426 (M+) (77) 3-Z-[1 -(4-((2-dimetylaminoetyl)-/\/-metánsulfonyl-amino)-fenylamino)-1 -fenylmetylén]-5-amido-2-indolinónMass spectrum: m / z = 426 (M + ) (77) 3-Z- [1- (4 - ((2-dimethylaminoethyl) - N -methanesulfonylamino) -phenylamino) -1-phenylmethylene] -5 amido-2-indolinone

Rf: 0,1 (silikagél; metylénchlorid/metanol = 9:1) Rf: 0.1 (silica gel, methylene chloride / methanol = 9: 1)

027Η250480 27 Η 2 9 Ν 5 0 4 8

Hmotnostné spektrum: m/z = 519 (M+)Mass Spectrum: m / z = 519 (M &lt; + &gt; )

-50(78) 3-Z-[1 -(4-(W-(etoxykarbonylmetyl)-/V-metánsulfonyl-amino)-fenylamino)-1 -fenyl metylén]-5-amido-2-indolinón-50 (78) 3-Z- [1- (4- (N - (ethoxycarbonylmethyl) - N -methanesulfonyl-amino) -phenylamino) -1-phenyl-methylene] -5-amido-2-indolinone

Rf: 0,57 (silikagél; metylénchlorid/metanol = 9:1) θ27^26^4θ6 Rf: 0.57 (silica gel; methylene chloride / methanol = 9: 1) θ27 ^ 26 ^ 4θ6

Hmotnostné spektrum: m/z = 534 (M+) (79) 3-Z-[1 -(4-(W-(kyanometyl)-A/-metánsulfonyl-amino)-fenylamino)-1 -fenylmetylén]-5-amido-2-indolinónMass Spectrum: m / z = 534 (M + ) (79) 3- Z - [1- (4- (N - (cyanomethyl) - N -methanesulfonyl-amino) -phenylamino) -1-phenylmethylene] -5- amido-2-indolinone

Rf: 0,49 (silikagél; metylénchlorid/metanol = 9:1) Rf: 0.49 (silica gel; methylene chloride / methanol = 9: 1)

C25H21N5O4SC 25 H 21 N 5 O 4 N

Hmotnostné spektrum: m/z = 487 (IVľ) (80) 3-Z-[ 1 -(4-(/V-metyl-/\/-metánsulfonyl-amino)-fenylamino)-1 -fenyl-metylén]-5amido-2-indolinónMass Spectrum: m / z = 487 (M +) (80) 3- Z - [1- (4- (N -methyl- N - methanesulfonyl-amino) -phenylamino) -1-phenyl-methylene] -5-amido -2-indolinone

R,: 0,46 (silikagél; metylénchlorid/metanol = 9:1)Rf: 0.46 (silica gel; methylene chloride / methanol = 9: 1)

C24H22N4O4SC 24 H 22 N 4 O 4 S

Hmotnostné spektrum: m/z = 462 (M+) (81) 3-Z-[1-(4-(2-oxo-pyrolidín-1-yl-metyl)-fenylamino)-1 -fenyl-metylén]-5-amido-2indolinón θ27^24Ν403Mass Spectrum: m / z = 462 (M + ) (81) 3- [1- (4- (2-oxo-pyrrolidin-1-ylmethyl) -phenylamino) -1-phenyl-methylene] -5 -amido-2-indolinone θ27 ^ 2 4 Ν 4 03

Hmotnostné spektrum: m/z = 452 (IVľ) (82) 3-Z-[ 1 -(4-(2-oxo-piperidín-1 -yl-metyl-fenylamino)-1 -fenyl-metylén]-5-amido-2indolinónMass Spectrum: m / z = 452 (M +) (82) 3-Z- [1- (4- (2-Oxo-piperidin-1-ylmethyl-phenylamino) -1-phenyl-methylene] -5-amido -2indolinón

C28H26N4O3 C 28 H 26 N 4 O 3

Hmotnostné spektrum: m/z = 466 (M+) (83) 3-Z-[ 1 -(4-(4-cyklohexyl-piperidín-metyl)-fenylamino)-1 -fenyl-metylén]-5-amido2-indolinón-trifluóracetát θ34Η38Ν402Mass Spectrum: m / z = 466 (M &lt; + &gt; ) (83) 3-Z- [1- (4- (4-cyclohexyl-piperidin-methyl) -phenylamino) -1-phenyl-methylene] -5-amido-2-indolinone -trifluoroacetate θ34Η 38 Ν 4 02

-51 Hmotnostné spektrum: m/z = 534 (M+) (84) 3-Z-[1 -(4-(2,6-dimetyl-piperidín-metyl)-fenylamino)-1 -fenyl-metylén]-5-amido-2 indolinón-trifluóracetát θ3θΝ32Ν402 -51 Mass spectrum: m / z = 534 (M + ) (84) 3- Z- [1- (4- (2,6-dimethyl-piperidin-methyl) -phenylamino) -1-phenyl-methylene] -5 -amido-2 indolinone trifluoroacetate θ3θΝ32Ν 4 0 2

Hmotnostné spektrum: m/z = 480 (M+) (85) 3-Z-[ 1 -(4-(4-fenyl-4-hydroxy-piperidín-metyl)-fenylamino)-1 -fenyl-metylén]-5amido-2-indolinón-trifluóracetátMass Spectrum: m / z = 480 (M &lt; + &gt; ) (85) 3-Z- [1- (4- (4-phenyl-4-hydroxy-piperidin-methyl) -phenylamino) -1-phenyl-methylene] -5-amido 2-indolinone-trifluoroacetate

C34H32N4O3 C 3 4H 32 N 4 O 3

Hmotnostné spektrum: m/z = 545 (M+)Mass Spectrum: m / z = 545 (M &lt; + &gt; )

Rf: 0,66 (silikagél; metylénchlorid/metanol = 4:1) (86) 3-Z-[1-(4-(2-metoxykarbonyl-pyrolidín-metyl)-fenylamino)-1-fenyl-metylén]-5amido-2-indolinón-trifluóracetát θ29Η28Ν4θ4 Rf: 0.66 (silica gel; methylene chloride / methanol = 4: 1) (86) 3-Z- [1- (4- (2-methoxycarbonyl-pyrrolidin-methyl) phenylamino) -1-phenyl-methylene] - 5 amido-2-indolinone trifluoroacetate θ29 Η 28 Ν 4θ4

Hmotnostné spektrum: m/z = 497 (M+H)+ Mass spectrum: m / z = 497 (M + H) &lt; + &gt; .

Rf: 0,65 (silikagél; metylénchlorid/metanol = 4:1) (87) 3-Z-[1-(4-(1-oxo-tiomorfolín-4-ylmetyl)-fenylamino)-1-fenyl-metylén]-5-amido-2indolinón-trifluóracetát θ27^2βΝ4θ3δR f : 0.65 (silica gel; methylene chloride / methanol = 4: 1) (87) 3-Z- [1- (4- (1-oxo-thiomorpholin-4-ylmethyl) -phenylamino) -1-phenyl-methylene ] -5-amido-2-indolinone trifluoroacetate θ27 ^ 2βΝ 4 θ3δ

Hmotnostné spektrum: m/z = 487 (M+H)+ Mass spectrum: m / z = 487 (M + H) &lt; + &gt; .

Rf: 0,68 (silikagél; metylénchlorid/metanol = 4:1) (88) 3-Z-[1-(4-(3,6-dihydro-2H-pyridín-1-ylmetyl)-fenylamino)-1-fenyl-metylén]-5amido-2-indolinón-trifluóracetát θ28^26^4θ2 Rf: 0.68 (silica gel; methylene chloride / methanol = 4: 1) (88) 3-Z- [1- (4- (3,6-dihydro-2H-pyridin-1-ylmethyl) phenylamino) -1 -phenyl-methylene] -5-amido-2-indolinone trifluoroacetate

Hmotnostné spektrum: m/z = 451 (M+H)+ Mass spectrum: m / z = 451 (M + H) &lt; + &gt; .

-52(89) 3-Ζ-[1 -(4-(2,5-dihydro-pyrol-1 -ylmetyl)-fenylamino)-1 -fenyl-metylén]-5-amido-2 indolinón-trifluóracetát-52 (89) 3- Ζ- [1- (4- (2,5-dihydro-pyrrol-1-ylmethyl) -phenylamino) -1-phenyl-methylene] -5-amido-2 indolinone trifluoroacetate

C27H24N4O2C27H24N4O2

Hmotnostné spektrum: m/z = 437 (M+H)+ Mass spectrum: m / z = 437 (M + H) &lt; + &gt; .

Rf: 0,49 (silikagél; metylénchlorid/metanol = 4:1) (90) 3-Z-[1-(4-(tiomorfolín-4-ylmetyl)-fenylamino)-1-fenyl-metylén]-5-amido-2indolinón-trifluóracetát Rf: 0.49 (silica gel; methylene chloride / methanol = 4: 1) (90) 3-Z- [1- (4- (thiomorpholin-4-ylmethyl) phenylamino) -1-phenyl-methylene] -5- amide trifluoroacetate 2indolinón

C27H26N4O2SC 27 H 26 N 4 O 2 S

Hmotnostné spektrum: m/z = 471 (M+H)+ Mass spectrum: m / z = 471 (M + H) &lt; + &gt; .

Rf: 0,78 (silikagél; metylénchlorid/metanol = 4:1) (91) 3-Z-[1-(4-(4-(6,7-dimetoxy-tetrahydroizochinolín-2-ylmetyl)-fenylamino)-1 -fenyl metylén]-5-amido-2-indolinón-trifluóracetát θ34Η32Ν4Ο4 Rf: 0.78 (silica gel; methylene chloride / methanol = 4: 1) (91) 3-Z- [1- (4- (4- (6,7-dimethoxy-tetrahydroisoquinolin-2-ylmethyl) phenylamino) - 1-phenyl methylene] -5-amido-2-indolinone-trifluoroacetate θ34Η 32 Ν Ο 4 4

Hmotnostné spektrum: m/z = 561 (M+H)+ Mass spectrum: m / z = 561 (M + H) &lt; + &gt; .

R,: 0,8 (silikagél; metylénchlorid/metanol = 4:1) (92) 3-Z-[1 -(4-(4-fenyl-piperazín-1 -ylmetyl))-fenylamino)-1 -fenyl-metylén]-5-amido-2 indolinón-trifluóracetát θ33Η3ΐΝ5Ο2 R f: 0.8 (silica gel; methylene chloride / methanol = 4: 1) (92) 3-Z- [1- (4- (4-phenyl-piperazin-1-ylmethyl)) - phenylamino) -1-phenyl- methylene] -5-amido-2- indolinone-trifluoroacetate θ33Η3ΐΝ 5 Ο 2

Hmotnostné spektrum: m/z = 530 (M+H)+ Mass spectrum: m / z = 530 (M + H) &lt; + &gt; .

Rf: 0,78 (silikagél; metylénchlorid/metanol = 4:1) (93) 3-Z-[ 1 -(4-(3,5-dimetyl-piperidín-metyl)-fenylamino)-1 -fenyl-metylén]-5-amido-2indolinón-trifluóracetát θ3θΗ32Ν402 Rf: 0.78 (silica gel; methylene chloride / methanol = 4: 1) (93) 3-Z- [1 - (4- (3,5-dimethyl-piperidino-methyl) phenylamino) -1-phenyl-methylene ] -5-Amido-2-indolinone trifluoroacetate θ3θΗ 32 Ν 4 0 2

Hmotnostné spektrum: m/z = 480 (M+)Mass Spectrum: m / z = 480 (M &lt; + &gt; )

R,: 0,54 (silikagél; metylénchlorid/metanol = 4:1)Rf: 0.54 (silica gel; methylene chloride / methanol = 4: 1)

-53(94) 3-Ζ-[ 1 -(4-(/V-metyl-/V-benzyl-amino-metyl)-fenylamino)-1 -fenyl-metylén]-5amido-2-indolinón-trifluóracetát £31^29^04-53 (94) 3- Ζ- [1- (4 - (N-methyl- N -benzylamino-methyl) -phenylamino) -1-phenyl-methylene] -5-amido-2-indolinone trifluoroacetate ^ 29 ^ 04

Hmotnostné spektrum: m/z = 488 (M+) (95) 3-Z-[1-(3,4-dimetoxy-fenylamino)-1-fenyl-metylén]-5-amido-2-indolinón C24H22N3O4 Mass Spectrum: m / z = 488 (M &lt; + &gt; ) (95) 3-Z- [1- (3,4-dimethoxy-phenylamino) -1-phenyl-methylene] -5-amido-2-indolinone C 24 H 22 N 3 O 4

Hmotnostné spektrum: m/z = 415 (M+)Mass Spectrum: m / z = 415 (M &lt; + &gt; )

Rf: 0,5 (silikagél; metylénchlorid/metanol = 9:1) (96) 3-Z-[ 1 -(4-triflulórmetoxy-fenylamino)-1 -fenyl-metylén]-5-amido-2-indolinón ^23^16^ 3^03 Rf: 0.5 (silica gel, methylene chloride / methanol = 9: 1) (96) 3-Z- [1 - (4-triflulórmetoxy-phenylamino) -1-phenyl-methylene] -5-amido-2-indolinone ^ 23 ^ 16 ^ 3 ^ 03

Hmotnostné spektrum: m/z = 439 (M+)Mass Spectrum: m / z = 439 (M &lt; + &gt; )

Rf: 0,5 (silikagél; metylénchlorid/metanol = 9:1) (97) 3-Z-[1 -(3-etoxykarbonyl-fenylamino)-1 -fenyl-metylén]-5-amido-2-indolinón C25H21N3O4 Rf: 0.5 (silica gel, methylene chloride / methanol = 9: 1) (97) 3-Z- [1 - (3-ethoxycarbonyl-phenylamino) -1-phenyl-methylene] -5-amido-2-indolinone C 25 H 21 N 3 O 4

Hmotnostné spektrum: m/z = 427 (M+)Mass Spectrum: m / z = 427 (M &lt; + &gt; )

Rf: 0,52 (silikagél; metylénchlorid/metanol = 9:1) (98) 3-Z-[1 -(3-karboxy-fenylamino)-1 -fenyl-metylén]-5-amido-2-indolinón C23H17N3O4 Rf: 0.52 (silica gel; methylene chloride / methanol = 9: 1) (98) 3-Z- [1 - (3-carboxy-phenylamino) -1-phenyl-methylene] -5-amido-2-indolinone C 23 H 17 N 3 O 4

Hmotnostné spektrum: m/z = 399 (M+)Mass Spectrum: m / z = 399 (M &lt; + &gt; )

Rf: 0,14 (silikagél; metylénchlorid/metanol = 9:1) (99) 3-Z-[1-(3-dietylkarbamoyl-fenylamino)-1-fenyl-metylén]-5-amido-2-indolinón θ27^26^4θ3 Rf: 0.14 (silica gel; methylene chloride / methanol = 9: 1) (99) 3-Z- [1- (3-diethylcarbamoyl-phenylamino) -1-phenyl-methylene] -5-amido-2-indolinone θ27 ^ 26 ^ 4 θ3

Hmotnostné spektrum: m/z = 454 (M+)Mass Spectrum: m / z = 454 (M &lt; + &gt; )

Rf: 0,48 (silikagél; metylénchlorid/metanol = 9:1) Rf: 0.48 (silica gel; methylene chloride / methanol = 9: 1)

-54(100) 3-Z-[1 -(3-etylkarbamoyl-fenylamino)-1 -fenyl-metylén]-5-amido-2-indolinón C25H22N4O3-54 (100) 3-Z- [1- (3-ethylcarbamoyl-phenylamino) -1-phenyl-methylene] -5-amido-2-indolinone C25H22N4O3

Hmotnostné spektrum: m/z = 426 (M+)Mass Spectrum: m / z = 426 (M &lt; + &gt; )

R,: 0,42 (silikagél; metylénchlorid/metanol = 9:1) (101) 3-Z-[1 -(3-trifluórmetoxy-fenylamino)-1 -fenyl-metylén]-5-amido-2-indolinón θ23^16^ 3N3O3Rf: 0.42 (silica gel; methylene chloride / methanol = 9: 1) (101) 3-Z- [1- (3-trifluoromethoxy-phenylamino) -1-phenyl-methylene] -5-amido-2-indolinone ^ 16 ^ 3N3O3

Hmotnostné spektrum: m/z = 439 (M+)Mass Spectrum: m / z = 439 (M &lt; + &gt; )

Rf: 0,5 (silikagél; metylénchlorid/metanol = 9:1) (102) 3-Z-[1-(3-etoxy-fenylamino)-1-fenyl-metylén]-5-amido-2-indolinón θ24^21^3θ3 Rf: 0.5 (silica gel, methylene chloride / methanol = 9: 1) (102) 3-Z- [1- (3-ethoxy-phenylamino) -1-phenyl-methylene] -5-amido-2-indolinone θ24 ^ 21 ^ 3θ3

Hmotnostné spektrum: m/z = 399 (M+)Mass Spectrum: m / z = 399 (M &lt; + &gt; )

Rf: 0,49 (silikagél; metylénchlorid/metanol = 9:1) (103) 3-Z-[1-(4-metoxymetyl-fenylamino)-1-fenyl-metylén]-5-amido-2-indolinón C24H21N3O3 Rf: 0.49 (silica gel; methylene chloride / methanol = 9: 1) (103) 3-Z- [1- (4-methoxymethyl-phenylamino) -1-phenyl-methylene] -5-amido-2-indolinone C 24 H 21 N 3 O 3

Hmotnostné spektrum: m/z = 399 (M+)Mass Spectrum: m / z = 399 (M &lt; + &gt; )

Rf: 0,4 (silikagél; metylénchlorid/metanol = 4:1) (104) 3-Z-[1 -(4-etyl-fenylamino)-1-fenyl-metylén]-5-amido-2-indolinón C24H21N3O2 Rf: 0.4 (silica gel, methylene chloride / methanol = 4: 1) (104) 3-Z- [1 - (4-ethyl-phenylamino) -1-phenyl-methylene] -5-amido-2-indolinone C 24 H 21 N 3 O 2

Hmotnostné spektrum: m/z = 383 (M+)Mass Spectrum: m / z = 383 (M &lt; + &gt; )

R,: 0,52 (silikagél; metylénchlorid/metanol = 4:1) (105) 3-Z-[1-(4-metyl-3-nitro-fenylamino)-1-fenyl-metylén]-5-amido-2-indolinón θ23^1βΝ4θ4R f: 0.52 (silica gel; methylene chloride / methanol = 4: 1) (105) 3-Z- [1- (4-methyl-3-nitro-phenylamino) -1-phenyl-methylene] -5-amido- 2-indolinone θ23 ^ 1βΝ 4 θ4

Hmotnostné spektrum: m/z = 414 (M+) (106) 3-Z-[1 -(4-metyl-3-metoxy-fenylamino)-1 -fenyl-metylén]-5-amido-2-indolinón ^24^21^03Mass spectrum: m / z = 414 (M + ) (106) 3- Z- [1- (4-methyl-3-methoxy-phenylamino) -1-phenyl-methylene] -5-amido-2-indolinone ^ 24 ^ 21 ^ 03

-55Hmotnostné spektrum: m/z = 399 (M+) (107) 3-Z-[ 1 -(4-(4-aminofenyl-metyl)-fenylamino)-1 -fenyl-metylén]-5-amido-2indolinón-trifluóracetát θ29^24^4θ2-55 Mass spectrum: m / z = 399 (M + ) (107) 3- Z- [1- (4- (4-aminophenylmethyl) phenylamino) -1-phenylmethylene] -5-amido-2-indolinone- trifluoroacetate θ29 ^ 24 ^ 4θ2

Hmotnostné spektrum: m/z = 460 (M+) (108) 3-Z-[1-(4-metoxykarbonyl-3-metyl-fenylamino)-1-fenyl-metylén]-5-amido-2 indolinónMass Spectrum: m / z = 460 (M &lt; + &gt; ) (108) 3-Z- [1- (4-methoxycarbonyl-3-methyl-phenylamino) -1-phenyl-methylene] -5-amido-2 indolinone

C25H21N3O4 C 25 H 21 N 3 O 4

Hmotnostné spektrum: m/z = 427 (M+)Mass Spectrum: m / z = 427 (M &lt; + &gt; )

Rf: 0,56 (silikagél; metylénchlorid/metanol = 4:1) (109) 3-Z-[1-(4-kyanofenylamino)-1-fenyl-metylén]-5-amido-2-indolinón θ23ΗιβΝ4Ο2 Rf: 0.56 (silica gel; methylene chloride / methanol = 4: 1) (109) 3-Z- [1- (4-cyano-phenylamino) -1-phenyl-methylene] -5-amido-2-indolinone θ23ΗιβΝ 4 Ο 2

Hmotnostné spektrum: m/z = 380 (M+)Mass Spectrum: m / z = 380 (M &lt; + &gt; )

R,: 0,65 (silikagél; metylénchlorid/metanol = 9:1) (110) 3-Z-[1-(5-metyl-pyridín-2-yl-amino)-1-fenyl-metylén]-5-amido-2-indolinón Rf: 0,6 (silikagél; metylénchlorid/metanol = 9:1)R f: 0.65 (silica gel; methylene chloride / methanol = 9: 1) (110) 3-Z- [1- (5-methyl-pyridin-2-ylamino) -1-phenyl-methylene] -5- amido-2-indolinone R f : 0.6 (silica gel; methylene chloride / methanol = 9: 1)

C22H18N4O2 C 22 H 18 N 4 O 2

Hmotnostné spektrum: m/z = 370 (M+) (111) 3-Z-[1-(5-bróm-pyridín-2-yl-amino)-1-fenyl-metylén]-5-amido-2-indolinón Rf: 0,65 (silikagél; metylénchlorid/metanol = 9:1) θ2ΐΗΐ5θΓΝ4Ο2 Mass Spectrum: m / z = 370 (M + ) (111) 3-Z- [1- (5-bromo-pyridin-2-ylamino) -1-phenyl-methylene] -5-amido-2-indolinone Rf: 0.65 (silica gel; methylene chloride / methanol = 9: 1) θ2ΐΗΐ5θΓΝ 4 Ο 2

Hmotnostné spektrum: m/z = 434/436 (M+) (112) 3-Z-[1-(2-chlór-pyridín-5-yl-amino)-1-fenyl-metylén]-5-amido-2-indolinón Rf: 0,49 (silikagél; metylénchlorid/metanol = 9:1)Mass Spectrum: m / z = 434/436 (M &lt; + &gt; ) (112) 3-Z- [1- (2-chloro-pyridin-5-yl-amino) -1-phenyl-methylene] -5-amido-2 -indolinón Rf: 0.49 (silica gel; methylene chloride / methanol = 9: 1)

C21H15CIN4O2 C 21 H 15 CIN 4 O 2

-56Hmotnostné spektrum: m/z = 390/392 (M+) (113) 3-Z-[1-(3-kyanofenylamino)-1-fenyl-metylén]-5-amido-2-indolinón-56 Mass spectrum: m / z = 390/392 (M + ) (113) 3- Z- [1- (3-cyanophenylamino) -1-phenylmethylene] -5-amido-2-indolinone

C23H16N4O2C23H16N4O2

Hmotnostné spektrum: m/z = 380 (IVľ)Mass Spectrum: m / z = 380 (MH +)

R,: 0,57 (silikagél; metylénchlorid/metanol = 9:1) (114) 3-Z-[1-(4-(/V-fenyl-amino-metyl)-fenylamino)-1-fenyl-metylén]-5-amido-2indolinónR f: 0.57 (silica gel; methylene chloride / methanol = 9: 1) (114) 3-Z- [1- (4- (N-phenyl-amino-methyl) -phenylamino) -1-phenyl-methylene] -5-amido-2indolinón

C29H24N4O2C29H24N4O2

Hmotnostné spektrum: m/z = 460 (IVľ)Mass Spectrum: m / z = 460 (MH +)

Rf: 0,74 (silikagél; metylénchlorid/metanol = 9:1) (115) 3-Z-[1 -(4-(A/-metyl-/V-fenyl-aminometyl-fenylamino)-1 -fenyl-metylén]-5-amido Rf: 0.74 (silica gel; methylene chloride / methanol = 9: 1) (115) 3-Z- [1 - (4- (N / methyl / V-phenyl-aminomethyl-phenylamino) -1-phenyl methylene] -5-amido

2-indolinón θ30^26^4θ22-indolinone θ30 ^ 26 ^ 4θ2

Hmotnostné spektrum: m/z = 474 (M+)Mass Spectrum: m / z = 474 (M &lt; + &gt; )

Rf: 0,75 (silikagél; metylénchlorid/metanol = 9:1) (116) 3-Z-[1 -(4-(/V-etyl-aminometyl)-fenylamino)-1 -fenyl-metylén]-5-amido-2indolinón-trifluóracetát θ25^24^4θ2 Rf: 0.75 (silica gel; methylene chloride / methanol = 9: 1) (116) 3-Z- [1 - (4 - (/ V-ethyl-aminomethyl) phenylamino) -1-phenyl-methylene] -5 amido-2-indolinone trifluoroacetate θ25 ^ 24 ^ 4θ2

Hmotnostné spektrum: m/z = 412 (IVľ) (117) 3-Z-[1 -(4-(/V-(4-chlórfenyl-metyl)-aminometyl)-fenylamino)-1 -fenyl-metylén]-5 amido-2-indolinón-trifluóracetát θ30^25θ'^4θ2Mass Spectrum: m / z = 412 (MH +) (117) 3-Z- [1- (4- (N - (4-chlorophenylmethyl) aminomethyl) phenylamino) -1-phenylmethylene] -5 amido-2-indolinone trifluoroacetate θ30 25 25θ 4 4 θ2

Hmotnostné spektrum: m/z = 508/510 (M+) (118) 3-Z-[1 -(4-(/V-cyklohexyl-aminometyl)-fenylamino)-1 -fenyl-metylén]-5-amido-2 indolinón-trifluóracetátMass Spectrum: m / z = 508/510 (M + ) (118) 3- Z- [1- (4- (N-cyclohexyl-aminomethyl) -phenylamino) -1-phenyl-methylene] -5-amido- 2 indolinone trifluoroacetate

-57C29H30N4O2-57C29H30N4O2

Hmotnostné spektrum: m/z = 466 (M+) (119) 3-Z-[1 -(4-(/V-izopropyl-aminometyl)-fenylamino)-1 -fenyl-metylén]-5-amido-2indolinón-trifluóracetát θ26^26^4θ2Mass Spectrum: m / z = 466 (M &lt; + &gt; ) (119) 3-Z- [1- (4- (N-isopropyl-aminomethyl) -phenylamino) -1-phenyl-methylene] -5-amido-2-indolinone- trifluoroacetate θ26 ^ 26 ^ 4θ2

Hmotnostné spektrum: m/z = 426 (M+) (120) 3-Z-[1-(4-(N-butyl-aminometyl)-fenylamino)-1-fenyl-metylén]-5-amido-2indolinón θ27^28^4θ2Mass Spectrum: m / z = 426 (M &lt; + &gt; ) (120) 3-Z- [1- (4- (N-Butyl-aminomethyl) -phenylamino) -1-phenyl-methylene] -5-amido-2-indolinone [27] 28 ^ 4θ2

Hmotnostné spektrum: m/z = 440 (M+) (121) 3-Z-[1-(4-(/V-metoxykarbonyl-metylamino-metyl)-fenylamino)-1-fenyl-metylén] 5-amido-2-indolinón-trifluóracetát θ26^24Ν4Ο4 Mass Spectrum: m / z = 440 (M &lt; + &gt; ) (121) 3-Z- [1- (4- (N-methoxycarbonyl-methylamino-methyl) -phenylamino) -1-phenyl-methylene] 5-amido-2 -indolinone trifluoroacetate θ26 ^ 2 4 Ν 4 Ο 4

Hmotnostné spektrum: m/z = 456 (IVľ) (122) 3-Z-[1 -(4-(/V-(fenyl-metyl)-aminometyl)-fenylamino)-1 -fenyl-metylén]-5-amido2-indolinón-trifluóracetát θ30^26^4θ2Mass Spectrum: m / z = 456 (M +) (122) 3- Z - [1- (4 - (N - (Phenylmethyl) aminomethyl) phenylamino) -1-phenylmethylene] -5-amido 2 -indolinone trifluoroacetate θ30 ^ 26 ^ 4θ2

Hmotnostné spektrum: m/z = 464 (IVľ) (123) 3-Z-[ 1 -(4-(/V-acetyl-/\/-etoxykarbonylmetyl-amino)-fenylamino)-1 -fenylmetylén]-5-amido-2-indolinón θ28^26^4θ5Mass Spectrum: m / z = 464 (MH +) (123) 3-Z- [1- (4- (N-acetyl-1H-ethoxycarbonylmethyl-amino) -phenylamino) -1-phenylmethylene] -5-amido -2-indolinone θ28 ^ 26 ^ 4θ5

Hmotnostné spektrum: m/z = 498 (IVľ) (124) 3-Z-[1 -(4-metyl-3-sulfamoyl-fenylamino)-1 -fenyl-metylén]-5-amido-2-indolinón θ23^2θΝ4θ4δMass Spectrum: m / z = 498 (MH +) (124) 3-Z- [1- (4-methyl-3-sulfamoyl-phenylamino) -1-phenyl-methylene] -5-amido-2-indolinone θ23 ^ 2θΝ 4 θ 4 δ

Hmotnostné spektrum: m/z = 448 (IVľ)Mass Spectrum: m / z = 448 (M +)

-58(125) 3-Z-[1 -(4-(W-metánsulfonyl-N-(metylkarbamoylmetyl)-amino)-fenylamino)-1 fenyl-metylén]-5-amido-2-indolinón ^26^25^5θ5θ-58 (125) 3-Z- [1- (4- (N-methanesulfonyl-N- (methylcarbamoylmethyl) -amino) -phenylamino) -1-phenylmethylene] -5-amido-2-indolinone ^ 26 ^ 25 ^ 5θ5θ

Hmotnostné spektrum: m/z = 519 (M+) (126) 3-Z-[1 -(4-(/\/-metánsulfonyl-/\/-(piperidín-karbonyl-metyl)-amino)-fenylamino)-1 fenyl-metylén]-5-amido-2-indolinónMass Spectrum: m / z = 519 (M &lt; + &gt; ) (126) 3-Z- [1- (4- (N-methanesulfonyl - N - (piperidine-carbonyl-methyl) -amino) -phenylamino) - 1 phenyl-methylene] -5-amido-2-indolinone

C30H31N5O5SC 30 H 31 N 5 O 5 N

Hmotnostné spektrum: m/z = 573 (IVľ) (127) 3-Z-[1-(4-karboxy-fenylamino)-1-fenyl-metylén]-5-amido-2-indolinón C23H17N3O4 Mass spectrum: m / z = 573 (M +) (127) 3-Z- [1- (4-Carboxy-phenylamino) -1-phenyl-methylene] -5-amido-2-indolinone C 23 H 17 N 3 O 4

Hmotnostné spektrum: m/z = 398 (M-H+) (128) 3-Z-[1 -(4-karboxy-3-metyl-fenylamino)-1 -fenyl-metylén]-5-amido-2-indolinón 024Η19Ν304 Mass spectrum: m / z = 398 (MH + ) (128) 3- Z- [1- (4-carboxy-3-methyl-phenylamino) -1-phenyl-methylene] -5-amido-2-indolinone 0 24 Η 19 Ν 3 0 5

Hmotnostné spektrum: m/z = 412 (M-H+) (129) 3-Z-[1-(4-(3-dietylamino-propoxy)-fenylamino)-1-fenyl-metylén]-5-amido-2indolinón-trifluóracetát θ29^32^4θ3Mass Spectrum: m / z = 412 (MH + ) (129) 3- [1- (4- (3-diethylamino-propoxy) -phenylamino) -1-phenyl-methylene] -5-amido-2-indolinone trifluoroacetate θ29 ^ 32 ^ 4θ3

Hmotnostné spektrum: m/z = 484 (M+) (130) 3-Z-[1 -(4-(2-piperidín-etoxy)-fenylamino)-1 -fenyl-metylén]-5-amido-2indolinón-trifluóracetát θ29^30^4θ3Mass Spectrum: m / z = 484 (M &lt; + &gt; ) (130) 3-Z- [1- (4- (2-piperidine-ethoxy) -phenylamino) -1-phenyl-methylene] -5-amido-2-indolinone trifluoroacetate θ29 ^ 30 ^ 4θ3

Hmotnostné spektrum: m/z = 483 (M+H)+ (131) 3-Z-[1 -(4-(3-piperidín-propoxy)-fenylamino)-1 -fenyl-metylén]-5-amido-2indolinón-trifluóracetátMass Spectrum: m / z = 483 (M + H) + (131) 3- Z- [1- (4- (3-piperidine-propoxy) -phenylamino) -1-phenyl-methylene] -5-amido-2-indolinone -trifluoroacetate

-59θ30^32^4θ3-59θ30 ^ 32 ^ 4θ3

Hmotnostné spektrum: m/z = 496 (M+) (132) 3-Z-[1-(4-(3-dimetylamino-propoxy)-fenylamino)-1 -fenyl-metylénJ-5-amido-2indolinón-trifluóracetát θ27^28^4θ3Mass Spectrum: m / z = 496 (M &lt; + &gt; ) (132) 3- [1- (4- (3-dimethylamino-propoxy) -phenylamino) -1-phenyl-methylene] -5-amido-2-indolinone trifluoroacetate # 27 ^ 28 ^ 4θ3

Hmotnostné spektrum: m/z = 457 (M+H)+ (133) 3-Z-[1-(4-(3-A/-metyl-A/-benzylamino-propoxy)-fenylamino)-1-fenyl-metylén]-5 amido-2-indolinón-trifluóracetátMass spectrum: m / z = 457 (M + H) + (133) 3- Z- [1- (4- (3-N-methyl-N-benzylamino-propoxy) -phenylamino) -1-phenyl- methylene] -5-amido-2-indolinone trifluoroacetate

C33H32N4O3C33H32N4O3

Hmotnostné spektrum: m/z = 533 (M+H)+ (134) 3-Z-[ 1 -(4-(2-dimetylamino-etoxy)-fenylamino)-1 -fenyl-metylén]-5-amido-2indolinón-trifluóracetát θ2β[ί2β^4θ3Mass Spectrum: m / z = 533 (M + H) + (134) 3- Z- [1- (4- (2-dimethylamino-ethoxy) -phenylamino) -1-phenyl-methylene] -5-amido-2-indolinone -trifluoroacetate θ2β [β2β ^ 4θ3

Hmotnostné spektrum: m/z = 443 (M+H)+ (135) 3-Z-[1-(4-(A/-etyl-/\/-benzyl-aminometyl)-fenylamino)-1-fenyl-metylén]-5-amido 2-indolinón (136) 3-Z-[1-(4-(/\/-propyl-W-benzyl-aminometyl)-fenylamino)-1-fenyl-metylén]-5amido-2-indolinón (137) 3-Z-[1-(4-(/V-metyl-/V-(4-chlórfenyl-metyl)-aminometyl)-fenylamino)-1-fenylmetylén]-5-amido-2-indolinón (138) 3-Z-[1-(4-(A/-metyl-/\/-(4-brómfenyl-metyl)-amino-metyl)-fenylamino)-1 -fenylmetylén]-5-amido-2-indolinónMass Spectrum: m / z = 443 (M + H) + (135) 3- Z- [1- (4- (N -ethyl- N -benzylaminomethyl) phenylamino) -1-phenylmethylene 5-amido 2-indolinone (136) 3- [1- (4- (N-propyl-N-benzyl-aminomethyl) -phenylamino) -1-phenyl-methylene] -5-amido-2-indolinone (137) 3-N- [1- (4- (N-methyl- N - (4-chlorophenyl-methyl) -aminomethyl) -phenylamino) -1-phenylmethylene] -5-amido-2-indolinone (138) 13-N- [1- (4- (N-methyl-N- (4-bromophenylmethyl) amino-methyl) -phenylamino) -1-phenylmethylene] -5-amido-2-indolinone

-60(139) 3-Z-[1-(4-(/V-metyl-/V-(3-chlórfenyl-metyl)-amino-metyl)-fenylamino)-1-fenylmetylén]-5-amido-2-indolinón (140) 3-Z-[1-(4-(A/-metyl-A/-(3)4-dimetoxyfenyl-metyl)-amino-metyl)-fenylamino)-1fenyl-metylén]-5-amido-2-indolinón (141) 3-Z-[1-(4-(/V-metyl-A/-(4-metoxyfenyl-metyl)-amino-metyl)-fenylamino)-1-fenylmetylén]-5-amido-2-indolinón (142) 3-Z-[1-(4-(N-trifluóretyl-/V-(fenyl-metyl)-amino-metyl)-fenylamino)-1-fenylmetylén]-5-amido-2-indolinón (143) 3-Z-[1-(4-(/V-trifluóretyl-/V-(4-chlórfenyl-metyl)-aminometyl)-fenylamino)-1fenyl-metylén]-5-amido-2-indolinón-60 (139) 3- [1- (4- (N-methyl- N - (3-chlorophenyl-methyl) amino-methyl) -phenylamino) -1-phenylmethylene] -5-amido-2 -indolinone (140) 3-N- [1- (4- (N-methyl-N - (3 ) 4-dimethoxyphenyl-methyl) -amino-methyl) -phenylamino) -1-phenyl-methylene] -5-amido -2-indolinone (141) 3- [1- (4 - (N-methyl-N- (4-methoxyphenyl-methyl) amino-methyl) -phenylamino) -1-phenylmethylene] -5-amido -2-indolinone (142) 3- [1- (4- (N-trifluoroethyl- N - (phenylmethyl) amino-methyl) phenylamino) -1-phenylmethylene] -5-amido-2- indolinone (143) 3-N- [1- (4- (N-trifluoroethyl- N - (4-chlorophenylmethyl) aminomethyl) phenylamino) -1-phenylmethylene] -5-amido-2-indolinone

Príklad 5Example 5

3-Z-[1-(4-(4-acetyl-piperazinylmetyl)-fenylamino)-1-fenyl-metylén]-5-amido-2indolinón mg 3-Z-[1-(4-(piperazinylmetyl)-fenylamino)-1-fenyl-metylén]-5-amido-2indolinónu a 0,02 g trietylamínu sa rozpustí v 10 ml metylénchloridu a zmieša sa s 5 mg acetylchloridu a roztok sa mieša 16 hodín pri izbovej teplote. Potom sa premyje vodou a organická fáza sa odparí.3-Z- [1- (4- (4-acetyl-piperazinylmethyl) -phenylamino) -1-phenyl-methylene] -5-amido-2-indolinone mg 3-Z- [1- (4- (piperazinylmethyl) -phenylamino)] 1-Phenylmethylene] -5-amido-2-indolinone and 0.02 g of triethylamine are dissolved in 10 ml of methylene chloride and treated with 5 mg of acetyl chloride and stirred at room temperature for 16 hours. It is then washed with water and the organic phase is evaporated.

Výťažok: 15 mg (68 % teoretickej hodnoty)Yield: 15 mg (68% of theory)

C29H29N5O3C29H29N5O3

Hmotnostné spektrum: m/z = 495 (M+)Mass Spectrum: m / z = 495 (M &lt; + &gt; )

Analogicky sa pripraví nasledovná zlúčenina:The following compound was prepared analogously:

(1) 3-Z-[1 -(4-(4-benzoyl-piperazinylmetyl)-fenylamino)-1 -fenyl-metylén]-5-amido-2indolinón(1) 3-Z- [1- (4- (4-Benzoyl-piperazinylmethyl) -phenylamino) -1-phenyl-methylene] -5-amido-2-indolinone

-61 Pripraví sa z 3-Z-[1-(4-(piperazinyl-metyl-fenylamino)-1-fenyl-metylén]-5amido-2-indolinónu a benzoylchloridu.Prepared from 3-Z- [1- (4- (piperazinyl-methyl-phenylamino) -1-phenyl-methylene] -5-amido-2-indolinone and benzoyl chloride.

Výťažok: 91 % teoretickej hodnotyYield: 91% of theory

C34H31N5O3C34H31N5O3

Hmotnostné spektrum: m/z = 557 (M+)Mass Spectrum: m / z = 557 (M &lt; + &gt; )

Príklad 6Example 6

3- Z-[1-(4-dietylkarbamoyl-fenylamino-1-fenyl-metylén]-5-amido-2-indolinón g živice z kroku IV sa analogicky s krokom IV zmieša s etylesterom kyseliny3- Z- [1- (4-diethylcarbamoyl-phenylamino-1-phenyl-methylene) -5-amido-2-indolinone g resin from step IV is mixed with ethyl acid ester in analogy to step IV

4- aminobenzoovej. Vlhká naplnená živica sa suspenduje v 30 ml dioxánu a 30 ml metanolu a mieša sa 40 hodín s 25 ml 1 N lúhu sodného. Neutralizuje sa zriedenou kyselinou chlorovodíkovou a premyje sa metylénchloridom, metanolom a dimetylformamidom. Potom sa 300 mg živice suspenduje v 3 ml dimetylformamidu a nechá sa stáť 60 hodín pri izbovej teplote s 0,2 ml dietylamínu, 0,5 g O(benzotriazol-l-ylj-A/./V./VW-tetrametylurónium-tetrafluórboritanu a 0,8 ml etyldiizopropylamínu. Nakoniec sa produkt štiepi živicou podľa príkladu 4.4-aminobenzoic acid. The wet loaded resin was suspended in 30 ml dioxane and 30 ml methanol and stirred with 25 ml 1 N sodium hydroxide solution for 40 hours. Neutralize with dilute hydrochloric acid and wash with methylene chloride, methanol and dimethylformamide. Then 300 mg of the resin is suspended in 3 ml of dimethylformamide and allowed to stand at room temperature for 60 hours with 0.2 ml of diethylamine, 0.5 g of O (benzotriazol-1-yl) -N./V.- N -tetramethyluroniumtetrafluoroborate and 0.8 ml of ethyldiisopropylamine Finally, the product is cleaved with the resin of Example 4.

Výťažok: 29 mgYield: 29 mg

Rf: 0,46 (silikagél; metylénchlorid/metanol = 9:1) Rf: 0.46 (silica gel; methylene chloride / methanol = 9: 1)

C27H26N4O3C27H26N4O3

Hmotnostné spektrum: m/z = 454 (M+)Mass Spectrum: m / z = 454 (M &lt; + &gt; )

Analogicky sa pripraví:Analogously prepare:

(1) 3-Z-[1-(4-(piperidínkarbonyl)-fenylamino)-1-fenyl-metylén]-5-amido-2-indolinón Rf: 0,43 (silikagél; metylénchlorid/metanol = 9:1)(1) 3-Z- [1- (4- (Piperidinecarbonyl) -phenylamino) -1-phenyl-methylene] -5-amido-2-indolinone R f : 0.43 (silica gel; methylene chloride / methanol = 9: 1) )

C28H26N4O3C28H26N4O3

Hmotnostné spektrum: m/z = 466 (M+) (2) 3-Z-[ 1 -(4-(4-metylpiperazínkarbonyl)-fenylamino)-1 -fenyl-metylén]-5-amido-2indolinón-trifluóracetátMass Spectrum: m / z = 466 (M + ) (2) 3-Z- [1- (4- (4-methylpiperazinecarbonyl) phenylamino) -1-phenylmethylene] -5-amido-2-indolinone trifluoroacetate

Rf: 0,84 (silikagél; metylénchlorid/metanol = 4:1) Rf: 0.84 (silica gel; methylene chloride / methanol = 4: 1)

-62θ28^27^5θ3-62θ28 ^ 27 ^ 5θ3

Hmotnostné spektrum: m/z = 481 (M+) (3) 3-Z-[1 -(4-(/V-(2-dimetylamino-etyl)-/V-metyl-karbamoyl)-fenylamino)-1 -fenylmetylén]-5-amido-2-indolinón-trifluóracetátMass Spectrum: m / z = 481 (M + ) (3) 3-Z- [1- (4 - (N - (2-dimethylamino-ethyl) - N -methyl-carbamoyl) -phenylamino) -1- phenylmethylene] -5-amido-2-indolinone-trifluoroacetate

R,: 0,25 (silikagél: metylénchlorid/metanol = 9:1) ^28^29^503Rf: 0.25 (silica gel: methylene chloride / methanol = 9: 1) ^ 28 ^ 29 ^ 503

Hmotnostné spektrum: m/z = 484 (M+H)+ (4) 3-Z-[ 1 -(4-(/V-metoxykarbonylmetyl-karbamoyl)-fenylamino)-1 -fenyl-metylén]-5amido-2-indolinónMass Spectrum: m / z = 484 (M + H) + (4) 3-Z- [1- (4- (N-methoxycarbonylmethylcarbamoyl) phenylamino) -1-phenylmethylene] -5-amido-2- indolinone

Rf: 0,4 (silikagél; metylénchlorid/metanol = 9:1) Rf: 0.4 (silica gel, methylene chloride / methanol = 9: 1)

C26H22N4O5 C 26 H 22 N 4 O 5

Hmotnostné spektrum: m/z = 470 (M+) (5) 3-Z-[ 1 -(4-benzylkarbamoyl-fenylamino)-1 -fenyl-metylén]-5-amido-2-indolinón Rf: 0,48 (silikagél; metylénchlorid/metanol = 9:1)MS: m / z = 470 (M +) (5) 3-Z- [1 - (4-benzylcarbamoyl-phenylamino) -1-phenyl-methylene] -5-amido-2-indolinone Rf: 0.48 (silica gel; methylene chloride / methanol = 9: 1)

O30H24N4O3O30H24N4O3

Hmotnostné spektrum: m/z = 488 (M+)Mass Spectrum: m / z = 488 (M &lt; + &gt; )

Príklad 7Example 7

3-Z-[1-(4-(A/-metyl-benzoylamino)-fenylamino)-1-fenyl-metylén-5-amido-2-indolinón3-Z- [1- (4- (A / N-methyl-benzoylamino) phenylamino) -1-phenyl-methylene-5-amido-2-indolinone

4,5 g živice z kroku IV sa analogicky s príkladom 4 zmiešalo s 3,4 g 4-(9Hfluorén-9-ylmetoxykarbonyl)-metyl-amino)-anilínom v dimetylformamide. Následne sa 9H-fluorénová ochranná skupina odštiepi 4 ml 30%-ného piperidínu v dimetylformamide a živica sa niekoľkokrát premyje. Potom sa 400 mg živice suspenduje v 4 ml dimetylformamidu a 0,3 ml trietylamínu a mieša sa s 0,3 ml benzoylchloridu 1 hodinu pri izbovej teplote. Nakoniec sa produkt štiepi živicou podľa príkladu 4.4.5 g of the resin from Step IV was treated analogously to Example 4 with 3.4 g of 4- (9H-fluoren-9-ylmethoxycarbonyl) -methyl-amino) -aniline in dimethylformamide. Subsequently, the 9H-fluorene protecting group is cleaved with 4 ml of 30% piperidine in dimethylformamide and the resin is washed several times. Then 400 mg of the resin is suspended in 4 ml of dimethylformamide and 0.3 ml of triethylamine and stirred with 0.3 ml of benzoyl chloride for 1 hour at room temperature. Finally, the product is cleaved with the resin of Example 4.

Výťažok: 33 mgYield: 33 mg

-63Rf: 0,45 (silikagél; metylénchlorid/metanol = 9:1) θ30^24Ν4θ3-63R f : 0.45 (silica gel; methylene chloride / methanol = 9: 1) θ30 ^ 2 4 Ν 4 θ3

Hmotnostné spektrum: m/z = 488 (M+)Mass Spectrum: m / z = 488 (M &lt; + &gt; )

Analogicky sa pripraví:Analogously prepare:

(1) 3-Z-[ 1 -(4-(A/-metyl-propionylamino)-fenylamino)-1 -fenyl-metylén-5-amido-2indolinón(1) 3-Z- [1- (4- (N-methyl-propionylamino) -phenylamino) -1-phenyl-methylene-5-amido-2-indolinone

Rf: 0,42 (silikagél; metylénchlorid/metanol = 9:1) θ26^24Ν4Ο3 Rf: 0.42 (silica gel; methylene chloride / methanol = 9: 1) θ26 ^ Ν 2 4 4 3 Ο

Hmotnostné spektrum: m/z = 440 (M*) (2) 3-Z-[1 -(4-(A/-metyl-butyrylamino)-fenylamino)-1 -fenyl-metylén-5-amido-2indolinónMass spectrum: m / z = 440 (M +) (2) 3-Z- [1- (4- (N-methyl-butyrylamino) -phenylamino) -1-phenyl-methylene-5-amido-2-indolinone

Rf: 0,44 (silikagél; metylénchlorid/metanol = 9:1) Rf: 0.44 (silica gel; methylene chloride / methanol = 9: 1)

C27H2gN4O3 C 27 H 2 gN 4 O 3

Hmotnostné spektrum: m/z = 453 (M-H+) (3) 3-Z-[1-(4-(W-metyl-etylsulfonylamino)-fenylamino)-1-fenyl-metylén-5-amido-2indolinónMass Spectrum: m / z = 453 (MH + ) (3) 3-Z- [1- (4- (N-methyl-ethylsulfonylamino) -phenylamino) -1-phenyl-methylene-5-amido-2-indolinone

R,: 0,42 (silikagél; metylénchlorid/metanol = 9:1)Rf: 0.42 (silica gel; methylene chloride / methanol = 9: 1)

C25H24N4O4SC 25 H 24 N 4 O 4 S

Hmotnostné spektrum: m/z = 475 (M-H*) (4) 3-Z-[1-(4-(A/-metyl-propylsulfonylamino)-fenylamino)-1-fenyl-metylén-5-amido-2 indolinónMass spectrum: m / z = 475 (M-H +) (4) 3-Z- [1- (4- (N-methyl-propylsulfonylamino) -phenylamino) -1-phenyl-methylene-5-amido-2 indolinone

Rf: 0,44 (silikagél; metylénchlorid/metanol = 9:1) θ25^26^4θ4θ Rf: 0.44 (silica gel; methylene chloride / methanol = 9: 1) θ25 ^ 26 ^ 4θ4θ

Hmotnostné spektrum: m/z = 491 (M+H)* (5) 3-Z-[1-(4-(W-metyl-fenylsulfonylamino)-fenylamino)-1-fenyl-metylén-5-amido-2indolinónMass Spectrum: m / z = 491 (M + H) + (S) 3-Z- [1- (4- (N-methyl-phenylsulfonylamino) -phenylamino) -1-phenyl-methylene-5-amido-2-indolinone

-64Rf: 0,53 (silikagél; metylénchlorid/metanol = 9:1) ^29^24^048-64R f : 0.53 (silica gel; methylene chloride / methanol = 9: 1) ^ 29 ^ 24 ^ 048

Hmotnostné spektrum: m/z = 524 (M+)Mass Spectrum: m / z = 524 (M &lt; + &gt; )

Príklad 8Example 8

Suchá ampulka so 75 mg účinnej látky na 10 mlDry ampoule with 75 mg of active substance per 10 ml

Zloženie:Ingredients:

účinná látka 75,0 mg manitol 50,0 mg voda na injekcie do 10,0 mlactive substance 75.0 mg mannitol 50.0 mg water for injections up to 10.0 ml

Príprava:Preparation:

Účinná látka a manitol sa rozpustí vo vode. Po naplnení sa lyofllizuje. Hotový roztok pred použitím sa pripraví vodou na injekcie.The active substance and mannitol are dissolved in water. After filling, it is lyophilized. The ready-to-use solution is prepared with water for injections before use.

Príklad 9Example 9

Suchá ampulka s 35 mg účinnej látky na 2 mlDry ampoule with 35 mg of active substance per 2 ml

Zloženie:Ingredients:

účinná látka 35,0 mg manitol 100,0 mg voda na injekcie do 2,0 mlactive substance 35.0 mg mannitol 100.0 mg water for injections to 2.0 ml

Príprava:Preparation:

Účinná látka a manitol sa rozpustia vo vode. Po naplnení sa lyofllizuje. Hotový roztok pred použitím sa pripraví vodou na injekcie.The active substance and mannitol are dissolved in water. After filling, it is lyophilized. The ready-to-use solution is prepared with water for injections before use.

Príklad 10Example 10

Tableta s 50 mg účinnej látkyTablet with 50 mg of the active substance

Zloženie: Ingredients: (1) účinná látka (1) active substance 50,0 mg 50.0 mg (2) mliečny cukor (2) milk sugar 98,0 mg 98.0 mg (3) kukuričný škrob (3) corn starch 50,0 mg 50.0 mg (4) polyvinylpyrolidón (4) polyvinylpyrrolidone 15,0 mg 15.0 mg (5) stearan horečnatý (5) magnesium stearate 2.0 ma 215,0 mg 2.0 ma 215.0 mg

Príprava:Preparation:

(1), (2) a (3) sa zmieša a granuluje sa s vodným roztokom (4). K usušenému granulátu sa primieša (5). Z tejto zmesi sa lisujú tablety ploché, s fazetami na oboch stranách a s deliacim žliabkom na jednej strane.(1), (2) and (3) are mixed and granulated with an aqueous solution (4). Add (5) to the dried granulate. From this mixture, tablets are compressed flat, with facets on both sides and with a dividing groove on one side.

Priemer tabliet: 9 mmTablet diameter: 9 mm

Príklad 11Example 11

Tableta s 350 mg účinnej látkyTablet with 350 mg of the active substance

Zloženie: Ingredients: (1) účinná látka (1) active substance 350 mg 350 mg (2) mliečny cukor (2) milk sugar 136,0 mg 136.0 mg (3) kukuričný škrob (3) corn starch 80,0 mg 80.0 mg (4) polyvinylpyrolidón (4) polyvinylpyrrolidone 30,0 mg 30.0 mg (5) stearan horečnatý (5) magnesium stearate 4.0 mg 600,0 mg 4.0 mg 600.0 mg

Príprava:Preparation:

(1), (2) a (3) sa zmieša a granuluje sa s vodným roztokom (4). K usušenému granulátu sa primieša (5). Z tejto zmesi sa lisujú tablety ploché, s fazetami na oboch stranách a s deliacim žliabkom na jednej strane.(1), (2) and (3) are mixed and granulated with an aqueous solution (4). Add (5) to the dried granulate. From this mixture, tablets are compressed flat, with facets on both sides and with a dividing groove on one side.

Priemer tabliet: 12 mmTablet diameter: 12 mm

-66Príklad 12-66Example 12

Kapsuly s 50 mg účinnej látkyCapsules containing 50 mg of the active substance

Zloženie:Ingredients:

(1) účinná látka (2) sušený kukuričný škrob (3) práškový mliečny cukor (4) stearan horečnatý(1) active ingredient (2) dried corn starch (3) milk powdered sugar (4) magnesium stearate

50,0 mg 58,0 mg 50,0 mg50.0 mg 58.0 mg 50.0 mg

2.0 mg2.0 mg

160,0 mg160.0 mg

Príprava:Preparation:

(1) sa rozmieša s (3). Táto zmes sa intenzívneho miešania pridá do zmesi pozostávajúcej z (2) a (4).(1) is mixed with (3). This mixture is added vigorously to the mixture consisting of (2) and (4).

Táto prášková zmes sa plní do kapsúl veľkosti 3 z tvrdej želatíny pomocou stroja na plnenie kapsúl.This powder mixture is filled into size 3 hard gelatin capsules using a capsule filling machine.

Príklad 13Example 13

Kapsuly s 350 mg účinnej látkyCapsules with 350 mg of the active substance

Zloženie:Ingredients:

(1) účinná látka (2) sušený kukuričný škrob (3) práškový mliečny cukor (4) stearan horečnatý(1) active ingredient (2) dried corn starch (3) milk powdered sugar (4) magnesium stearate

350,0 mg350.0 mg

46,0 mg 30,0 mg 4.0 mg46.0 mg 30.0 mg 4.0 mg

430,0 mg430.0 mg

Príprava:Preparation:

(1) sa rozmieša s (3). Táto zmes sa intenzívneho miešania pridá do zmesi pozostávajúcej z (2) a (4).(1) is mixed with (3). This mixture is added vigorously to the mixture consisting of (2) and (4).

Táto prášková zmes sa plní do kapsúl veľkosti 0 z tvrdej želatíny pomocou stroja na plnenie kapsúl.This powder blend is filled into hard gelatin size 0 capsules using a capsule filling machine.

-67Príklad 14-67Example 14

Čapíky so 100 mg účinnej látkySuppositories containing 100 mg of active ingredient

1 čapík obsahuje: 1 suppository contains: účinná látka active substance 100,0 mg 100.0 mg polyetylénglykol (m. h. 1500) polyethylene glycol (MW 1500) 600,0 mg 600.0 mg polyetylénglykol (m. h. 6000) polyethylene glycol (MW 6000) 460,0 mg 460.0 mg polyetylénsorbitanmonostearan polyetylénsorbitanmonostearan 840.0 ma 2000,0 mg 840.0 ma 2000.0 mg

Príprava:Preparation:

Polyetylénglykol sa spolu s polyetylénsorbitanmonostearanom roztopí. Pri 40 °C sa rozomletá účinná látka rovnomerne rozptýli do taveniny. Ochladí sa na 38 °C a odleje sa do dopredu slabo vychladených foriem na čapíky.The polyethylene glycol melts together with the polyethylene sorbitan monostearate. At 40 ° C, the milled active substance is uniformly distributed in the melt. Cool to 38 ° C and pour into pre-chilled suppository molds.

Claims (9)

PATENTOVÉ NÁROKYPATENT CLAIMS 1. Substituované indolinóny všeobecného vzorca I v ktoromSubstituted indolinones of the general formula I in which X je atóm kyslíka alebo síry,X is an oxygen or sulfur atom, R1 je atóm vodíka, C^-alkoxy-karbonylová alebo C2.4-alkanoylová skupina,R 1 is hydrogen, C 1-4 -alkoxycarbonyl or C 2 . 4- alkanoyl group, R2 je karboxy-, C^-alkoxy-karbonylová alebo aminokarbonylová skupina, v ktorej aminoskupina môže byť substituovaná jednou alebo dvoma C^-alkylovými skupinami a substituenty môžu byť rovnaké alebo rôzne,R 2 is a carboxy-, C 1-4 -alkoxy-carbonyl or aminocarbonyl group in which the amino group may be substituted by one or two C 1-6 -alkyl groups and the substituents may be the same or different, R3 je fenylová alebo naftylová skupina, ktorá môže byť substituovaná atómami fluóru, chlóru alebo brómu, C ^-alkylovou, C^-alkoxy-, kyano-, trifluórmetylovou, nitro-, amino-, CYalkylamino-, di-fC^-alkyO-amino-, C2.4-alkanoyl-amino-, /V-fC^alkyl)-C2.4-alkanoylamino-, /\/-(C1.3-alkyl)-C2.4-alkanoylamino-1 C1.3alkylsulfonylamino-, amino-C^-alkylovou, C^-alkylamino-C^-alkylovou, di-ÍC^-alkylJ-amino-C^alkylovou, A/-(C-2.4-alkanoyl)-amino-C1.3-alkylovou alebo /V-ÍC^-alkanoyQ-Cvgalkylamino-C^g-alkylovou skupinou a substituenty môžu byť rovnaké alebo rôzne,R 3 is a phenyl or naphthyl group which may be substituted by fluorine, chlorine or bromine atoms, C 1-6 -alkyl, C 1-6 -alkoxy-, cyano-, trifluoromethyl, nitro-, amino-, CYalkylamino-, di-C 1-6 -alkylO -amino-, C 2 . 4-alkanoyl amino, / V-fC ^ alkyl) -C second 4 -alkanoylamino-, / \ / - (C first 3 -alkyl) -C second 4 1 C -alkanoylamino- first 3 alkylsulfonylamino, amino-C ^ -alkyl, C ^ alkylamino-C ^ -alkyl, di-IC -alkylJ-amino-C ^ alkyl, A / - (C 2nd 4 alkanoyl) amino-C 1 . The 3- alkyl or N, N-alkanoyl-C 1-6 alkylamino-C 1-6 -alkyl group and the substituents may be the same or different, R4 je atóm vodíka alebo C^-alkylová skupina aR 4 is a hydrogen atom or a C 1-6 -alkyl group; R5 je atóm vodíka,R 5 is a hydrogen atom, C^-alkylová skupina voliteľne substituovaná fenylovou, karboxy- alebo (\3-alkoxykarbonylovou skupinou,C 1-6 -alkyl optionally substituted by phenyl, carboxy- or (β-alkoxycarbonyl), C3.7-cykloalkylová skupina voliteľne substituovaná C^-alkylovou skupinou, indanylová skupina voliteľne substituovaná C^-alkylovou skupinou,C 3 . A 7- cycloalkyl group optionally substituted with a C 1-6 alkyl group, an indanyl group optionally substituted with a C 1-6 alkyl group, -695-členná heteroarylová skupina, ktorá obsahuje iminoskupinu voliteľne substituovanú C1_3-alkylovou skupinou, atóm kyslíka alebo síry, alebo iminoskupinu voliteľne substituovanú C^-alkylovou skupinou a atóm kyslíka, síry alebo dusíka alebo dva atómy dusíka, alebo 6-členná heteroarylová skupina, ktorá obsahuje 1 až 3 atómy dusíka, pričom cez dva susedné atómy uhlíka alebo cez atóm dusíka a susednú iminoskupinu uvedenej 5- a 6-č len nej heteroarylovej skupiny možno pripojiť 1,3-butadienylénový mostík a uhlíkové jadro uvedených mono- a bicyklických kruhov môže byť mono- alebo disubstituované atómami chlóru, brómu alebo jódu, C^-alkylovou alebo kyanoskupinou a substituenty môžu byť rovnaké alebo rôzne, pyrolidinylová alebo piperidinylová skupina pripojená cez atóm uhlíka, ktorá na atóme dusíka môže byť substituovaná C^-alkylovou skupinou, fenylová skupina voliteľne disubstituovaná atómami fluóru, chlóru, brómu alebo jódu, C^-alkylovou, C^-alkoxy-, karboxy-, C V3-a I koxy karbony lovou, aminosulfonylovou, nitro- alebo kyanoskupinou, pričom substituenty môžu byť rovnaké alebo rôzne, fenylová, pyridylová, pyrimidylová alebo tienylová skupina, ktorá je substituovaná trifluórmetoxyskupinou, atómom fluóru, chlóru, brómu alebo jódu, C^s-alkoxyskupinou, ktorá v polohe 2 alebo 3 môže byť substituovaná amino-, C^alkylamino, di-(C1.3-alkyl)-amino-, fenylovou, C1.3-alkylamino-, /V-fC^-alkylJ-fenylC13-alkylamino-, pyrolidínovou alebo piperidínovou skupinou, fenyl-C^a-alkylamino-C^g-alkylamino-C^g-alkylovou skupinou, ktorá vo fenylovom jadre môže byť mono- alebo disubstituovaná trifluórmetylovou skupinou, atómami fluóru, chlóru, brómu alebo jódu, C^-alkylovými alebo C^-alkoxyskupinami, pričom substituenty môžu byť rovnaké alebo rôzne, a na dusíkovom atóme amínu dodatočne C^-alkylovou skupinou, v ktorej atómy vodíka môžu byť od polohy 2 nahradené celkom alebo čiastočne atómami fluóru,-695-membered heteroaryl group contains an imino group optionally substituted by C 1 _ 3 -alkyl, O, S, NH, or an optionally substituted C ^ -alkyl, and O, S or N, or two nitrogen atoms, or a 6-membered a heteroaryl group having 1 to 3 nitrogen atoms, wherein the 1,3-butadienylene bridge and the carbon core of said mono- and di-carbon atoms can be attached via two adjacent carbon atoms or via a nitrogen atom and the adjacent imino group of said 5- and 6-membered heteroaryl group bicyclic rings may be mono- or disubstituted by chlorine, bromine or iodine atoms, the C 1-4 alkyl or cyano group and the substituents may be the same or different, the pyrrolidinyl or piperidinyl group attached via a carbon atom which may be substituted by the C 1-4 alkyl group on the nitrogen atom , a phenyl group optionally disubstituted with fluorine, chlorine, bromine and because I, C ^ -alkyl, C ^ -alkoxy, carboxy, C V3 I-a alkoxy carbonyl nominal, aminosulfonyl, nitro or cyano groups, wherein the substituents may be the same or different, phenyl, pyridyl, pyrimidyl or thienyl, which is substituted with trifluoromethoxy, fluorine, chlorine, bromine or iodine, C 1-6 -alkoxy which in the 2 or 3 position may be substituted by amino-, C 1-4 -alkylamino, di- (C 1-6 -alkyloxy ) ; 3-alkyl) amino, phenyl, C first 3- alkylamino-, N-C 1-6 -alkyl-phenyl-C 13 -alkylamino-, pyrrolidine or piperidine, phenyl-C 1-6 -alkylamino-C 1-6 -alkylamino-C 1-6 -alkyl, which in the phenyl core can be mono- or disubstituted with trifluoromethyl, fluorine, chlorine, bromine or iodine, C 1-4 -alkyl or C 1-4 -alkoxy groups, the substituents may be the same or different, and additionally C 1-4 -alkyl on the amine nitrogen atom in which the atoms are from position 2, hydrogen may be replaced in whole or in part by fluorine atoms, C^g-alkylovou, fenylovou, imidazolylovou, C3.7-cykloalkylovou, C^-alkoxy-C^alkoxy-, fenyl-C^-alkoxy-, karboxy-C^-alkylovou, CV3-alkoxykarbonyl-C.,.3alkylovou, karboxy-, C1_3-alkoxykarbonylovou, aminokarbonylovou, C^-alkylaminokarbonylovou, di-ÍC^-alkylj-aminokarbonylovou, fenyl-C13-alkylaminokarbonylovou,C ^ g-alkyl, phenyl, imidazolyl, C 3. 7 -cycloalkyl, C ^ -alkoxy-C ^ alkoxy, phenyl-C ^ -alkoxy, carboxy-C ^ -alkyl, C V3 -alkoxycarbonyl-C.,. 3 alkyl, carboxy, C 1 _ 3 alkoxycarbonyl, aminocarbonyl, C ^ -alkylaminokarbonylovou, di-IC -alkylj-aminocarbonyl, phenyl-C 13 -alkylaminokarbonylovou. -70A/-(C1.3-alkyl)-fenyl-C1.3-alkylaminokarbonylovou, piperazínkarbonylovou, N-(C-,.3alkyl)-piperazínkarbonylovou, nitro-, amino-, C^-alkylamino-, di-ÍC^-alkylJ-amino-, pyrolidínovou, piperidínovou, morfolínovou, CM-alkanoylamino-, /V-íC^-alkylj-C^alkanoylamino-, benzoylamino- alebo ^-(C^-alkylj-benzoylaminoskupinou, /\/-(C1_3-alkyl)-C2^-alkanoylaminoskupinou, ktorá je v alkylovej časti substituovaná dodatočne karboxy- alebo C^-alkoxykarbonylovou skupinou,-70A / - (C first 3-alkyl) -phenyl-C first 3- alkylaminocarbonyl, piperazinecarbonyl, N- (C 1-3 alkyl) piperazinecarbonyl, nitro-, amino-, C 1-4 -alkylamino-, di-C 1-4 -alkyl-amino, pyrrolidine, piperidine, morpholine, C M - alkanoylamino, / V-IC -alkylj-C ^ alkanoylamino, benzoylamino, or ^ - (C ^ -alkylj-benzoylamino, / \ / - (C 1 _ 3 alkyl) 2, -C ^ -alkanoylaminoskupinou which is in the alkyl moiety substituted additionally by a carboxy- or C 1-4 -alkoxycarbonyl group, C1.3-alkylaminokarbonylovou alebo di-íC^-alkylj-aminokarbonylovou skupinou, v ktorých je alkylová časť dodatočne substituovaná diýC^-alkylJ-aminoskupinou, alebo /V-íCvg-alkyO-Cva-alkylsulfonylamino- alebo A/-(C.,.3-alkyl)-fenylsulfonylaminoskupinou, v ktorých alkylová časť môže byť dodatočne substituovaná kyano-, karboxy-, C^-alkoxykarbonylovou, C^-alkylamino-, di-ÍC^-alkylj-amino-, aminokarbonylovou, C^g-alkylaminokarbonylovou, di-ÍCva-alkylJ-aminokarbonylovou, piperidínkarbonylovou alebo 2-[di-(C1.3-alkylamino)]-etylaminokarbonylovou skupinou, fenylová alebo tienylová skupina, ktorá je substituovaná C^-alkylovou skupinou, v ktorej alkylová časť je substituovaná hydroxy-, C13-alkoxy-, karboxy-, C.,.3-alkoxykarbonylovou, amino-, C^-alkylamino-, diýC^-alkyO-amino-, C^-alkanoylamino-, /V-íC^g-alkyO-C^-alkanoylamino-, pyrolidínovou, dehydropyrolidínovou, piperidínovou, dehydropiperidínovou, 3-hydroxypiperidínovou, 4-hydroxypiperidínovou, hexametylénimino-, morfolínovou, tiomorfolínovou, piperazínovou, 4-(Cw-alkyl)piperazínovou, 4-fenyl-piperazínovou, 4-(C2Jl-alkanoyl)-piperazínovou, 4-benzoylpiperazínovou alebo imidazolylovou skupinou, pričom uvedené nasýtené cykloalkyléniminokruhy, C^-alkylamino- alebo di-íC^alkyl)-aminoskupiny môžu byť dodatočne substituované jednou alebo dvoma C15alkylovými skupinami, C3.7-cykloalkylovou, hydroxy-, C^-alkoxy-, karboxy-, Ο,.3alkoxykarbonylovou, aminokarbonylovou, C^-alkylaminokarbonylovou alebo di(C^g-alkylj-aminokarbonylovou skupinou, fenyl-C^-alkyl- alebo fenylovou skupinou, ktorá vo fenylovom jadre môže byť dodatočne mono- alebo disubstituovaná atómami fluóru, chlóru, brómu alebo jódu, C^-alkylovými alebo kyanoskupinami, pričom substituenty môžu byť rovnaké alebo rôzne,C 1 . 3 -alkylaminokarbonylovou or di-IC -alkylj-aminocarbonyl, wherein the alkyl moiety is additionally substituted diýC ^ -alkylJ-amino group, and / V-alkylation íCvg-CVA-alkylsulfonylamino or A / - (C.,. 3 -alkyl) -phenylsulfonylamino group in which the alkyl moiety may be additionally substituted by cyano-, carboxy-, C 1-6 -alkoxycarbonyl, C 1-6 -alkylamino-, di-C 1-6 -alkyl-amino-, aminocarbonyl, C 1-6 -alkylaminocarbonyl, di -ÍCva-aminocarbonyl-alkyl is, piperidinocarbonyl or 2- [di- (C first 3 -alkylamino)] - ethylaminocarbonyl group, a phenyl or thienyl, which is substituted by C ^ -alkyl, wherein the alkyl moiety is substituted by hydroxy, C 13 -alkoxy, carboxy, C.,. 3- alkoxycarbonyl, amino-, C 1-4 -alkylamino-, di-C 1-4 -alkyl-amino-, C 1-4 -alkanoylamino-, N-C 1-8 -alkyl-C 1-4 -alkanoylamino-, pyrrolidine, dehydropyrrolidine, piperidine, dehydropiperidine, 3-hydroxypiperidine, 4-hydroxypiperidine, hexamethyleneimino-, morpholine, thiomorpholine, piperazine, 4- (C 1-6 -alkyl) piperazine, 4-phenyl-piperazine, 4- (C 2-11 -alkanoyl) -piperazine, 4-benzoylpiperazine or imidide wherein said saturated cykloalkyléniminokruhy, C ^ -alkylamino or di-IR alkyl) amino can additionally be substituted by one or two C 15 alkyl groups, C 3. 7- cycloalkyl, hydroxy, C 1-6 -alkoxy, carboxy, Ο,.. 3 alkoxycarbonyl, aminocarbonyl, C 1-4 -alkylaminocarbonyl or di (C 1-8 -alkyl) aminocarbonyl, phenyl-C 1-4 -alkyl- or phenyl, which in the phenyl core may additionally be mono- or disubstituted by fluorine, chlorine, bromine or iodine, C 1-6 -alkyl or cyano, wherein the substituents may be the same or different, -71 alebo metylénová skupina susediaca s atómom dusíka v uvedených cykloalkyléniminokruhoch môže byť nahradená karbonylovou alebo sulfonylovou skupinou, a uvedené monosubstituované fenylové skupiny môžu byť dodatočne substituované atómom fluóru, chlóru alebo brómu, metylovou, amino-, (\3-alkylamin0- alebo di(C^-alkylJ-aminoskupinou, alebo na jednom z uvedených nesubstituovaných cykloalkyléniminokruhoch môže byť cez dva susedné atómy uhlíka nakondenzované fenylové jadro voliteľne substituované jednou alebo dvoma C^-alkoxyskupinami, pričom karboxyskupiny uvedené pri definícii spomenutých zvyškov môžu byť okrem toho nahradené skupinou, ktorú možno in vivo prekonvertovať na karboxyskupinu, a amino- a iminoskupiny uvedené pri definícii spomenutých zvyškov môžu byť okrem toho substituované zvyškom, ktorý je in vivo odštiepiteľný, ich izoméry a soli.-71 or a methylene group adjacent to a nitrogen atom in said cycloalkyleneiminocycles may be replaced by a carbonyl or sulfonyl group, and said monosubstituted phenyl groups may be additionally substituted by a fluorine, chlorine or bromine atom, methyl, amino-, (β-alkylamino) - or di ( The C 1-4 -alkyl-amino group or one of the above-mentioned unsubstituted cycloalkyleneimino rings may be fused via a two adjacent carbon atoms optionally substituted by one or two C 1-4 -alkoxy groups, wherein the carboxy groups mentioned in the definition of said residues may additionally be replaced by a group in vivo to convert to a carboxy group, and the amino and imino groups defined in the definition of said residues may additionally be substituted with a residue which is cleavable in vivo, their isomers and salts. 2. Substituované indolinóny všeobecného vzorca I podľa nároku 1, v ktorých X je atóm kyslíka,Substituted indolinones of general formula I according to claim 1, in which X is an oxygen atom, R1 je atóm vodíka, CM-alkoxy-karbonylová skupina,R 1 is hydrogen, C 1-4 alkoxycarbonyl, R2 je karboxy-, CM-alkoxy-karbonylová alebo aminokarbonylová skupina, v ktorej aminočasť môže byť substituovaná jednou alebo dvoma C1.3-alkylovými skupinami a substituenty môžu byť rovnaké alebo rôzne,R 2 is a carboxy-, C 1-4 -alkoxy-carbonyl or aminocarbonyl group in which the amino moiety may be substituted by one or two C 1 . The 3- alkyl groups and substituents may be the same or different, R3 je fenylová skupina voliteľne substituovaná atómom fluóru, chlóru alebo brómu, metylovou, kyano-, alebo aminometylovou skupinou,R 3 is a phenyl group optionally substituted by a fluorine, chlorine or bromine atom, a methyl, cyano, or aminomethyl group, R4 je atóm vodíka alebo metylová skupina a R5je atóm vodíka,R 4 is a hydrogen atom or a methyl group and R 5 is a hydrogen atom, C15-alkylová skupina voliteľne substituovaná karboxy- alebo C13-alkoxykarbonylovou skupinou alebo benzylová skupina,C 15 -alkyl optionally substituted by carboxy- or C 13 -alkoxycarbonyl or benzyl, C3.7-cykloalkylová skupina voliteľne substituovaná metylovou skupinou, indanylová, pyridylová, oxazolylová, tiazolylová alebo imidazolylová skupina voliteľne substituovaná metylovou skupinou, na ktorej cez dva susedné atómy uhlíka môže byť dodatočne nakondenzované fenylové jadro,C 3 . A 7- cycloalkyl group optionally substituted by a methyl group, an indanyl, pyridyl, oxazolyl, thiazolyl or imidazolyl group optionally substituted by a methyl group on which the phenyl core may be additionally fused via two adjacent carbon atoms, -72metylfenylová skupina voliteľne substituovaná atómom fluóru, chlóru alebo brómu, metoxy-, karboxy-, C^-alkyloxykarbonylovou, nitro- alebo aminosulfonylovou skupinou, alebo dimetoxyfenylová skupina, pyrolidinylová alebo piperidinylová skupina pripojená cez atóm uhlíka, ktorá je na atóme dusíka substituovaná C1.3-alkylovou skupinou, fenylová skupina, ktorá je substituovaná trifluórmetoxyskupinou, atómom fluóru, chlóru, brómu alebo jódu, C1.3-alkoxyskupinou, ktorá v polohe 2 alebo 3 môže byť substituovaná amino-, Ον3alkylamino-, di-(C.,.3-alkyl)-amino-, fenyl-C^g-alkylamino-, AZ-ÍC^g-alkylJ-fenyl-C^galkylamino-, pyrolidínovou alebo piperidínovou skupinou, fenyl-C^-alkylamino-C^-alkylovou skupinou, ktorá vo fenylovom jadre môže byť substituovaná atómom fluóru, chlóru, brómu alebo jódu, C^-alkylovou, C1.3-alkoxyalebo trifluórmetylovou skupinou a dodatočne na atóme dusíka amínu môže byť substituovaná C13-alkyloovu skupinou, v ktorej atómy vodíka od polohy 2 môžu byť celkom alebo čiastočne nahradené atómami fluóru,-72methylphenyl optionally substituted by fluorine, chlorine or bromine, methoxy, carboxy, C 1-4 -alkyloxycarbonyl, nitro- or aminosulfonyl, or dimethoxyphenyl, pyrrolidinyl or piperidinyl attached via a carbon atom which is substituted on the nitrogen atom by C 1 . 3 -alkyl, phenyl which is substituted by trifluoromethoxy, fluorine, chlorine, bromine, iodine, C first 3- alkoxy, which may be substituted at the 2- or 3-position by amino, β 1-3 alkylamino-, di- (C 1-3 -alkyl) amino, phenyl-C 1-8 -alkylamino-, AZ-C 1-4 -alkyl; -alkyl-phenyl-C 1-4 -alkylamino-, pyrrolidine or piperidine, phenyl-C 1-4 -alkylamino-C 1-4 -alkyl which may be substituted in the phenyl ring by a fluorine, chlorine, bromine or iodine atom, C 1-4 -alkyl, C 1 . The 3- alkoxy or trifluoromethyl group and additionally at the amine nitrogen atom may be substituted by a C 13 -alkylo group in which the hydrogen atoms from the 2-position may be replaced in whole or in part by fluorine atoms, C^g-alkylovou, fenylovou, imidazolylovou, C3.7-cykloalkylovou, C13-alkoxy-C13alkoxy-, fenyl-C^-alkoxy-, karboxy-C13-alkylovou, C^-alkoxykarbonyl-C^alkylovou, karboxy-, C^-alkoxykarbonylovou, aminokarbonylovou, C^-alkylaminokarbonylovou, di-íC^-alkylJ-aminokarbonylovou, fenyl-C^-alkylaminokarbonylovou, /V-ÍC^-alkyO-fenyl-C^-alkylaminokarbonylovou, piperazínkarbonylovou, N-(C^.3alkyl)-piperazínkarbonylovou, nitro-, amino-, C1.3-alkylamino-, di-ÍC^-alkylJ-amino-, pyrolidínovou, piperidínovou, morfolínovou, C2.4-alkanoylamino-, /V-(C13-alkyl)-C2.4alkanoylamino-, benzoylamino- alebo /V-íC^-alkyO-benzoylaminoskupinou, /\/-(C1.3-alkyl)-C2J,-alkanoylaminoskupinou, ktorá je v alkylovej časti dodatočne substituovaná karboxy- alebo (\3-alkoxykarbonylovou skupinou,C ^ g-alkyl, phenyl, imidazolyl, C 3. 7- cycloalkyl, C 13 -alkoxy-C 13 alkoxy-, phenyl-C 1-6 -alkoxy-, carboxy-C 13 -alkyl, C 1-6 -alkoxycarbonyl-C 1-6 alkyl, carboxy-, C 1-6 -alkoxycarbonyl, aminocarbonyl, C 1-6 -alkyl -alkylaminokarbonylovou, di-IC -alkylJ-aminocarbonyl, phenyl-C ^ -alkylaminokarbonylovou, / V-IC--alkyl and phenyl-C ^ -alkylaminokarbonylovou, piperazinecarbonyl, N- (C ^. 3 alkyl) -piperazínkarbonylovou, nitro- , amino, C first 3 -alkylamino, di-IC -alkylJ-amino, pyrrolidino, piperidino, morpholino, C 2nd 4- alkanoylamino- N - (C 13 -alkyl) -C 2 . 4 alkanoylamino, benzoylamino, or / V-IC-benzoylamino -alkyl, / \ / - (C first 3 alkyl) C 2R, -alkanoylaminoskupinou which is additionally substituted by alkyl or carboxy (\ 3 alkoxycarbonyl, C^g-alkylaminokarbonylovou alebo di-(C.,.3-alkyl)-aminokarbonylovou skupinou, v ktorých alkylová časť je dodatočne substituovaná di-(C1.3-alkyl)-aminoskupinou, alebo /V-íC^-alkylJ-C^-alkylsulfonylamino- alebo /V-CC^-alkylJ-fenylsulfonylaminoskupinou, v ktorých alkylová časť môže byť dodatočne substituovaná kyano-, karboxy-, C^-alkoxykarbonylovou, C^-alkylamino-, di-(C.,.3-alkyl)-amino-, amino-73karbonylovou, C^-alkylaminokarbonylovou, di-ÍC^-alkylJ-aminokarbonylovou, piperidínkarbonylovou alebo 2-[di-(C1.3-alkylamino)]-etylaminokarbonylovou skupinou, fenylová skupina voliteľne substituovaná C^-alkylovou skupinou, v ktorej alkylová časť je substituovaná hydroxy-, C^-alkoxy-, karboxy-, C1.3-alkoxy-karbonylovou, amino-, C^-alkylamino-, di-íC^-alkylJ-amino-, C^-alkanoylamino-, N-ÍC^-alkyl)C^-alkanoylamino-, py rolid í novou, dehydropyrolidínovou, piperidínovou, dehydropiperidínovou, 3-hydroxypiperidínovou, 4-hydroxypiperidínovou, hexametylénimino-, morfolínovou, tiomorfolínovou, piperazínovou, 4-(C1.3-alkyl)-piperazínovou, 4-fenylpiperazí novou, 4-(C2^-alkanoyl)-piperazínovou, 4-benzoyl-piperazínovou alebo imidazolylovou skupinou, pričom uvedené nasýtené cykloalkyléniminokruhy, Cvg-alkylamino- alebo di-(C15alkyl)-aminoskupiny môžu byť dodatočne substituované jednou alebo dvoma C.,.5alkylovou skupinou, C3.7-cykloalkylovou, hydroxy-, C^-alkoxy-, karboxy-, Ον3alkoxykarbonylovou, aminokarbonylovou, C1.3-alkylaminokarbonylovou alebo di(C^-alkyQ-aminokarbonylovou skupinou, fenyl-C^-alkylovou alebo fenylovou skupinou, ktorá vo fenylovom jadre môže byť dodatočne mono- alebo disubstituované atómami fluóru, chlóru, brómu alebo jódu, CV3-alkylovými alebo kyanoskupinami, pričom substituenty môžu byť rovnaké alebo rôzne, alebo metylénskupina susediaca s atómom dusíka v uvedených cykloalkyléniminokruhoch môže byť nahradená karbonylovou alebo sulfonylovou skupinou, a uvedené monosubstituované fenylové skupiny môžu byť dodatočne substituované atómom fluóru, chlóru alebo brómu, metylovou, amino-, C^-alkylamino- alebo di(C1.3-alkyl)-aminoskupinou, alebo na jednom z uvedených nesubstituovaných cykloalkyléniminokruhoch môže byť cez dva susedné atómy uhlíka nakondenzované fenylové jadro voliteľne substituované jednou alebo dvoma C^-alkoxyskupinami, ich izoméry a ich soli.C ^ g-alkylaminocarbonyl and di (C.,. 3 alkyl) -aminokarbonylovou group in which the alkyl moiety is additionally substituted by di (C1. 3 alkyl) amino, or / V-IC -alkylJ- C 1-4 -alkylsulfonylamino- or N-C 1-4 -alkyl-phenylsulfonylamino, in which the alkyl moiety may be additionally substituted by cyano-, carboxy-, C 1-4 -alkoxycarbonyl, C 1-4 -alkylamino-, di- (C 1-3- ) alkyl) amino, amino-73karbonylovou, C ^ -alkylaminokarbonylovou, di-IC -alkylJ-aminocarbonyl, piperidinocarbonyl or 2- [di- (C first 3 -alkylamino)] - ethylaminocarbonyl group, a phenyl group optionally substituted with C ^ -alkyl, wherein the alkyl moiety is substituted by hydroxy, C ^ -alkoxy, carboxy, C first 3 -alkoxycarbonyl, amino-, C1-4 -alkylamino-, di-C1-4-alkyl-4-amino-, C1-4-alkanoylamino-, N-C1-alkyl-C1-4-alkanoylamino-, pyrrolidine, dehydropyrrolidine , piperidine, dehydropiperidínovou, 3-hydroxypiperidine, 4-hydroxypiperidine, hexametylénimino-, morpholino, thiomorpholino, piperazino, 4- (C first 3 -alkyl) -piperazine, 4-phenylpiperazinyl new, 4- (2 C ^ alkanoyl) - piperazine, 4-benzoyl-piperazine or imidazolyl group, wherein said saturated cycloalkyleneimino rings, C 1-8 -alkylamino- or di- (C 15 -alkyl) amino groups may be additionally substituted with one or two C 1-6 -alkylene groups. 5 alkyl, C 3. 7- cycloalkyl, hydroxy-, C 1-4 -alkoxy-, carboxy-, ony 13 alkoxycarbonyl, aminocarbonyl, C 1 . 3- alkylaminocarbonyl or di (C 1-6 -alkyl) aminocarbonyl, phenyl-C 1-6 -alkyl or phenyl which may additionally be mono- or disubstituted in the phenyl ring by fluorine, chlorine, bromine or iodine atoms, C 3-6 -alkyl or cyano groups wherein the substituents may be the same or different, or the methylene group adjacent to the nitrogen atom in said cycloalkyleneimino rings may be replaced by a carbonyl or sulfonyl group, and said monosubstituted phenyl groups may be additionally substituted by a fluorine, chlorine or bromine atom, methyl, amino- alkylamino or di (C1. 3 alkyl) amino, or one of the said unsubstituted cykloalkyléniminokruhoch may be through two adjacent carbon atoms fused phenyl ring optionally substituted by one or two C ^ alkoxy, the isomers and salts thereof. 3. Substituované indolinóny všeobecného vzorca I podľa nároku 1, v ktorých X je atóm kyslíka,Substituted indolinones of formula I according to claim 1, in which X is an oxygen atom, -74R1 je atóm vodíka,-74R 1 is H, R2 je karboxy-, C^-alkoxy-karbonylová alebo aminokarbonylová skupina, v ktorej aminočasť môže byť substituovaná jednou alebo dvoma C1.3-alkylovými skupinami a substituenty môžu byť rovnaké alebo rôzne,R 2 is a carboxy-, C 1-4 -alkoxy-carbonyl or aminocarbonyl group in which the amino moiety may be substituted with one or two C 1 . The 3- alkyl groups and substituents may be the same or different, R3 je fenylová skupina voliteľne substituovaná metylovou skupinou,R 3 is a phenyl group optionally substituted with a methyl group, R4 je atóm vodíka alebo metylová skupina aR 4 is a hydrogen atom or a methyl group; and R5je atóm vodíka,R 5 is a hydrogen atom, C^-alkylová skupina, benzylová skupina alebo metylová alebo etylová skupina substituovaná karboxy- alebo C^-alkoxy-karbonylovou skupinou,C 1-6 -alkyl, benzyl or methyl or ethyl substituted by carboxy- or C 1-6 -alkoxy-carbonyl, C3.7-cykloalkylová skupina voliteľne substituovaná metylovou skupinou, indanylová, pyridylová, oxazolylová, tiazolylová alebo imidazolylová skupina voliteľne substituovaná metylovou skupinou, na ktorej cez dva susedné atómy uhlíka môže byť dodatočne nakondenzované fenylové jadro, metylfenylová skupina voliteľne substituovaná atómom fluóru, chlóru alebo brómu, metoxy-, karboxy-, C^-alkyloxykarbonylovou, nitro- alebo aminosulfonylovou skupinou, alebo dimetoxyfenylová skupina,C 3 . 7- cycloalkyl optionally substituted by methyl, indanyl, pyridyl, oxazolyl, thiazolyl or imidazolyl optionally substituted by methyl, on which the two-ring carbon atoms can be additionally fused with a phenyl nucleus, methylphenyl optionally substituted with fluorine, chlorine, chlorine or chlorine -, carboxy-, C 1-4 -alkyloxycarbonyl, nitro- or aminosulfonyl, or dimethoxyphenyl, 3-pyrolidinylová alebo 4-piperidinylová skupina, ktorá je na atóme dusíka substituovaná C^-alkylovou skupinou, fenylová skupina, ktorá je substituovaná trifluórmetoxy-, benzyloxy, kyano- alebo nitroskupinou, atómom fluóru, chlóru, alebo brómu,A 3-pyrrolidinyl or 4-piperidinyl group which is substituted on the nitrogen atom by a C 1-6 -alkyl group, a phenyl group which is substituted by a trifluoromethoxy, benzyloxy, cyano or nitro group, a fluorine, chlorine or bromine atom, C^s-alkoxyskupinou, pričom etoxy- a n-propoxyskupina môže byť na konci substituovaná dimetylamino-, dietylamino-, /V-etyl-metylamino-, /V-benzyl-metylamino- alebo piperidínovou skupinou, fenyl-C1.3-alkylamino-C1.3-alkylovou skupinou, ktorá vo fenylovom jadre môže byť substituovaná atómom fluóru, chlóru, brómu alebo jódu, metylovou, metoxy- alebo trifluórmetylovou skupinou a dodatočne a atóme dusíka aminoskupiny môže byť substituovaná C^-alkyl- alebo 2,2,2-triflúóretylovou skupinou,The C 3-8 alkoxy group, wherein the ethoxy and n-propoxy group may be terminally substituted with dimethylamino-, diethylamino-, N -ethyl-methylamino-, N -benzyl-methylamino- or piperidine, phenyl-C 1 . 3 -alkylamino-C first A 3- alkyl group which in the phenyl ring may be substituted by a fluorine, chlorine, bromine or iodine atom, a methyl, methoxy or trifluoromethyl group, and additionally and an amino nitrogen atom may be substituted by a C 1-4 -alkyl- or 2,2,2-trifluoroethyl group group, C14-alkylovou, fenylovou, imidazoly lovou, cyklohexylovou, metoxymetylovou, karboxymetylovou, C^g-alkoxykarbonyl-metylovou, karboxy-, C^-alkoxykarbonylovou, aminokarbonylovou, C^-a lky lam inokarbony lovou, di-(C13-alkyl)-75aminokarbonylovou, fenyl-C^-alkylaminokarbonylovou, /V-íC^-alkyO-fenyl-C^alkylaminokarbonylovou, piperazínkarbonylovou, /V-íC^-alkylJ-piperazínkarbonylovou, amino-, C^-alkylamino-, di-ÍCvä-alkyO-amino-, pyrolidínovou, piperidínovou, morfolínovou, CM-alkanoylamino-, N-íCvj-alkylJ-C^-alkanoylamino-, benzoylamino- alebo /^-(C^-alkyQ-benzoylaminoskupinou, /V-íC^-alkylJ-C^-alkanoylaminoskupinou, ktorá je v alkylovej časti dodatočne substituovaná karboxy- alebo C^-alkoxykarbonylovou skupinou, C^-alkylaminokarbonylovou alebo di-(C1.3-alkyl)-aminokarbonylovou skupinou, v ktorých alkylová časť je dodatočne substituovaná di-CC^-alkylJ-aminoskupinou, aleboC 14 -alkyl, phenyl, imidazolyl, cyclohexyl, methoxymethyl, carboxymethyl, C 1-8 -alkoxycarbonylmethyl, carboxy-, C 1-4 -alkoxycarbonyl, aminocarbonyl, C 1-4 -alkylaminocarbonyl, di- (C 13 -alkyl) -75-aminocarbonyl, phenyl-C 1-4 -alkylaminocarbonyl, N-C 1-4 -alkyl-phenyl-C 1-4 alkylaminocarbonyl, piperazinecarbonyl, N-C 1-4 -alkyl-piperazinecarbonyl, amino-, C 1-4 -alkylamino-, di-C 1-8 -alkylaminocarbonyl, piperazinecarbonyl, alkyO-amino-, pyrrolidine, piperidine, morpholine, C 1-4 -alkanoylamino-, N-C 1-4 -alkyl-C 1-4 -alkanoylamino-, benzoylamino- or N - (C 1-4 -alkyl) -benzoylamino, N-C 1-4 -alkyl; -C -alkanoylaminoskupinou which is additionally substituted by alkyl or carboxy-C ^ alkyloxycarbonyl, C ^ -alkylaminokarbonylovou or di- (C first 3 alkyl) -aminokarbonylovou group in which the alkyl moiety is additionally substituted by di C 1-6 -alkyl-amino, or A/-(C1_3-alkyl)-C1.3-alkylsulfonylamino- alebo A/^C^-alkylj-fenylsulfonylaminoskupinou, v ktorých alkylová časť môže byť dodatočne substituovaná kyano-, karboxy-, C1.3-alkoxykarbonylovou, C^-alkylamino-, di-(C1.3-alkyl)-amino-, aminokarbonylovou, C^-alkylaminokarbonylovou, dHC^-alkylj-aminokarbonylovou, piperidínkarbonylovou alebo 2-[di-(C1.3-alkylamino)]-etylaminokarbonylovou skupinou, fenylová skupina voliteľne substituovaná C1.3-alkylovou skupinou, v ktorej alkylová časť je substituovaná hydroxy-, C^-alkoxy-, karboxy-, C^-alkoxy-karbonylovou, amino-, C^-alkylamino-, di-ÍC^-alkylJ-amino- 1 -alkanoylamino-, N-fC^-alkyl)CM-alkanoylamino-, pyrolidínovou, dehydropyrolidínovou, piperidínovou, dehydropiperidínovou, 4-hydroxypiperidínovou, hexametylénimino-, morfolínovou, tiomorfolínovou, piperazínovou, 4-(C1.3-alkyl)-piperazínovou, 4-fenyl-piperazínovou, 4-(CM-alkanoyl)-piperazínovou, 4-benzoyl-piperazínovou alebo imidazolylovou skupinou, pričom uvedené nasýtené cykloalkyléniminokruhy, môžu byť dodatočne substituované fenylovou skupinou alebo jednou alebo dvoma metylovými skupinami, uvedené C15-alkylamino- a di-CC^-alkylj-aminoskupiny môžu byť dodatočne substituované jednou alebo dvoma C^-alkylovými skupinami, cyklohexylovou, hydroxy-, C^-alkoxy-, karboxy-, C^-alkoxykarbonylovou, aminokarbonylovou, C1<3alkylaminokarbonylovou alebo di-íC^-alkylJ-aminokarbonylovou skupinou, fenyl-76Cvg-alkyl- alebo fenylovou skupinou, ktorá vo fenylovom jadre môže byť voliteľne substituovaná atómom fluóru, chlóru, brómu alebo jódu, metylovou alebo kyanoskupinou, alebo metylová skupina susediaca s atómom dusíka v uvedených cykloalkyléniminokruhoch môže byť nahradená karbonylovou alebo sulfonylovou skupinou, a uvedené monosubstituované fenylové skupiny môžu byť dodatočne substituované atómom fluóru, chlóru alebo brómu, metylovou, amino-, C1.3-alkylamino- alebo di(C.,.3-alkyl)-aminoskupinou, alebo na jednom z uvedených nesubstituovaných cykloalkyléniminokruhoch môže byť cez dva susedné atómy uhlíka nakondenzované fenylové jadro voliteľne substituované jednou alebo dvoma C^-alkoxyskupinami, ich izoméry a ich soli.A / - (C 1 _ 3 alkyl) -C first 3 -alkylsulfonylamino- or A / ^ C ^ -alkylj-phenylsulfonylamino, wherein the alkyl moiety may additionally be substituted by cyano, carboxy, C first 3 alkoxycarbonyl, C ^ -alkylamino, di (C first 3 alkyl) amino, aminocarbonyl, C ^ -alkylaminokarbonylovou, dHC ^ -alkylj-aminocarbonyl, piperidinocarbonyl or 2- [di- (C first 3 -alkylamino)] - ethylaminocarbonyl, phenyl optionally substituted with C 1 . A 3- alkyl group in which the alkyl moiety is substituted with hydroxy-, C 1-6 -alkoxy-, carboxy-, C 1-6 -alkoxy-carbonyl, amino-, C 1-6 -alkylamino-, di-C 1-6 -alkyl-1-amino-1- alkanoylamino, N-fC ^ alkyl) C M -alkanoylamino-, pyrrolidino, dehydropyrolidínovou, piperidine, dehydropiperidínovou, 4-hydroxypiperidine, hexametylénimino-, morpholino, thiomorpholino, piperazino, 4- (C first 3 -alkyl) -piperazine, 4-phenyl-piperazine, 4- (C 1-4 -alkanoyl) -piperazine, 4-benzoyl-piperazine or imidazolyl, wherein said saturated cycloalkyleneimino rings may be additionally substituted with phenyl or with one or two methyl groups, said C 15 -alkylamino- and the di-C 1-4 -alkyl-amino groups may be additionally substituted with one or two C 1-4 -alkyl groups, cyclohexyl, hydroxy-, C 1-4 -alkoxy-, carboxy-, C 1-4 -alkoxycarbonyl, aminocarbonyl, C 1-3 alkylaminocarbonyl or di -C 1-6 -alkyl-aminocarbonyl a phenyl, 76C18 alkyl or phenyl group which in the phenyl ring may be optionally substituted by a fluorine, chlorine, bromine or iodine atom, a methyl or cyano group, or a methyl group adjacent to a nitrogen atom in said cycloalkyleneiminocycles may be replaced by a carbonyl or sulfones , and the monosubstituted phenyl groups may additionally be substituted by F, Cl, Br, methyl, amino, C first The 3- alkylamino- or di (C 1-3 -alkyl) amino group, or on one of said unsubstituted cycloalkyleneiminocycles, the fused phenyl ring optionally substituted by one or two C 1-4 -alkoxy groups, their isomers and their salts can be substituted via two adjacent carbon atoms . 4. Substituované indolinóny všeobecného vzorca I podľa nároku 1, v ktorých X je atóm kyslíka,4. A compound according to claim 1, wherein X is oxygen, R1 je atóm vodíka,R 1 is a hydrogen atom, R2 je karboxy- alebo aminokarbonylová skupina, v ktorej aminočasť môže byť substituovaná jednou alebo dvoma C^-alkylovými skupinami a substituenty môžu byť rovnaké alebo rôzne,R 2 is a carboxy- or aminocarbonyl group in which the amino moiety may be substituted by one or two C 1-6 -alkyl groups and the substituents may be the same or different, R3 je fenylová skupina voliteľne substituovaná metylovou skupinou,R 3 is a phenyl group optionally substituted with a methyl group, R4 je atóm vodíka aR 4 is hydrogen and R5 je atóm vodíka,R 5 is a hydrogen atom, 3-pyrolidinylová alebo 4-piperidinylová skupina, ktoré sú na atóme dusíka substituované C^-alkylovouskupinou, fenylová skupina, ktorá je substituovaná C ^-alkoxyskupinou, pričom etoxy- a n-propoxyskupina môže byť na konci substituovaná dimetylamino-, dietylamino-, /V-etyl-metylamino-, /V-benzylmetylamino- alebo piperidínovou skupinou, fenyl-C^-alkylamino-C^-alkylovou skupinou, ktorá vo fenylovom jadre môže byť substituovaná atómom fluóru, chlóru, brómu alebo jódu, metylovou, metoxy- aleboA 3-pyrrolidinyl or 4-piperidinyl group which is substituted on the nitrogen atom by a C 1-6 -alkyl group, a phenyl group which is substituted by a C 1-6 -alkoxy group, wherein the ethoxy and n-propoxy group may be terminally substituted by dimethylamino-, diethylamino-, N-ethyl-methylamino-, N -benzylmethylamino- or piperidine, phenyl-C 1-4 -alkylamino-C 1-4 -alkyl, which in the phenyl ring may be substituted by fluorine, chlorine, bromine or iodine, methyl, methoxy- or -77trifluórmetylovou skupinou a dodatočne a atóme dusíka aminoskupiny môže byť substituovaná C^-alkyl- alebo 2,2,2-trifluóretylovou skupinou, fenylová skupina voliteľne substituovaná C^-alkylovou skupinou, v ktorej alkylová časť je substituovaná hydroxy-, (\3-alk0xy-, karboxy-, C ^-alkoxy karbony lovou, amino-, C^-alkylamino-, di-ÍC^-alkyb-amino-, C2.4-alkanoylamino-, N-fC^-alkyl)C2_4-alkanoylamino-, pyrolidínovou, dehydropyrolidínovou, piperidínovou, dehydropiperidínovou, 4-hydroxypiperidínovou, hexametylénimino-, morfolínovou, tiomorfolínovou, piperazínovou, 4-(C1.3-alkyl)-piperazínovou, 4-fenyl-piperazínovou, 4-(C2.4-alkanoyl)-piperazínovou, 4-benzoyl-piperazí novou alebo imidazolyiovou skupinou, pričom uvedené nasýtené cykloalkyléniminokruhy, môžu byť dodatočne substituované fenylovou skupinou alebo jednou alebo dvoma metylovými skupinami, .uvedené C^-alkylamino- a di-(C.,.5-alkyl)-aminoskupiny môžu byť dodatočne substituované jednou alebo dvoma C1.3-alkylovými skupinami, cyklohexylovou, hydroxy-, C^-alkoxy-, karboxy-, C ^-alkoxy karbony lovou, aminokarbonylovou, C^alkylaminokarbonylovou alebo di-(C1.3-alkyl)-aminokarbonylovou skupinou, fenylC^g-alkylovou alebo fenylovou skupinou, ktorá vo fenylovom jadre môže byť voliteľne substituovaná atómom fluóru, chlóru, brómu alebo jódu, metylovou alebo kyanoskupinou, alebo metylová skupina susediaca s atómom dusíka v uvedených cykloalkyléniminokruhoch môže byť nahradená karbonylovou alebo sulfonylovou skupinou, a uvedené monosubstituované fenylové skupiny môžu byť dodatočne substituované atómom fluóru, chlóru alebo brómu, metylovou, amino-, C1_3-alkylamino- alebo di(C^-alkylJ-aminoskupinou, alebo na jednom z uvedených nesubstituovaných cykloalkyléniminokruhoch môže byť cez dva susedné atómy uhlíka nakondenzované fenylové jadro voliteľne substituované jednou alebo dvoma C1.3-alkoxyskupinami, ich izoméry a ich soli.-77trifluoromethyl and additionally and the amino nitrogen atom may be substituted with a C 1-4 -alkyl- or 2,2,2-trifluoroethyl group, a phenyl group optionally substituted with a C 1-4 -alkyl group in which the alkyl moiety is substituted with hydroxy- alk0xy-, carboxy, alkoxy carbonyl C ^ nominal, amino, C ^ -alkylamino, di-IC -alkyb-amino, C second -alkanoylamino- 4, N-fC ^ alkyl) C 2 _4 -alkanoylamino-, pyrrolidino, dehydropyrolidínovou, piperidine, dehydropiperidínovou, 4-hydroxypiperidine, hexametylénimino-, morpholino, thiomorpholino, piperazino, 4- (C first 3 -alkyl) -piperazine, 4-phenyl-piperazine, 4- (C 2nd 4- alkanoyl) -piperazine, 4-benzoyl-piperazine or imidazolyl, wherein said saturated cycloalkyleneimino rings may be additionally substituted by phenyl or by one or two methyl groups, said C 1-6 -alkylamino and di- (C 1-6 -alkanoyl) -piperazine. 5- alkyl) amino groups may additionally be substituted uova one or two C first 3 alkyl groups, cyclohexyl, hydroxy, C ^ -alkoxy, carboxy, C ^ alkoxy carbonyl nominal, aminocarbonyl, C ^ alkylaminocarbonyl or di (C first 3 alkyl) -aminokarbonylovou group, phenyl ^ g- an alkyl or phenyl group which in the phenyl ring may be optionally substituted by a fluorine, chlorine, bromine or iodine atom, a methyl or cyano group, or a methyl group adjacent to a nitrogen atom in said cycloalkyleneimino rings may be replaced by a carbonyl or sulfonyl group; additionally be substituted by F, Cl, Br, methyl, amino, C 1 _ 3 -alkylamino or di (C ^ -alkylJ-amino group, or one of the said unsubstituted cykloalkyléniminokruhoch may be through two adjacent carbon atoms optionally fused phenyl ring substituted by one or two C1. 3 -alkoxy groups, the isomers and salts thereof. -785. Substituované indolinóny všeobecného vzorca I aspoň podľa jedného z nárokov 1 až 4, v ktorých zvyšok R2 je v polohe-785. Substituted indolinones of the formula I according to at least one of Claims 1 to 4, in which the residue R 2 is in the position 5.5th 6. Substituované indolinóny všeobecného vzorca I podľa nároku 1 vybrané zo skupiny:6. A compound according to claim 1 selected from the group consisting of: (a) 3-Z-[1 -(4-aminometyl-fenylamino)-1 -fenyl-metylén]-5-amido-2-indolinón, (b) 3-Z-[ 1 -(1 -fenylamino)-1 -fenyl-metylén]-5-amido-2-indolinón, (c) 3-Z-[1 -(4-bróm-fenylamino)-1 -fenyl-metylén]-5-amido-2-indolÍnón, (d) 3-Z-[ 1 -(4-dimetylamino-metyl)-fenylamino)-1 -fenyl-metylén]-5-amido-2-indolinón, (e) 3-Z-[1-(4-pyrolidínmetyl-fenylamino)-1-fenyl-metylén]-5-amido-2-indolinón, (f) 3-Z-[1 -(4-piperidínmetyl-fenylamino)-1 -fenyl-metylén]-5-amido-2-indolinón, (g) 3-Z-[ 1 -(4-hexametyléniminometyl-fenylamino)-1 -fenyl-metylén]-5-amido-2indolinón, (h) 3-Z-[ 1 -(4-benzyl-piperidín)-metyl)-fenylamino)-1 -fenyl-metylén]-5-amido-2indolinón, (i) 3-Z-[1-(4-(/V-butyl-aminometyl)-fenylamino)-1-fenyl-metylén]-5-amido-2-indolinón, (j) 3-Z-[1 -(4-(/\/-(fenyl-metyl)-aminometyl)-fenylamino)-1 -fenyl-metylén]-5-amido-2indolinón, (k) 3-Z-[ 1 -(4-(A/-metyl-A/-benzyl-amino-metyl)-fenylamino)-1 -fenyl-metylén]-5-amido2-indolinón, (l) 3-Z-[ 1 -(4-piperidín-metyl-fenylamino)-1 -fenyl-metylén]-5-dimetylkarbamoyl-2indolinón, (m) 3-Z-[1 -(4-piperidín-metyl-fenylannino)-1 -fenyl-metylén]-5-dietylkarbamoyl-2indolinón, (n) 3-Z-[1 -(4-(3-dietylamino-propoxy)-fenylamino)-1 -fenyl-metylén]-5-amido-2indolinón, a ich soli.(a) 3-Z- [1- (4-aminomethyl-phenylamino) -1-phenyl-methylene] -5-amido-2-indolinone, (b) 3-Z- [1- (1-phenylamino) -1] -phenyl-methylene] -5-amido-2-indolinone, (c) 3-Z- [1- (4-bromo-phenylamino) -1-phenyl-methylene] -5-amido-2-indolinone, (d) 3-Z- [1- (4-dimethylamino-methyl) -phenylamino) -1-phenyl-methylene] -5-amido-2-indolinone, (e) 3-Z- [1- (4-pyrrolidinomethyl-phenylamino)] -1-phenyl-methylene] -5-amido-2-indolinone, (f) 3-Z- [1- (4-piperidinomethyl-phenylamino) -1-phenyl-methylene] -5-amido-2-indolinone, ( g) 3-Z- [1- (4-hexamethyleneiminomethyl-phenylamino) -1-phenyl-methylene] -5-amido-2-indolinone, (h) 3-Z- [1- (4-benzyl-piperidine) -methyl] -phenylamino) -1-phenyl-methylene] -5-amido-2-indolinone, (i) 3-Z- [1- (4- (N-butyl-aminomethyl) -phenylamino) -1-phenyl-methylene] -5 -amido-2-indolinone, (j) 3-Z- [1- (4- (N - (phenylmethyl) aminomethyl) phenylamino) -1-phenylmethylene] -5-amido-2-indolinone, (k) 3-Z- [1- (4- (N-methyl-N-benzyl-amino-methyl) -phenylamino) -1-phenyl-methylene] -5-amido-2-indolinone, (1) 3- Z- [1- (4-Piperidine-methyl-phenylamino) -1-f enyl-methylene] -5-dimethylcarbamoyl-2-indolinone, (m) 3-Z- [1- (4-piperidin-methyl-phenylannino) -1-phenyl-methylene] -5-diethylcarbamoyl-2-indolinone, (n) 3-Z - [1- (4- (3-diethylamino-propoxy) -phenylamino) -1-phenyl-methylene] -5-amido-2-indolinone, and salts thereof. 7. Fyziologicky prijateľné soli zlúčenín podľa nárokov 1 až 6.Physiologically acceptable salts of the compounds according to claims 1 to 6. -798. Spôsob prípravy zlúčenín podľa nárokov 1 až 7, vyznačujúci sa t ý m, že zahrnuje nasledujúce kroky:-798. Process for the preparation of compounds according to claims 1 to 7, characterized in that it comprises the following steps: a) zlúčenina všeobecného vzorca II v ktorom(a) a compound of formula II in which: X, R2 a R3 sú určené v nárokoch 1 až 6,X, R 2 and R 3 are as defined in claims 1 to 6, R6 je atóm vodíka, ochranná skupina pre atóm dusíka laktámovej skupiny alebo väzba na tuhú fázu aR 6 is a hydrogen atom, a protecting group for a nitrogen atom of a lactam group or a solid phase bond; and Z1 je atóm halogénu, hydroxy-, alkoxy- alebo aralkoxyskupina, reaguje s amínom všeobecného vzorca lll yZ 1 is halogen, hydroxy, alkoxy or aralkoxy, reacts with an amine of formula III; (lll) v ktorom(lll) in which R4 a R5 sú určené v nárokoch 1 až 6 a v prípade potreby sa následne použitá ochranná skupina dusíka laktámovej skupiny alebo takto získaná zlúčenina sa od tuhej fázy odštiepi, aleboR 4 and R 5 are as defined in claims 1 to 6 and, if necessary, the subsequent nitrogen protecting group of the lactam group or the compound thus obtained is cleaved from the solid phase, or b) na prípravu zlúčeniny všeobecného vzorca I, ktorá obsahuje aminometylovú skupinu a X je atóm kyslíka, sa redukuje zlúčenina všeobecného vzorca IV kdeb) for the preparation of a compound of formula I which contains an aminomethyl group and X is an oxygen atom, a compound of formula IV is reduced wherein: R1 až R4 bolo určené v nárokoch 1 až 6 aR 1 to R 4 have been defined as in claims 1 to 6 and R7 má význam určený pre R5 v nárokoch 1 až 6, pričom R5 obsahuje kyanoskupinu, a v prípade potreby sa takýmto spôsobom pripravená zlúčenina všeobecného vzorca I, ktorá obsahuje alkoxykarbonylovú skupinu, následne hydrolyticky prekonvertuje na zodpovedajúcu karboxyzlúčeninu, alebo takýmto spôsobom pripravená zlúčenina všeobecného vzorca I, ktorá obsahuje amino- alebo alkylaminoskupinu, sa alkyláciou alebo redukčnou alkyláciou prekonvertuje na zodpovedajúcu alkylamino- alebo dialkylaminozlúčeninu, alebo takýmto spôsobom pripravená zlúčenina všeobecného vzorca I, ktorá obsahuje amino- alebo alkylaminoskupinu, sa acyláciou prekonvertuje na zodpovedajúcu acylzlúčeninu, alebo takýmto spôsobom pripravená zlúčenina všeobecného vzorca I, ktorá obsahuje karboxyskupinu, sa esterifikáciou alebo amidizáciou prekonvertuje na t zodpovedajúcu ester- alebo aminokarbonylovú zlúčeninu, aleboR 7 is as defined for R 5 in claims 1 to 6, wherein R 5 contains a cyano group and, if desired, a compound of the formula I which contains an alkoxycarbonyl group is hydrolyzed to the corresponding carboxy compound or a compound of the general formula of formula I which contains an amino or alkylamino group is converted by the alkylation or reductive alkylation to the corresponding alkylamino- or dialkylamino compound, or a compound of the formula I which contains an amino- or alkylamino group prepared in this way is converted by acylation to the corresponding acyl compound or a compound of formula I containing a carboxy group is converted by esterification or amidation of ester to the corresponding t or aminocarbonyl compound, or t. v prípade potreby sa ochranný zvyšok použitý počas reakcie na ochranu reaktívnych skupín odštiepi, alebo v prípade potreby sa takýmto spôsobom pripravená zlúčenina všeobecného vzorca I následne rozdelí na stereoizoméry, alebo takýmto spôsobom pripravená zlúčenina všeobecného vzorca sa I prekonvertuje na soli, osobitne pre farmaceutické použitie na fyziologicky prijateľné soli, a to pomocou anorganickej alebo organickej kyseliny alebo zásady.t. if desired, the protective moiety used during the reaction to protect the reactive groups is cleaved or, if desired, the compound of formula I thus prepared is subsequently separated into stereoisomers, or the compound of formula I thus prepared is converted into salts, especially for pharmaceutical use for physiologically acceptable salts using an inorganic or organic acid or base. -81 9. Farmaceutický prostriedok, vyznačujúci sa tým, že obsahuje substituovaný indolinón podľa aspoň jedného z nárokov 1 až 6 alebo soľ podľa nároku 7 voliteľne s jedným alebo viacerými inertnými nosičmi a/alebo riedidlami.A pharmaceutical composition comprising a substituted indolinone according to at least one of claims 1 to 6 or a salt according to claim 7 optionally with one or more inert carriers and / or diluents. 10. Spôsob prípravy farmaceutického prostriedku podľa nároku 9, vyznačuj ú c i sa tým, že substituovaný indolinón podľa aspoň jedného z nárokov 1 až 6 alebo soľ podľa nároku 7 sa nechemickým spôsobom zlúči s jedným alebo viacerými inertnými nosičmi a/alebo riedidlami.Process for the preparation of a pharmaceutical composition according to claim 9, characterized in that the substituted indolinone according to at least one of claims 1 to 6 or the salt according to claim 7 is non-chemically combined with one or more inert carriers and / or diluents. 11. Použitie substituovaných indolinónov podľa aspoň jedného z nárokov 1 až 6 alebo ich soli podľa nároku 7 na prípravu liečiva na liečenie rozsiahlej alebo anomálnej proliferácie buniek.Use of substituted indolinones according to at least one of claims 1 to 6 or a salt thereof according to claim 7 for the preparation of a medicament for the treatment of widespread or anomalous cell proliferation.
SK1513-2000A 1998-04-15 1999-04-10 Substituted indolinones, method for their production, pharmaceutical composition containing them and use thereof SK283824B6 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19816624A DE19816624A1 (en) 1998-04-15 1998-04-15 Novel substituted indolinones, their preparation and their use as pharmaceuticals
PCT/EP1999/002436 WO1999052869A1 (en) 1998-04-15 1999-04-10 Substituted indolinones having an inhibiting effect on kinases and cycline/cdk complexes

Publications (2)

Publication Number Publication Date
SK15132000A3 true SK15132000A3 (en) 2001-03-12
SK283824B6 SK283824B6 (en) 2004-02-03

Family

ID=7864562

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1513-2000A SK283824B6 (en) 1998-04-15 1999-04-10 Substituted indolinones, method for their production, pharmaceutical composition containing them and use thereof

Country Status (31)

Country Link
EP (1) EP1071665B1 (en)
JP (1) JP4015365B2 (en)
KR (1) KR100588250B1 (en)
CN (1) CN100338036C (en)
AR (1) AR015763A1 (en)
AT (1) ATE251138T1 (en)
AU (1) AU749829B2 (en)
BG (1) BG64443B1 (en)
BR (1) BR9909688A (en)
CA (1) CA2323111C (en)
CO (1) CO5011040A1 (en)
DE (2) DE19816624A1 (en)
DK (1) DK1071665T3 (en)
EA (1) EA003532B1 (en)
EE (1) EE04432B1 (en)
ES (1) ES2207209T3 (en)
HU (1) HUP0101568A3 (en)
ID (1) ID26420A (en)
IL (1) IL138036A0 (en)
MY (1) MY122357A (en)
NO (1) NO317298B1 (en)
NZ (1) NZ507967A (en)
PL (1) PL343314A1 (en)
PT (1) PT1071665E (en)
SK (1) SK283824B6 (en)
TR (1) TR200002980T2 (en)
TW (1) TW510897B (en)
UA (1) UA63009C2 (en)
WO (1) WO1999052869A1 (en)
YU (1) YU59800A (en)
ZA (1) ZA200004623B (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6569868B2 (en) 1998-04-16 2003-05-27 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
GB9904995D0 (en) * 1999-03-04 1999-04-28 Glaxo Group Ltd Substituted aza-oxindole derivatives
US6624171B1 (en) 1999-03-04 2003-09-23 Smithkline Beecham Corporation Substituted aza-oxindole derivatives
GB9904933D0 (en) 1999-03-04 1999-04-28 Glaxo Group Ltd Compounds
GB9904932D0 (en) * 1999-03-04 1999-04-28 Glaxo Group Ltd Composition and method for preventing/reducing the severity of side effects of chemotherapy and/or radiation therapy
DE19924401A1 (en) * 1999-05-27 2000-11-30 Boehringer Ingelheim Pharma Novel substituted indolinones, their preparation and their use as pharmaceuticals
WO2001016130A1 (en) 1999-08-27 2001-03-08 Boehringer Ingelheim Pharma Kg Substituted indolinones as tyrosine kinase inhibitors
US6762180B1 (en) 1999-10-13 2004-07-13 Boehringer Ingelheim Pharma Kg Substituted indolines which inhibit receptor tyrosine kinases
UA75054C2 (en) * 1999-10-13 2006-03-15 Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг Substituted in position 6 indolinones, producing and use thereof as medicament
US6620818B1 (en) 2000-03-01 2003-09-16 Smithkline Beecham Corporation Method for reducing the severity of side effects of chemotherapy and/or radiation therapy
MY128450A (en) 2000-05-24 2007-02-28 Upjohn Co 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
CA2410509A1 (en) 2000-06-02 2001-12-13 Sugen, Inc. Indolinone derivatives as protein kinase/phosphatase inhibitors
NZ525892A (en) * 2000-11-27 2004-11-26 Pharmacia Italia S Phenylacetamido- pyrazole derivatives their use as antitumor agents and preparation process thereof
DE10117204A1 (en) 2001-04-06 2002-10-10 Boehringer Ingelheim Pharma Indolinones substituted in the 6-position, their preparation and their use as medicaments
US6599902B2 (en) 2001-05-30 2003-07-29 Sugen, Inc. 5-aralkysufonyl-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
ES2298508T3 (en) 2002-03-26 2008-05-16 Boehringer Ingelheim Pharmaceuticals Inc. GLUCOCORTICOID MIMETICS, METHODS TO PREPARE THEM, PHARMACEUTICAL COMPOSITIONS AND THEIR USES.
US7169936B2 (en) 2002-07-23 2007-01-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinone derivatives substituted in the 6-position, their preparation and their use as medicaments
DE10233500A1 (en) * 2002-07-24 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-Z- [1- (4- (N - ((4-methyl-piperazin-1-yl) -methylcarbonyl) -N-methyl-amino) -anilino) -1-phenyl-methylene] -6-methoxycarbonyl- 2-indolinone monoethanesulfonate and its use as a medicament
DE10237423A1 (en) 2002-08-16 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Treating immunological (or related) diseases, e.g. inflammatory bowel disease, rheumatoid arthritis or psoriasis, comprises administration of 3-methylene-2-indolinone derivative or quinazoline compound
JP4879492B2 (en) * 2002-11-27 2012-02-22 アラーガン、インコーポレイテッド Kinase inhibitors for the treatment of diseases
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
UY28526A1 (en) 2003-09-24 2005-04-29 Boehringer Ingelheim Pharma GLUCOCORTICOID MIMETICS, METHODS OF PREPARATION PHARMACEUTICAL COMPOSITIONS AND USES OF THE SAME
JP4949845B2 (en) * 2003-10-03 2012-06-13 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド Fluorescent probes for use in protein kinase inhibitor binding assays
DE102004012070A1 (en) * 2004-03-12 2005-09-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg New cycloalkyl-containing 5-acylindolinones, their preparation and their use as medicaments
US7795272B2 (en) 2004-03-13 2010-09-14 Boehringer Ingelheim Pharmaceutical, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof
PE20060777A1 (en) 2004-12-24 2006-10-06 Boehringer Ingelheim Int INDOLINONE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES
JP2008525525A (en) 2004-12-27 2008-07-17 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド Glucocorticoid mimetic, its production, pharmaceutical composition and use
AU2006254758B2 (en) * 2005-06-10 2012-04-05 Merck Patent Gmbh Oxindoles as kinase inhibitors
WO2007057399A2 (en) * 2005-11-15 2007-05-24 Boehringer Ingelheim International Gmbh Treatment of cancer with indole derivatives
KR20090097908A (en) 2006-12-06 2009-09-16 베링거 인겔하임 인터내셔날 게엠베하 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
SI2300472T1 (en) 2008-06-06 2012-05-31 Boehringer Ingelheim Int Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US20170065529A1 (en) 2015-09-09 2017-03-09 Boehringer Ingelheim International Gmbh Pharmaceutical dosage form for immediate release of an indolinone derivative
WO2011032320A1 (en) * 2009-09-21 2011-03-24 F. Hoffmann-La Roche Ag Novel alkene oxindole derivatives
CN109293551A (en) 2011-11-14 2019-02-01 利亘制药公司 Method and composition relevant to granulocyte colony stimulating factor receptor
WO2014150252A1 (en) * 2013-03-15 2014-09-25 Ligand Pharmaceuticals Incorporated Methods of treatment associated with the granulocyte colony-stimulating factor receptor
CN107033064B (en) * 2017-04-28 2019-07-09 西安医学院 A kind of 3- (morpholine replaces fragrant imido grpup) Benzazole compounds and its preparation method and application
CN111285872B (en) * 2018-12-06 2022-05-17 北京志健金瑞生物医药科技有限公司 Indole-2-ketone derivative and preparation method and application thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501567D0 (en) * 1995-01-26 1995-03-15 Pharmacia Spa Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
GB9718913D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
DE19824922A1 (en) * 1998-06-04 1999-12-09 Boehringer Ingelheim Pharma Novel substituted indolinones, their preparation and their use as pharmaceuticals
UA75054C2 (en) * 1999-10-13 2006-03-15 Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг Substituted in position 6 indolinones, producing and use thereof as medicament

Also Published As

Publication number Publication date
JP4015365B2 (en) 2007-11-28
CA2323111C (en) 2009-09-15
CN100338036C (en) 2007-09-19
MY122357A (en) 2006-04-29
KR20010042731A (en) 2001-05-25
JP2002511449A (en) 2002-04-16
CN1297438A (en) 2001-05-30
EA003532B1 (en) 2003-06-26
ZA200004623B (en) 2001-05-30
BG104813A (en) 2001-08-31
ATE251138T1 (en) 2003-10-15
AR015763A1 (en) 2001-05-16
BG64443B1 (en) 2005-02-28
AU3814999A (en) 1999-11-01
DK1071665T3 (en) 2004-01-05
ES2207209T3 (en) 2004-05-16
EA200001021A1 (en) 2001-06-25
ID26420A (en) 2000-12-21
HUP0101568A3 (en) 2002-12-28
DE59907199D1 (en) 2003-11-06
EP1071665B1 (en) 2003-10-01
TR200002980T2 (en) 2001-02-21
WO1999052869A1 (en) 1999-10-21
HUP0101568A2 (en) 2001-09-28
CO5011040A1 (en) 2001-02-28
AU749829B2 (en) 2002-07-04
BR9909688A (en) 2000-12-19
CA2323111A1 (en) 1999-10-21
NO20005151D0 (en) 2000-10-13
TW510897B (en) 2002-11-21
EP1071665A1 (en) 2001-01-31
NO20005151L (en) 2000-10-13
NO317298B1 (en) 2004-10-04
DE19816624A1 (en) 1999-10-21
KR100588250B1 (en) 2006-06-13
SK283824B6 (en) 2004-02-03
EE04432B1 (en) 2005-02-15
EE200000598A (en) 2002-04-15
IL138036A0 (en) 2001-10-31
UA63009C2 (en) 2004-01-15
PT1071665E (en) 2004-02-27
PL343314A1 (en) 2001-08-13
NZ507967A (en) 2003-04-29
YU59800A (en) 2003-04-30

Similar Documents

Publication Publication Date Title
SK15132000A3 (en) Substituted indolinones having an inhibiting effect on kinases and cycline/cdk complexes
AU764782B2 (en) Substituted indolinones, the production thereof and their use as medicaments
US6169106B1 (en) Indolinones having kinase inhibitory activity
US7160901B2 (en) Substituted indolinones, preparation thereof and their use as pharmaceutical compositions
DE19924401A1 (en) Novel substituted indolinones, their preparation and their use as pharmaceuticals
DE19949209A1 (en) 5-substituted indolinones, their preparation and their use as pharmaceuticals
SK12412003A3 (en) Indolinones, substituted in position 6, and their use as kinase inhibitors
DE10054019A1 (en) New substituted indolinones, their production and their use as medicines
US6319918B1 (en) Substituted indolinones with kinase inhibitory activity
CZ20003788A3 (en) Substituted indolinones
DE19940829A1 (en) New 3-(anilino-methylidene)-2-indolinone derivatives, are kinase inhibitors and cell proliferation inhibitors, useful e.g. for treating tumors, metastasis, rheumatoid arthritis or psoriasis
MXPA00008541A (en) Substituted indolinones having an inhibiting effect on kinases and cycline/cdk complexes
MXPA00010095A (en) Substituted indolinones, the production thereof and their use as medicaments